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ABSTRACT 
 
 
VICKI RICHARDSON: In Vitro Thyroid Hormone Metabolism: 
Effects of nuclear receptor activation on the metabolic profiles of thyroxine in rat and human 
hepatocytes 
(Under the direction of Michael J. DeVito, PhD) 
 
 Thyroid hormones are critical in the normal growth and development of amphibians, 
birds, fish, and mammals. There are numerous xenobiotics that interfere with thyroid 
hormone homeostasis; therefore, exposure to these xenobiotics could be detrimental to the 
growth and development.. Xenobiotics categorized as thyroid hormone disruptors have been 
defined by their ability to reduce circulating concentrations of thyroid hormone in serum. It is 
has been proposed that thyroid hormone disruption occurs through the induction of thyroxine 
(T4) glucuronidation and biliary elimination which ultimately results in reduced serum T4 
concentrations. This mode of action has been described using animal models, but the 
relevance to humans has not been determined. This research tests the hypothesis that there 
are species differences in the hepatic metabolism of thyroid hormones and these differences 
occur via nuclear receptor activation. Here we demonstrate the utility of sandwich-cultured 
rat and human hepatocytes in measuring T4 metabolism following the activation of Aryl 
hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) or pregnane x receptor 
(PXR). The relationship between T4 metabolism and nuclear receptor activation was studied 
through the establishment of an in vitro assay for the qualitative and quantitative 
iv 
 
measurement of T4 metabolites.  Here we report that hepatic glucuronidation may be a more 
important pathway for T4 metabolism in rats whereas T4 deiodination may be a favored 
pathway in humans. Following nuclear receptor activation, glucuronidation is a primary route 
of T4 metabolism in rat and humans hepatocytes. Agonists of CAR/PXR are more consistent 
in the induction of T4 glucuronidation in rat and human hepatocytes. We also show 
similarities in the in vivo and in vitro effect on T4 metabolism in response to the 
environmental contaminant, 2,2′,4,4′-tetrabromodiphenyl ether (BDE 47). These results 
indicate possible species differences in hepatic T4 metabolism and these differences may be 
based on nuclear receptor activation. 
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CHAPTER 1 
 
INTRODUCTION 
 
A. Overview 
Thyroid hormones (THs) are essential to development, growth and metabolism in 
humans with its most prominent effects occurring during fetal development and early 
childhood. The lack of TH in childhood delays growth and in adults the primary effect is an 
alteration in metabolism. A broad spectrum of xenobiotics decrease serum THs levels in 
rodents and these decreases are often associated with the induction of xenobiotics 
metabolizing enzymes which result in increases in thyroxine (T4) metabolism and biliary 
elimination (Barter and Klaassen, 1992;  Liu et al., 1995;  Kolaja and Klaassen, 1998;  Hood 
et al., 1999;  Hood and Klaassen, 2000a;  Hood and Klaassen, 2000b;  Hood et al., 2003). 
Xenobiotics that activate the nuclear receptors, such as aryl hydrocarbon receptor (AhR), 
constitutive androstane receptor (CAR), and pregnane X receptor (PXR), appear to 
consistently decrease circulating TH concentrations (Barter and Klaassen 1992; Kretschmer 
and Baldwin 2005; Qatanani et al. 2005).  One commonality of these receptors is their 
regulation of xenobiotic metabolizing enzymes (XMEs), in particular uridine diphosphate 
glucuronosyltransferase (UGT) and sulfotransferase (SULT) and transporters. For example, 
through the activation of constitutive androstane receptor (CAR), phenobarbital (PB), 
induces hepatic UGTs in rat (Vansell and Klaassen, 2001;  Vansell and Klaassen, 2002a),
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which is associated with an increase in the biliary elimination of T4-glucuronides 
(Oppenheimer et al., 1968;  McClain et al., 1989;  Wong et al., 2005). PB increases [125I] 
liver accumulation in rats (Kato et al., 2010) and increases biliary elimination of [125I]-T4 and 
[125I]-T4G suggesting the involvement of hepatic transporters in cellular uptake and biliary 
excretion (Mitchell et al., 2005;  Visser et al., 2011). PB also decreases serum T4 
concentrations in humans (Ohnhaus et al., 1981;  Eiris-Punal et al., 1999). Mechanistic 
studies in humans are limited; consequently, the hypothyroid effect of PB in humans is 
thought to occur through the same mechanism as rats. Induction of hepatic UGTs by 
xenobiotics appears to be a common mechanism in thyroid hormone disruption in rodents; 
however, it is uncertain if this occurs in humans. The goals of this research are to examine 
the species differences in T4 metabolism using human and rat hepatocytes and further explore 
how these differences are affected by exposure to AhR, CAR, and/or PXR agonists. 
 
B. Nuclear receptors  
 
B.1. Aryl Hydrocarbon Receptor  
 Aryl hydrocarbon receptor (AhR), also known as the dioxin receptor, is a ligand 
dependent basic helix-loop-helix/per-ARNT-Sim (bHLH/PAS) transcription factor and is 
activated by exogenous and endogenous compounds. Once activated, AhR induces or 
represses a large number of genes involved in biological or toxicological effects in several 
species and tissues (Hankinson, 2005;  Beischlag et al., 2008;  Furness and Whelan, 2009). 
Ligands for AhR include a wide variety of hydrophobic environmental contaminants, 
including polycyclic aromatic hydrocarbons (PAH) and halogenated aromatic hydrocarbons 
(HAH). The most toxic and environmentally and biologically persistent compounds are 
3 
HAHs, which include polychlorinated biphenyls (PCBs), polychlorinated dibenzo-p-dioxins 
(PCDD), and polychlorinated dibenzofurans (PCDF) (Safe, 1990). There are species 
differences in the ligand binding domain of AhR, which may be responsible for species 
differences in ligand binding and response (Bisson et al., 2009;  Pandini et al., 2009). 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) a prototypical ligand for AhR, produces toxic 
effects some of which include tumor promotion, dermal toxicity, disruption of endocrine 
homeostasis, wasting, and lethality. In humans, a point mutation in the ligand binding 
domain was found to lower the ability of AhR to bind TCDD by 10-fold compared to mouse 
AhR (Ema et al., 1994;  Ramadoss and Perdew, 2004). TCDD and 3-methylcholanthrene 
(3MC) induced AhR-regulated genes, CYP1A1 and CYP1A2, to a greater degree in wild 
type mice compared to AhR humanized mice, demonstrating mouse AhR has a higher 
binding affinity for TCDD and 3MC than human AhR (Moriguchi et al., 2003). 
 
B.2. Constitutive Androstane Receptor 
Constitutive androstane receptor (CAR) is a member of the NR1I3 subfamily of 
ligand activated transcription factors.  CAR is a promiscuous receptor that binds to a wide 
range of structurally unrelated compounds and regulates numerous genes involved in the 
metabolism and transport of exogenous and endogenous compounds. Abundantly expressed 
in the liver, CAR is important in regulating the metabolism and elimination of xenobiotics.  
Unlike many nuclear receptor orthologs, which share more than 90% homology, human and 
rodent CAR orthologs share only about 70% amino acid identity in the ligand-binding 
domain (Moore et al., 2002).  This evolutionary divergence in the ligand-binding domain 
between humans and rodents is apparent with differences in response to xenobiotics.  For 
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example, 1,4-bis-[2-(3,5,-dichloropyridyloxy)] benzene (TCPOBOP) is a potent CAR 
activator in rodents, but lacks activity in humans (Moore et al., 2000).  In contrast, 6-(4-
chlorophenyl :imidazo [2,1-b] thiazole-5-carbaldehyde O-(3,4 dichlorobenzyl) oxime 
(CITCO) is a potent activator of CAR in human, yet it lacks activity in rats and mice (Scheer 
et al., 2008).  With the divergence of ligand-binding domains between the species, there are 
compounds such as phenobarbital (PB), which activate both human and rodent nuclear 
receptors orthologs (Moore, et al., 2002); however this indirect activation is independent of 
the ligand binding domain (Sidhu and Omiecinski, 1995;  Honkakoski and Negishi, 1998).  
 
B.3. Pregnane X Receptor 
Pregnane X receptor (PXR) is a member of the NR1I2 family of nuclear receptors and 
acts as a xenosensor and transcriptional activator (Kliewer and Willson, 2002). PXR is 
activated by a variety of naturally occurring steroids of which pregnanes are the most potent 
(Kliewer et al., 1998;  Lehmann et al., 1998). Closely related, PXR and CAR share a variety 
of ligands and target genes (Maglich et al., 2002); however, PXR is more promiscuous than 
CAR, because it binds to a wide range of compounds that are of different molecular weights 
and are structurally dissimilar (Jones et al., 2000).  PXR exhibits a marked divergence across 
species within the ligand binding domain, where human and mouse PXR is only 76% 
homologous; however, the DNA binding domain is 96% homologous. The divergence in the 
ligand binding domain results in different ligand binding specificities. Pregnenolone 16α-
carbonitrile (PCN) is a ligand for rodent PXR, but not for human PXR. Human PXR is 
activated by rifampicin (Rif); however the rodent PXR is not activated by Rif. The species 
differences in PXR are consistent with the species differences in CYP3A induction. This 
5 
suggests that it is the species ortholog of the receptor and not the CYP3A gene promoter 
which determines the response.   
 
C. Thyroid Hormones 
 
C.1. Synthesis and Feedback 
The main function of the thyroid gland is to produce hormones, T4 and the active 
hormone, triiodothyronine (T3) (Figure 1). T4 and T3 are synthesized in the thyroid gland by 
thyroperoxidase (TPO) where TPO converts iodide to iodine and then attaches it to tyrosine 
residues.  Thyroglobulin (Tg), a large glycoprotein found within the thyroid follicular cells 
(thyrocytes), serves as a substrate for the synthesis and storage of THs and iodine.  When 
thyroid hormone is needed, Tg is internalized at the apical pole of thyrocytes, where it is 
digested by proteases, resulting in free T4 and T3.  After Tg digestion, T4 and T3 are released 
into the circulation.   
TH is regulated by a negative feedback loop from the pituitary gland. When the pituitary 
gland detects too much Thyroid stimulating hormone (TSH) is the predominant regulator of 
thyroid hormone synthesis and release.  Secreted from the pituitary, TSH interacts with its 
receptor (TSHR) in the thyrocytes to stimulate the accumulation of iodine and expression of 
the sodium/iodine symporter.  T4 and T3 regulate the synthesis and release of TSH at the 
pituitary level, as well as indirectly by affecting TSH synthesis via their effects on the 
synthesis of TRH.  TRH is the major positive regulator of TSH by activating the 
phospatidylinositol-protein kinase C pathway.  Once activated, TRH acts on the anterior 
pituitary to stimulate the release of TSH.  Collectively, these interrelated steps produce and 
6 
release thyroid hormones into the blood stream as well as regulate the amount of iodine 
available to the cells,  
 
C.2. Production and Clearance in Humans and Rats 
Although rats are often used to examine extrathyroidal TH metabolism, there are 
important differences in the production and kinetics of THs in rats and humans (Table 1).  In 
rats, normal plasma T4 concentrations are approximately 44nmol/L with a half-life (t1/2) of 
0.5-1 day.  T4 is cleared at a rate of about  50% per day in rats resulting in a daily production 
of approximately 1nmol/100g body weight(Bianco et al., 2002).  The mean normal 
concentration of total T4 in human plasma is approximately 100nmol/L (Larsen PR, 1998) 
amid a daily T4 production of 110 nmol/70kg body weight.  With a half-life (t1/2) of 5-9 days, 
about 10% or nearly 110nmol of T4 is cleared from the circulation per day in humans.  In rats 
and humans, plasma T3 is derived from thyroid gland secretion and extrathyroidal 
deiodination; however, only 20% of plasma T3 comes from thyroid secretions in humans, 
whereas 40% is secreted from the thyroid in rats.  Mean plasma T3 concentrations are 
approximately 750pmol/L in rats.  With a turnover rate of over 200% per day (t1/2 = 0.2 day), 
the daily production of T3 in rats is 415pmol/100g.  Humans have a mean normal plasma T3 
concentration of 1.8nmol/L with a daily production rate of 50nmol/70kg body weight and a 
t1/2 of 1.5 days; consequently, the fractional turnover rate of T3 in plasma is about 65% per 
day.  In humans, of the daily production of T4 (110nmol/day), 30-40% is converted to T3 
(40nmol) by peripheral deiodination, while the remaining amount (10nmol) is excreted 
directly from the thyroid(Larsen PR, 1998). In rats, approximately 415 pmol of T3 is 
produced daily.  About 20-25% of secreted T4 (1nmol/day) in rats is deiodinated to produce 
7 
225 pmol of T3 per day, while the remaining amount (190 pmol) is excreted directly from the 
thyroid (Oppenheimer et al., 1972;  Bianco, et al., 2002).  The molar ratio of T4/T3 in rat 
thyroid is 8:1 where as in humans the ratio is higher (15:1)(Abrams and Larsen, 1973;  Izumi 
and Larsen, 1977).  In comparing T4/T3 thyroidal secretion, the ratio is 5:1 in rats, while in 
humans the ratio is 11:1.  This indicates there are small contributions of thyroidal deiodinases 
to T4 to T3 conversion in both species.  
 
C.3. Serum Binding Proteins 
Specific proteins carry thyroid hormones in the blood and their high affinity binding 
to T4 and T3 are essential to the availability of the hormones to target tissues.  In humans, 
three major proteins bind (THs) in serum: thyroxine-binding globulin (TBG), transthyretin 
(TTR) and albumin (ALB) (Schussler, 2000).  TBG is a low capacity-high affinity binder of 
thyroid hormones, albumin is a high capacity-low affinity binder and TTR is an intermediate 
capacity and affinity binder (Power et al., 2000).  T4 affinity is greatest for TBG (Ka=1x10-10 
M), intermediate for TTR (Ka=7x10 -7 M), and lowest for ALB (Ka= 7x10 -5 M).  The affinity 
of T3 for the binding proteins is lower than that of T4, where the affinity for TBG is 
approximately 5x10 -8 M, for TTR it is 1x10 -7 M, and 1x10 -5 M for ALB (Robbins, 1991).  
All vertebrates have serum-binding proteins for thyroid hormone, but there are species 
differences in their specific composition within blood (Table 1).  In humans, TBG is the least 
abundant but almost 70% of T4 is bound to it (Benvenga, 2005).  In rats, TBG expression 
peaks postnatally and is not detectable by early maturity at 8 weeks, but reappears in 
senescence (Savu et al., 1991).  Thus, through most of their lives rats lack one of the major 
carrier proteins for T4, with TTR serving as the primary plasma transporter.  The binding 
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affinity of TTR for THs is less than the binding affinity of THs for TBG (Benvenga et al., 
2002).  In rodents, T4 is bound to TTR where as T3 is mainly bound to the least abundant 
TBG or albumin (Savu et al., 1987).  T4-TTR binding is thought to be more susceptible to 
chemical interference than T4-TBG binding (Munro et al., 1989).  This suggests that as a 
major circulating T4 binding protein, TTR may be important in the disruption of TH 
homeostasis in rodents.   
 
C.4. Metabolism 
 
C.4.1 Deiodination 
Tissue deiodinases are critical in the extrathyroidal conversion of T4 into its 
biologically active form, T3.  There are two isoenzymes that convert T4 to T3:  type I 5’-
deiodinase (D1) and type 2 deiodinase (D2).  D1 is located primarily in the liver, kidney and 
thyroid, and D2is located primarily in the brain, thyroid, anterior pituitary, brown adipose, 
placenta and skeletal muscle.  D1 is responsible for most of the conversion of T4 to T3 in the 
blood, while D2 provides conversion of T4 to T3 for intracellular use.  Type 3 deiodinase 
(D3) is located in the brain, placenta, fetal tissues and uterus during pregnancy and is 
responsible for inactivating thyroid hormones by converting T4 to rT3 and T3 to T2 (Figure 2).  
In humans, about 80% of circulating T3 derives from peripheral 5´-monodeiodination of T4, 
while the thyroid secretes 20% of the circulating T3 (Larsen PR, 1998).  Unlike humans, the 
intrathyroidal conversion of T4 to T3 provides 40% of the daily T3 production in rats and the 
other 60% is derived peripherally (Chanoine et al., 1993).  This suggests that peripheral 
deiodination may play a larger role in TH homeostasis in humans as compared to rodents.   
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C.4.2. Glucuronidation 
Glucuronidation involves the transfer of a sugar moiety on to uridine diphosphate 
(UDP)-glucuronic acid (UDPGA) to a substrate.  The enzymes responsible for 
glucuronidation of THs are UDP-glucuronoysyltransferases (UGT), which are located mainly 
in the endoplasmic reticulum of liver cells.  The TH glucuronide conjugate is excreted in 
bile, which may represent a reversible pathway as intestinal bacteria can hydrolyze the 
conjugates creating an enterohepatic cycle enabling reabsorption of free THs.  Induction of 
UGTs by xenobiotics may play an important role in chemically induced decreases in 
circulating THs (Hood and Klaassen, 2000a;  Klaassen and Hood, 2001;  Zhou et al., 2001).  
UGTs are also regulated by AhR, CAR and PXR (Maglich, et al., 2002;  Bock and Kohle, 
2004;  Wagner et al., 2005).  The degree to which chemicals reduce serum T4 is not always 
correlated with the increase in T4-UGT activity (Hood, et al., 2003;  Richardson et al., 2008).  
There are also differences between rats and mice in which Kenechlor-500, a mixture of 
polychlorinated biphenyls (PCBs) with PB-like effects on XMEs, reduces circulating levels 
of T4 in both rats and mice, but induces UGT activity in rats but not mice (Kato et al., 2003).  
In addition, Kenechlor-500 causes decreases in circulating T4 concentrations in the UGT1A 
deficient Gunn rats demonstrating that the decreases in circulating T4 is not necessarily solely 
dependent upon the induction of TH glucuronidation dependent (Kato et al., 2004).  As a 
result, it can be argued that UGT induction alone is not a uniform marker of the ability of 
chemicals to cause a reduction in serum TH, which could explain the inconsistencies 
observed in T4-UGT activity and T4 serum concentrations (Table 2).  Nonetheless, the ability 
of chemicals to reduce circulating levels of TH can be associated with UGT induction and an 
increase in fecal elimination of T4 (de Sandro et al., 1992;  Vansell and Klaassen, 2001). 
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C.4.3. Sulfation 
Sulfotransferases are a cytosolic group of phase II metabolizing enzymes important 
for the inactivation and elimination of endogenous and exogenous compounds.  Sulfation is a 
conjugation reaction in which a sulfate group from a sulfate donor, 3-phoshoadenosine-5-
phosphsulfate (PAPS), is transferred to a substrate.  Sulfoconjugation of THs is an alternative 
metabolic pathway that enhances enzymatic deiodination and facilitates their biliary and 
urinary excretion.  The TH-sulfate conjugate is rapidly deiodinated by type I deiodinase 
through successive deiodinations of the tyrosyl (inner) and phenolic (outer) rings, releasing 
iodine into the circulation for reutilization by the thyroid.  Sulfated conjugates are rapidly 
cleared in rats when deiodinase activity is inhibited.  TH sulfation is also thought to serve as 
a reservoir from which unconjugated hormone can be liberated through sulfatases in tissues 
or in intestinal bacteria (Hazenberg et al., 1988;  Kung et al., 1988).   
Because of their significance in xenobiotic metabolism and hormone metabolism, it 
has become important to understand the regulation of SULTs by nuclear receptors.  SULTs 
are regulated by AhR, CAR and PXR (Sonoda et al., 2002;  Saini et al., 2004); however, 
unlike UGTs, prototypical nuclear receptor activators may not markedly induce SULTs in 
rodents (Alnouti and Klaassen, 2008).  Human and rat SULTs catalyze THs though studies 
show significant species differences in SULT activity.  For example, even though there is an 
80% amino acid sequence homology between human and rat SULT1A1 (Yamazoe et al., 
1994;  Weinshilboum et al., 1997), human SULT1A1 catalyzes THs while the rat isoform 
does not.  Human SULT1A1 was also identified as a low Km sulfotransferase with similar 
Kms and TH substrate specificities as human hepatic and renal sulfotransferases (Visser et al., 
1998) (Kester et al., 1999).  This correlation between human SULT1A1 and sulfotranserase 
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activities toward THs suggests that human SULT1A1 is a prominent sulfotransferase in liver 
and kidney. 
 
C.4.4. Transporters 
Several AhR, CAR and PXR regulated transporters are known to actively transport 
glucuronides and/ or THs.  These comprise major efflux transporters in the ATP binding 
cassette (ABC) gene family, including multidrug resistance-associated proteins (MRPs), 
multidrug resistance proteins (MDRs).  There is also increasing evidence that uptake 
transporters such as, organic anion transport protein (OATP), and monocarboxylate 
transporter (MCT) are important in the intracellular access to THs for metabolism (Friesema 
et al., 1999;  Jansen et al., 2005).  There is a correlation between induction of hepatic UGTs 
(Ugt1a1), multidrug resistance protein-associated protein (Mrp2), and organic anion 
transporting proteins (Oatp1 and Oatp2) mRNA levels, with decreases in serum TH 
concentrations in treated with rats treated with 4-(3-pentylamino)-2, 7-dimethyl-8-(2-methyl-
4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (DMP 904)(Wong, et al., 2005;  Lecureux et 
al., 2009).  There are indications that multidrug resistance proteins (MDRs) are important in 
TH efflux (Mitchell, et al., 2005).  These studies indicate that active transport along with 
glucuronidation and altered serum binding are possibly involved in TH decreases.  
Cellular entry is required for TH metabolism; therefore, transport can determine the 
availability of THs in tissues.  Na+/taurocholate-cotransporting polypeptide (NTCP) 
,expressed only in liver, and the Na+-independent) organic anion transporting polypeptides 
(OATPs), expressed in liver kidney and brain, are major influx transporters of thyronines and 
their metabolites in humans and rats (Hagenbuch, 1997;  Kullak-Ublick, 1999).  Studies 
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using oocytes injected with human and rat NTCP or OATP mRNA, observed a significant 
uptake of thyronines (Friesema, et al., 1999).  Conversely, rat hepatocytes incubated with a 
transport-blocking antibody resulted in a decrease clearance of the iodothyronines from the 
media and iodide into the media, confirming that active transport is essential to the uptake 
and metabolism of THs (Hennemann et al., 1986).  De Jong et al., (de Jong et al., 1993) 
demonstrated that Ouabain, a Na+ gradient inhibitor, reduces the amount of T4 taken up into 
human hepatocytes and reduces the amount of iodide cleared into the media.  Together, these 
studies indicate that TH transport is rate limiting for subsequent metabolism and suggest that 
transporters may serve a regulatory role in bioavailability and metabolism. 
 
D. Thyroid Hormone Disruption 
 
D.1. Xenobiotics and Hepatic Thyroid Hormone Metabolism 
Although xenobiotics can disrupt TH homeostasis by directly disrupting the functions 
of the thyroid, increases in extrathyroidal metabolism are also involved in facilitating 
changes in TH homeostasis.  As a major site of xenobiotic metabolism, the liver is important 
in metabolism of THs in humans and rodents.   
Xenobiotics decrease serum TH concentrations through hepatic mechanisms 
(McClain, et al., 1989;  Liu, et al., 1995) and activators of AhR, CAR and PXR consistently 
affect TH homeostasis (Kretschmer and Baldwin, 2005;  Qatanani et al., 2005).  PB and 
PCN, through activation of CAR and PXR respectively, induce rat hepatic microsomal 
enzymes, such as UGTs (Barter and Klaassen, 1992;  Vansell and Klaassen, 2001;  Vansell 
and Klaassen, 2002a).  In vivo studies in rats also show that PB and PCN induce the biliary 
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elimination of T4-glucuronides (Oppenheimer, et al., 1968;  McClain, et al., 1989); 
confirming that enzyme inducers mediate the increase in biliary elimination of THs via the 
induction of hepatic metabolizing enzymes.   
 
D.2. Animal to Human Extrapolation 
There is data supporting the induction of hepatic metabolism by which xenobiotics 
decrease circulating TH concentrations in rats; however, the mechanisms in humans are 
unclear (Table 3).  Specifically, PB induces CYP2B enzymes in rat and human hepatocytes, 
implicating CAR as a modulator of effects on circulating TH concentrations (Barter and 
Klaassen, 1994;  Madan et al., 2003).  While PB decreases serum TH concentrations in 
humans and rats (McClain et al 1989, Benedetti et al., 2005) only the increased biliary 
elimination of T4-glucuronide has been observed in rat models. 
Although several studies show that UGT1A1 and UGT1A3 are important in hepatic 
metabolism of T4, Tong et al., (2007) demonstrated that UGT activities toward THs were 
higher in mouse and rat liver microsomes as compared to human, suggesting that UGTs may 
play a more significant role in the metabolism of THs in rodents than in humans.  
Conversely, sulfotransferase may be more important in the metabolism of THs in humans.  
SULT1E1 conjugates THs in humans, yet not in rats (Kester et al., 1999; Kester et al., 2003).  
This divergence in substrate specificity between the species, suggests that sulfation may be 
more important in TH metabolism in humans than in rats.  In general, human hepatic SULTs 
have lower Kms than UGTs toward THs, suggesting that sulfation may play a more 
important role than glucuronidation in metabolism of THs in humans.  While hepatic UGTs 
and SULTs may be important in decreasing circulating TH concentrations, it is uncertain if 
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increased hepatic conjugation plays as large of a role as suspected.  For instance, studies 
using UGT1A-deficient Gunn rats exposed to PB or PCBs demonstrate that decreases in 
serum total T4 are not necessarily glucuronidation-dependent (Collins and Capen, 1980;  
Kato, et al., 2004).  Many studies have also reported the inconsistencies in hepatic T4-UGT 
activity and decreases in circulations in which the degree of T4 decreases do not always 
correlate with increases in T4-UGT activity (see Table 3).  Because of these inconsistencies, 
it is uncertain how relevant extrathyroidal TH disruption in animals is to humans. 
Reports indicate that hepatic transport may also be responsible for decreases in serum 
TH concentrations.  For example, correlations between the mRNA induction of hepatic 
UGTs and hepatic uptake (Oatp1 and Oatp2) transporters mRNA levels, with decreases in 
circulating TH concentrations were observed (Wong, et al., 2005;  Lecureux, et al., 2009).  
Wong et al. (Wong, et al., 2005) reported a greater biliary elimination of parent T4 versus 
glucuronide conjugated T4 following exposure to 4-(3-pentylamino)-2, 7-dimethyl-8-(2-
methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (DMP 904) along with an increase in 
hepatic Mrp2 mRNA levels in rats.  DMP 904 also induced hepatic CYP2B1 and CYP3A1 
mRNA levels in rats, suggesting that it acts as an activator of CAR or PXR.  Together these 
studies show that hepatic uptake and efflux transporters play a role in increasing the 
metabolic availability of T4 as well as facilitating the clearance of unconjugated hormone.  
TH homeostasis depends greatly on transport by serum binding proteins.  In rats, TH is 
largely bound to transthyretin (TTR) while in humans; TH is mostly bound to thyroid binding 
globulin (TBG).  The differences in protein binding may cause THs in rats to be more 
susceptible to hepatic metabolism.  Binding to a higher affinity binding protein such as TBG 
may protect THs from metabolic degradation; therefore, species differences in serum binding 
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may be responsible for the sensitivity of rats to TH toxicants.  Although hydroxylated PCBs 
and PBDEs have been shown to bind to human and rodent TTR ex vivo, there are fewer 
compounds that compete for T4-TBG binding (Cheek et al., 1999;  Hallgren and Darnerud, 
2002).  This suggests that TH displacement from its binding protein may not necessarily be 
of concern for humans. 
 
E. Rationale for the Proposed Project 
 
TH concentrations are regulated by not only the hypothalamus-pituitary–thyroid axis, 
but also hepatic metabolism, and elimination; therefore, the liver is essential to the 
extrathyroidal regulation of THs.  Decreases in circulating TH concentrations by the 
induction of microsomal enzyme inducers have been linked to the increase in TH metabolism 
and biliary elimination (Barter and Klaassen, 1992;  Liu, et al., 1995;  Kolaja and Klaassen, 
1998;  Hood, et al., 1999;  Hood and Klaassen, 2000a;  Hood and Klaassen, 2000b;  Hood, et 
al., 2003).  The role of microsomal enzyme inducers on hepatic UGTs and their effects on 
circulating TH concentration have been thoroughly examined.  THs are not only 
glucuronidated but are also sulfated in the liver, for possible elimination into the bile.  
Although xenobiotics can cause decreases in circulating THs, xenobiotics do not necessarily 
induce hepatic UGTs to the same degree; therefore, it is important to determine why this 
occurs.  Attempts have been made to examine the hepatic metabolism of THs in rats and 
humans following xenobiotic exposures, but an investigation of species differences and what 
role the liver plays still need to be explored.  
Several studies show that primary hepatocytes are useful for examining the metabolic 
profiles of drugs (Bort et al., 1996a;  Bort et al., 1996b;  Hewitt et al., 2001;  Ponsoda et al., 
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2001).  For example, Ponsoda et al. (Ponsoda, et al., 2001), correlated the metabolites of 
aceclofenac, an anti-inflammatory analgesic drug, found in human urine, with the metabolites 
formed in human hepatocytes supporting the use of hepatocytes to predict what happens in 
vivo.  Furthermore, hepatocytes express nuclear receptor and therefore respond to xenobiotics 
through the induction of metabolizing enzymes.  Hepatocytes also express membrane bound 
transporters, which can influence the intracellular concentration of compounds therefore; 
hepatocytes can be used to define the mechanisms by which AhR, CAR, and PXR agonists 
can alter TH metabolism and clearance.   
Decisions concerning risk assessment have been based on animal to human 
extrapolations; therefore in vivo-in vitro comparisons are very important in the decision 
process.  In vivo responses to toxicity usually involve multiple mechanisms and multicellular 
interactions.  However, by focusing on a single cell type, data from in vitro studies becomes 
invaluable in evaluating the assumptions of specific mechanisms of action between species in 
toxicity studies.  The evaluation of potential species differences in hepatic T4 metabolism and 
the effect AhR, CAR, and PXR activation have on T4 metabolism were examined the 
following aims 
 
Aim 1:  Compare T4 metabolic profiles and clearance in rat and human hepatocytes. T4 
is metabolized by deiodination, glucuronidation and sulfation in the liver of rats and humans. 
It has been hypothesized that glucuronidation is a key step in the metabolism of THs in rats, 
whereas in humans, there is some evidence that sulfation may play a more pertinent role.  
These potential species differences in T4 metabolism in may quantitatively influence hepatic 
clearance of THs.  In this study, the examination of metabolites formed following hepatic 
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thyroid hormone clearance will provide a better understanding of the differences between rat 
and human TH metabolism  
 
a. Establish a radiometric UPLC method for determining T4 metabolites (T4G, T4S, 
T3, rT3) in the media of hepatocytes.  
b. Compare clearance and metabolic profile by incubating T4 with rat and human 
hepatocytes. 
 
Aim 2:  Determine hepatic clearance and the metabolic profile of THs in rat and human 
hepatocytes following exposure to Ahr, CAR, and PXR agonists.  Metabolism plays a 
major role in the homeostasis of THs and because many xenobiotics can increase the 
metabolism of THs, it is important to understand the impact xenobiotics have on TH 
homeostasis.  A major pathway of TH metabolism in the liver is the conjugation of the 
hormones to glucuroinides or sulfates.  Uridine 5-diphosphate-glucuronosyltransferase 
(UGT) and sulfotransferase (SULT) mediate the conjugation of THs.  The activation of these 
AhR, CAR or PXR by xenobiotics can induce metabolizing enzymes (UGT and SULT).  The 
induction of UGTs and SULTs is thought to increase the metabolism and subsequent 
elimination of THs.  To examine differences in human and rat hepatic metabolism of TH, this 
study will analyze metabolic profiles and gene involved in the metabolism of xenobiotics and 
THs. 
a. Determine the effects of AhR, CAR, and PXR agonists (prototypical and 
environmental) on clearance and metabolic profiles of T4 in rat and human 
hepatocytes.  
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b. Examine mRNA expression of genes related to xenobiotic and thyroid hormone 
metabolism.  Correlate changes in mRNA expression with changes in the metabolic 
profile of T4 following exposure to AhR, CAR and PXR agonists. 
 
Aim 3:  Compare the effects BDE-47 on T4 metabolism in rats and metabolic profiles 
and clearance in rat and human hepatocytes.BDE-47, a CAR/PXR agonist, decreases T4 
serum concentrations in rodents. This decrease is thought to occur via: (1) the increase in 
hepatic T4 metabolism and (2) the competitive binding of BDE-47 with TH binding proteins. 
Hepatocytes are a dependable model for studying the induction of xenobiotics metabolizing 
enzymes. In these experiments an in vivo –in vitro comparsion is made betweenTo compare 
the effects of BDE-47 Hepatocytes are used in the in vitro-in vivo extrapolation of metabolic 
activity toward a number of drugs. (LeCluyse, 2001;  Hewitt et al., 2007). Using primary rat 
and human sandwich-cultured hepatocytes this study makes comparisons of T4 metabolism in 
response to nuclear receptor activation by BDE-47. The present study also compares the 
effects of BDE-47 on the genes involved in TH homeostasis in rat liver and hepatocytes. 
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Figure 1.1 Stucture of thyroxine (T4) and triiodothyronine (T3) 
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From (Bianco and Kim, 2006) 
Figure 1.2 Deiodinase conversion of thyroid hormones 
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Table 1.1 
 
Physiological differences in thyroid hormone parameters 
 
                                             Human                             Rat                         Reference 
a Mean of reference range of 60-140nM in adult humans 
  
TBG 
(Serum 
concentration) 
Present 
(0.02mg/ml) 
Not Present 
 (Wade et al., 1988) 
TTR 
(Serum 
concentration) 
Present 
(0.2mg/ml) 
Present 
(0.5mg/ml) 
(Benvenga and 
Robbins, 1998) 
T4 t1/2 (days) 5-9 0.5- 1 
(Capan, 2001;  
Bianco, et al., 2002) 
T3 t1/2 (days) 1 0.25 
(Bianco, et al., 
2002) 
Mean Serum T4 
(nM) 100.0
1,a 43.82 
1(Stockigt, 2003) 
2(Woody et al., 
1998) 
Mean Serum T3 
(nM) 1.9
1 0.92 
1(Stockigt, 2003) 
2(Woody, et al., 
1998) 
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Table 1.2  
 
Inconsistencies in serum T4 and T4-UGT activity 
 
     Chemical          Nuclear Receptor       T4-UGT             Serum T4                 Reference 
    Activity 
↑ = increase 
↓ = decrease 
↔ = no change 
 
 
β-NF AhR ↑ ↑ ↑ ↓ ↓ ↓ 
(Hood and 
Klaassen, 2000) 
 
3-MC AhR ↑ ↑ ↓ ↓ 
(Hood and 
Klaassen, 2000) 
 
PCB AhR/PXR ↑ ↑ ↓ ↓ ↓ 
(Hood and 
Klaassen, 2000) 
 
PCN PXR ↑ ↑ ↓ ↓ 
(Hood and 
Klaassen, 2000) 
 
PB CAR ↑ ↑ ↓ ↓ ↓ 
(Hood and 
Klaassen, 2000) 
 
DE 71 AhR/CAR/PXR ↑↑ ↓ ↓ 
(Zhou et al., 
2002) 
 
BDE 47 CAR ↔ ↓ 
(Richardson et 
al., 2008) 
 
PB/PCB 
(Gunn Rat) AhR/CAR/PXR ↔ ↓ ↓ ↓ 
(Kato et al., 
2007) 
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Table 1.3 
 
Key events in thyroid hormone disruption and relevance to humans 
 
      Key Event               Evidence in Rats       Evidence in Humans       Reference 
 
  
Nuclear Receptor 
activation (CAR) 
 
Yes 
In vivo and in vitro 
 
Yes 
In vitro 
 
(Barter and 
Klaassen, 1994;  
Hood and Klaassen, 
2000a) 
 
Hepatic UGT 
Induction 
 
Yes 
In vivo and in vitro 
 
Yes 
In vitro 
 
(Barter and 
Klaassen, 1994;  
Hood and Klaassen, 
2000a) 
 
Increased TH or 
Conjugated TH 
Biliary Elimination 
 
Yes 
In vivo and in vitro 
 
No Data 
 
(Kato et al., 2005;  
Wong, et al., 2005) 
 
Hepatic Transporter 
Induction 
 
Yes 
In vivo 
 
No Data 
 
(Ribeiro et al., 
1996;  Mitchell, et 
al., 2005;  Wong, et 
al., 2005) 
 
TTR Binding 
 
Yes 
Ex vivo; 
hydroxylated 
compounds bind to 
rTTR1 
 
Yes 
Ex vivo; 
hydroxylated 
compounds bind to 
hTTR 
 
(Cheek, et al., 
1999);(Hallgren and 
Darnerud, 2002;  
Meerts et al., 2002) 
 
TBG Binding 
 
No Data 
(TBG not present) 
 
Yes 
Ex vivo 
 
(Cheek, et al., 
1999) 
 
Serum TH Decrease 
 
Yes 
In vivo 
 
Yes 
In vivo 
 
(Cavlieri et al., 
1973;  Brucker-
Davis, 1998) 
 
Increased hepatic TH 
uptake/accumulation 
Yes 
In vivo No Data (Kato, et al., 2007) 
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 CHAPTER 2 
 
IN VITRO METABOLISM OF THYROXINE BY RAT AND HUMAN 
HEPATOCYTES1 
 
A. INTRODUCTION 
The liver has a major influence on plasma concentrations of thyroid hormones (THs) 
and their metabolites (Ohnhaus and Studer, 1983;  Malik and Hodgson, 2002). Deiodinase I 
(DI), located primarily in the liver, is responsible for the extrathyroidal conversion of the 
prohormone, thyroxine (T4) to its biologically active form 3,3’,5-triiodothyronine (T3). DI is 
also critical in the inactivation of T3 to 3,3’,5’-triiodothyronine (rT3) and 3,3’-
diiodothyronine (T2). In the liver, THs also are metabolized to either glucuronide or sulfate 
conjugates and the resulting conjugates are excreted through the bile duct into the intestine. 
A portion of the conjugated hormone is hydrolyzed in the intestine and consequently the free 
hormones are reabsorbed into the systemic circulation while the conjugated portion is 
eliminated in the feces. 
There are species differences in the rates of these reactions of TH conjugation.  Tong 
et al., (2007) demonstrated that uridine diphosphate glucuronosyltransferase (UGT) activity 
toward T3 was higher in mouse and rat liver microsomes than human liver microsomes and  
___________________ 
1Richardson,V.M., Ferguson, S.S., Sey, Y.M., DeVito, M.J. (submitted) Xenobiotica 
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activity toward T4 is higher in mouse liver microsomes compared to rat and human liver 
microsomes. This suggests that UGTs may play a more significant role in the metabolism of 
THs in rodents than in humans. In contrast, the literature suggests that sulfotransferase 
(SULT) may be more important in the metabolism of THs in humans, as SULT1E1 
conjugates THs in humans, but not in rats (Kester, et al., 1999;  Kester et al., 2003). These 
studies suggest that regulation of serum TH concentrations involve both hypothalamus-
pituitary–thyroid (HPT) axis and hepatic metabolism and elimination. 
Hepatic uptake and efflux transporters contribute to the transport of endogenous and 
exogenous compounds from the systemic circulation to bile (Arias et al., 1993). Although it 
was once thought that THs traversed the plasma membrane by diffusion (Robbins and Rall, 
1960) it is now known that THs and their conjugates are also actively transported. 
Specifically, multidrug resistance-associated proteins (MRPs) and multidrug resistance 
proteins (MDRs) play a major role in efflux transport of THs (Friesema, et al., 1999;  
Mitchell, et al., 2005). There is also evidence that uptake transporters such as organic anion 
transporting polypeptides (OATPs), and monocarboxylate transporters (MCTs) are important 
in the intracellular accumulation of THs (Friesema, et al., 1999;  Jansen, et al., 2005). 
Because cellular entry is required for TH metabolism, it is likely that active transport is rate 
limiting with respect to bioavailability and metabolism of THs (de Jong, et al., 1993;  
Friesema, et al., 1999). 
Xenobiotics can alter TH homeostasis at the point of its biosynthesis, release, 
transport, metabolism and excretion. A number of environmental chemicals decrease 
circulating TH concentrations through the induction of xenobiotic metabolizing enzymes 
resulting in increases in TH metabolism and biliary elimination (Barter and Klaassen, 1992;  
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Liu, et al., 1995;  Kolaja and Klaassen, 1998;  Hood, et al., 1999;  Hood and Klaassen, 
2000a;  Hood and Klaassen, 2000b;  Hood, et al., 2003). For example, phenobarbital (PB), 
through the activation of the constitutive androstane receptor (CAR), induces rat hepatic 
xenobiotic metabolizing enzymes (XMEs), such as UGTs and increases the biliary 
elimination of T4 or T4-glucuronides (Oppenheimer, et al., 1968;  McClain, et al., 1989;  
Barter and Klaassen, 1992;  Vansell and Klaassen, 2001;  Vansell and Klaassen, 2002a). 
While PB decreases serum TH concentrations in humans and rats (McClain, et al., 1989;  
Benedetti et al., 2005), mechanistic studies are only available for rats. A PB-like inducer, 
2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB 153), also decreases serum T4 concentrations and 
induces hepatic microsomal T4-UGT activity in rats (Craft et al., 2002;  He et al., 2011). 
PCB 153 is a major component of Aroclor 1254 and is one of the PCBs with the highest 
human exposures (NHANES, 2012). Exposure to PCB 153 is associated with TH decreases 
in humans (Hagmar et al., 2001), but in vivo induction of hepatic metabolizing enzymes by 
PCB 153 in humans has not been demonstrated. In vitro, PCB 153 induces Ugt2b1 mRNA in 
rat hepatocytes; however, effects on TH metabolism were not determined (Ganem et al., 
1999). Overall, xenobiotics that induce hepatic UGTs result in a concomitant decrease in 
circulating TH concentrations in rodents; however, the mechanism by which TH disruption 
occurs in humans is unclear. 
To our knowledge, this is the first report to characterize the utility of sandwich-
cultured hepatocytes (SCH) in studying TH metabolism. This study aims to compare 
pathways involved in the hepatic metabolism of T4 in rats and humans, by examining the 
metabolic profiles of T4 following incubation with fresh SCH from rats and humans. 
Parameters for analysis include comparative examinations of the metabolic profiles in rat and 
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human hepatocytes over incubation time, T4 concentrations, culture days and following PCB 
153 treatment. T4 accumulation with hepatocytes was also explored to provide a better 
understanding of species differences in intercellular availability and hepatic metabolism of 
T4.  
 
B. MATERIALS AND METHODS 
 
Chemicals 
L-thyroxine (T4) and phenobarbital were purchased from Sigma-Aldrich Co. (St. 
Louis, MO). PCB 153 was purchased from Radian Corporation (Austin, TX). [125I]-T4, -T3, 
and -rT3, (116 Ci/mmol) were purchased from Perkin Elmer Life Sciences Inc. (Waltham, 
MA) and were purified to >98% immediately before use with Sephadex LH-20 (Sigma-
Aldrich) as described by Rutgers et al. (1989). All other reagents were of the highest grade 
commercially available. 
 
T4 glucuronidation assay 
T4 glucuronidation activity was evaluated in liver and intestinal microsomes from rat 
and humans (Zhou, et al., 2001) based on a previously published method (Visser et al., 
1993b). Microsomes were obtained from CellzDirect or Xenotech (Table 2.2). A 100 µl 
aliquot of microsomes (2 mg protein per ml 1M Tris/HCl buffer pH 7.4) was incubated at 
37°C with 4µM of cold T4, [125I]-T4 (100,000 cpm), 0.1mM 6-n-propyl-2-thiouracil (PTU), 
alamethicin (50 µg/mg microsomal protein) and 5mM uridine diphosphoglucuronic acid 
(UDPGA) for 1 hour. Sample blanks (without UDPGA) were analyzed concurrently.  The 
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reaction was stopped with methanol followed by centrifugation and mixing the supernatant 
with 0.1M HCl.  T4-glucuronide (T4G) was separated by chromatography using lipophilic 
Sephadex LH-20 columns and eluent was measured for radioactivity as previously described 
(Zhou, et al., 2001). 
 
T4 sulfation assay 
Rat and human liver cytosol were assayed for SULT activities as previously described 
(Szabo et al., 2009). Liver cytosols were obtained from CellzDirect (Table 2.2). 20 µg 
protein/ml of liver cytosol in the presence or absence (blank) of 50µM 3’-phosphoadenosine 
5’-phosphosulfate (PAPS; Sigma) in 0.2 ml of 0.1M phosphate (pH 7.2) and 2mM EDTA 
(Sigma) (Kaptein et al., 1997) was incubated with 4µM of T4, and 100,000 cpm of [125I]-T4 
for 30 min at 37°C.  The reactions were applied to 1 ml of lipophilic sephadex (Sigma) LH-
20 minicolumns (Superlco) equilibrated with 0.1M HCl. Iodine and T4-sulfate (T4S) were 
eluted with 2 X 1 ml of 0.1M HCl, and 6 X 1 ml of ethanol/water (20/80, vol/vol), 
respectively. Fractions were collected and 1 ml of the T4S fraction was quantitated by gamma 
spectroscopy (Perkin-Elmer Life Sciences Inc., Waltham, MA).  
 
Hepatocyte culture  
Fresh primary sandwich-cultured rat hepatocytes (SCRH), isolated from male 
Sprague-Dawley rats, and sandwich-cultured human hepatocytes (SCHH) in 24-well plates 
were obtained on culture day 2 from Life Technologies (Durham, NC) and maintained in 
Williams’ E medium with 0.1% dimethyl sulfoxide (DMSO) including Hepatocyte 
Maintenance Supplement (Life Technologies) which contains 0.1µM dexamethasone and 
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proprietary concentrations of penicillin-streptomycin, ITS+ (insulin, transferrin, selenium 
complex, BSA and linoleic acid), GlutaMAX™ and HEPES. Cultures were maintained for 
up to 6 days with medium replaced every 24 hours. Human donor demographics can be 
found in Table 2.1.  
 
Thyroxine and thyroxine metabolite separation, identification and quantitation from medium 
and hepatocytes. 
All medium samples were dried under N2 and then reconstituted with 40µl mobile 
phase consisting of 18% acetonitrile in 0.02M ammonium acetate (pH=4).  After addition of 
mobile phase, samples were centrifuged at 10,000 x g for 5 minutes at room temperature and 
the supernatants were placed in vials for UPLC analysis. UPLC equipped with a C18 – 2.1 x 
50mm x 1.7µm (Waters Corp.; Milford, MA) resolution column and fraction collector were 
used for separation and identification of T4 and T4 metabolites. Gradient elution was 
performed using a modified version of a previously established method by Rutgers et al. 
(1987) with a 16 minute gradient of 18-40% acetonitrile in 0.02M ammonium acetate 
(pH=4). Solvent flow rate was 0.4ml/min and 0.25 minute fractions were collected in test 
tubes. Peaks were then identified by analyzing collected fractions for radioactivity by gamma 
spectroscopy. Retention times for T4, T3, rT3, T4-glucuronide (T4G), and T4-sulfate (T4S) 
were determined using synthetic and biosynthetic compounds. Peaks for T3 and rT3 were 
often inseparable; therefore these peaks were added together and are presented in this study 
as T3+rT3. Figure 2.1 shows the results of a typical UPLC separation from the collected 
fractions for T4, T4G, T4S, T3, and rT3 from medium of SCRH. Protein content of the 
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hepatocytes was determined using a protein assay kit with bovine serum albumin as a 
standard (Bio-Rad Laboratories, Hercules, CA). 
Commercially available [125I]-T4, -T3, and -rT3 were used as references to determine 
retention times using UPLC with fraction collections.  T4-glucuronide and -sulfate conjugates 
were not commercially available, therefore T4G and T4S references were prepared using 
recombinant human UGT1A8 from BD Biosciences (San Jose, CA) and recombinant human 
SULT1E (US Biologicals, Swampscott, MA), respectively.    
T4G was synthesized by incubating 4µM T4 and 100,000 cpm of [125I]-T4 for 60 min 
at 37ºC with human recombinant UGT1A8 (BD Biosciences, San Jose, CA) (final 
concentration, 2 mg UGT1A8 protein/ml) in the presence or absence (blank) of 5mM uridine 
5′-diphosphoglucuronic acid (UDPGA) in 0.2 ml (total reaction volume) 75mM Tris-HCl 
(pH 7.8), 7.5mM MgC12 with alamethicin (50 µg/mg UGT1A8 protein). The reactions were 
stopped by the addition of 0.2 ml ice-cold methanol, and after centrifugation (10,000 x g for 
5 minutes at 4°C), supernatant was removed. The supernatant was then dried under N2 at 
40°C and prepared for UPLC analysis as mentioned above. T4G peaks were confirmed by β-
glucuronidase digestion (van der Heide et al., 2002). 
Recombinant human SULT1E (US Biologicals, Swampscott, MA) was used to 
synthesize T4S references.  T4S was synthesized by incubating 4µM T4 and 100,000 cpm 
[125I]-T4 incubated overnight at 37ºC with SULT1E (final concentration, 0.4 mg SULT1E 
protein /ml) in the presence or absence (blank) of 400µM adenosine 3′-phosphate 5′-
phosphosulfate (PAPS; Sigma-Aldrich) in 0.2 ml (total reaction volume) 0.1M potassium 
phosphate (pH 7.2), 2mM EDTA.  The reactions were stopped by the addition of 0.8 ml 
0.1M HCl.  Samples were then centrifuged at 10,000 x g for 5 minutes at 4°C. Supernatant 
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was collected, dried under N2 at 40°C, and prepared for UPLC analysis as mentioned above. 
T4S peaks were confirmed by acid solvolysis (van der Heide, et al., 2002). 
 
Comparisons of T4 metabolism across days in culture 
Fresh SCRH and SCHH were treated on culture day 3, 4, 5, or 6 with 0.05µM (rat) or 
0.1µM (human) [125I]-T4 (500,000 cpm/well) for 24 hours, after which media were collected 
and analyzed for T4 metabolites using the methods described above. Cells were washed twice 
with 0.5 ml/well of ice-cold PBS buffer.  Hepatocytes were collected by adding 0.5ml/well of 
0.1M NaOH and analyzed for protein content.  
 
T4 accumulation  
SCRH or SCHH were used to measure [125I]-T4 association over time. Hepatocytes 
were incubated with supplemented Williams’ E medium, as mentioned above, containing 
0.0005µM (5000 cpm) per well of [125I]-T4 for up to 5 minutes on culture day 6. After 
incubation, media were collected and cells were washed twice with 0.5 ml/well of ice-cold 
PBS buffer. After washing, hepatocytes were collected by adding 0.5ml/well of 0.1M NaOH. 
125I-derived radioactivity in collected media and hepatocytes were analyzed by gamma 
spectroscopy.  
 
Effects of incubation time on T4 metabolite levels and T4 depletion from medium 
Fresh SCRH and SCHH were treated on culture day 6 with 0.05µM (rat) or 0.1µM 
(human) [125I]-T4 (500,000 cpm/well) for up to 24 hours. After 4, 8, 12, or 24 hours, media 
and hepatocytes were collected. Mass balance was determined by preparing and analyzing 
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media and hepatocytes for T4 and T4 metabolites using the methods described above. 
Hepatocytes were collected and analyzed for protein content. 
 
Effects of T4 concentration on metabolite levels 
Fresh SCRH and SCHH were treated on culture day 6 with 0.05, 0.1, 5, 50, or 100 
µM of [125I]-T4 (500,000 cpm/well) in supplemented Williams’ E medium (0.5ml) for 24 
hours. Time course studies were performed using 0.05µM (rat) or 0.1µM (human) [125I]-T4. 
After 24 hours, medium was collected, prepared, and analyzed for T4 metabolites using the 
methods described above. Hepatocytes were collected and analyzed for protein content. 
 
Effects of PCB 153 on T4 metabolite levels 
Stock solutions of PCB 153 were diluted in DMSO and added to Williams’ E medium 
to a final DMSO concentration of 0.1%. On culture day 3, fresh SCRH and SCHH were 
exposed for 72 hours to the DMSO vehicle (0.1%) or PCB 153 (30µM). After 72 hours, 
medium was removed and replaced with Williams’ E medium containing physiological 
concentrations [0.05µM (rat) or 0.1µM (human)] of [125I]-T4 (500,000 cpm/well) for 24 
hours. Medium was collected, prepared and analyzed for T4 metabolites by the method 
described above. Hepatocytes were collected and analyzed for protein content. 
 
Data analysis  
Linear and nonlinear regression analyses were used to assess the relationship between 
[125I]-T4 accumulation in hepatocytes and appearance of T4 metabolites in medium and 
disappearance of T4 from the medium. A one-phase association exponential equation 
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Y=Y0 + (Plateau-Y0)*(1-exp (-K*x)), 
was fit to the accumulation data  where plateau is the Y value at infinite time and half time is 
the time it takes to reach half the plateau and is computed as ln(2)/K. A one-phase decay 
exponential equation,  
Y= (Y0-Plateau)*exp (-K*X) +Plateau, 
was fit to the [125I]-T4 disappearance data where the depletion rate constant (K) was 
determined. The half-life (t1/2) of all reactions was then determined as ln(2)/K. Using the rate 
of [125I]-T4 depletion, intrinsic clearance (CLint) estimates were determined as described by 
Obach (1997) using the equation, 
CLint, in vitro=KV/N, 
expressed as μl/min/106 cells, where K is ln(2)/ t1/2, V is the incubation volume and N is the 
number of hepatocytes used.  Human hepatocyte CLint (µl/min/106 cells) was scaled to in 
vivo CLint (ml/min/kg body weight) using the physiological parameters, human liver weight 
(22 g/kg body weight (and hepatocellularity (120 X 106 cells/g of liver) (Bayliss et al., 1999;  
Soars et al., 2002). Rat hepatocyte CLint (µl/min/106 cells) was scaled to in vivo CLint 
(ml/min/kg body weight) using the physiological parameters, rat liver weight (40 g/kg body 
weight (and hepatocellularity (120 X 106 cells/g of liver) (Bayliss, et al., 1999). 
Intergroup comparisons of control versus PCB 153 for SCRH were determined using 
a t-test.  GraphPad Prism 5.0 was used to analyze all data, (GraphPad Software San Diego, 
CA). The level of probability of statistical significance was p < 0.05. 
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C. RESULTS 
 
Glucuronidation of T4 in rat and human liver and intestinal microsomes  
To begin to understand variability in human liver metabolism of T4, human liver 
microsomes were obtained both pooled and individual, from two different suppliers (Table 
2.2).  T4G activity in these microsomes range approximately 5-fold, with the highest activity 
found in the pooled microsomes obtained from Xenotech and the lowest from an individual 
donor from Invitrogen (Table 2.3).  Compared to the pooled rat microsomes, T4G activity 
was 2 to 17.5 times lower in the human microsomes.  The T4G activity in the pooled human 
intestinal microsomes was 3 to 15 times higher than the T4G activity in the human liver 
microsomes. Compared to the pooled rat liver microsomal sample, the human liver 
microsomal samples were between 3 and 15 times lower for T4G activity (Table 2.3).  T4 
sulfation was also determined in rat and human liver cytosols.  T4 sulfation activity was 
approximately 10 times greater compared to T4G activity based on mg protein assayed and 
ranged from 4.0 to 4.8 pmol/mg protein/minute.  The pooled rat cytosol had a similar T4 
sulfation activity compared to the human cytosol (Table 2.3).   
 
T4 and T4 metabolite separation, identification and quantitation 
Retention times of commercially available [125I]-T4, -T3, and -rT3 were determined to 
be 12.75, 10.25, and 10.50 min, respectively. Conjugated metabolites of T4 were not 
commercially available; therefore T4G and T4S were biosynthesized using recombinant 
human UGT1A8 and SULT1E, respectively. Retention times for T4G and T4S were 
determined to be 5.50 and 8.25 min, respectively. Figure 2.1 illustrates the separation of T4 
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and its metabolites in medium of SCRH incubated with 5µM [125I]-T4 for 24 hours at 37ºC. 
The peaks correspond to the retention times of reference standards for T4, T3, rT3, T4G and 
T4S. 
 
Comparisons of T4 metabolism across days in culture in SCRH and SCHH 
Physiological serum concentrations of T4 in rat (0.05µM) and human (0.10µM) were 
used to measure changes in metabolite levels in media of SCRH and SCHH over days in 
culture. T4G and T4S were not detected in cell lysates, but were present in media. Figure 
2.2A shows T4G accumulation in the medium increased in SCRH from culture day 3 to 4 and 
plateaued on days 4 through 6. T4G in the medium of SCHH decreased until undetectable at 
day 5 (Hu8096) and day 6 (Hu8092). T4S reached maximum at day 4 and day 5 in media 
from SCHH and SCRH, respectively (Figure 2.2B). By day 5 and 6, similar amounts of T4S 
were found in the media of SCRH and SCHH. T3+rT3 levels plateaued between days 4 and 6 
in the medium of SCRH (Figure 2.2C). In medium of Hu8092, T3+rT3 reached a maximum at 
day 5 and plateaus at day 6. T3+rT3 in the medium of Hu8096 plateaued between culture days 
4 and 6. Overall, these data show that metabolic capacity differed quantitatively over culture 
days between species and between human donors, creating a challenge when examining 
species differences for TH metabolite appearance in this culture system. Given that intact 
canaliculi with increasing efflux transporter activity has been reported over culture days in 
SCH (Hoffmaster et al., 2004) and that biliary transport is a component of TH association 
and TH  metabolite elimination (Friesema, et al., 1999;  Mitchell, et al., 2005), we decided to 
add [125I]-T4 to hepatocytes on culture day 6 for all subsequent experiments. 
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T4 accumulation in SCRH and SCHH 
Cellular accumulation of T4 was evaluated by measuring radioactive [125I]-T4 from 1 
to 30 minutes on culture day 6 (Figure 2.3). Preliminary studies showed [125I]-T4 did not 
significantly bind to BD Matrigel® (BD Biosciences) or plastic ware (data not shown). [125I]-
T4 cellular associated radioactivity increased over time, but appeared to plateau between 10 
and 20 minutes. An exponential one-phase association model fit to each set of data indicates 
[125I]-T4 accumulation into SCRH was significantly different from accumulation into SCHH 
(F=5.46 (3,24); p=0.0053). [125I]-T4 accumulation in SCHH was greater and more rapid than 
in SCRH. The accumulation into the SCHH plateaued at approximately 11.7 ± 3.9% of the 
[125I]-T4 dose. In SCRH, the cellular accumulation plateaued at 5.5 ± 0.9%. Differences were 
also observed in [125I]-T4 accumulation half times, where the halftime of the SCRH was 6.1 
min and the SCHH was 16.0 min.  To understand the accumulation at the early time points, a 
linear model was used to fit the data from 1 to 5 minutes.  There was no significant 
difference in the accumulation of T4 in rat and human hepatocytes based on a linear model of 
the early time points (F=0.35 (1,21); p=0.56).   
 
Effects of incubation time on T4 metabolite concentrations in SCRH and SCHH 
On day 6 of culture, metabolite levels were measured in the media of SCRH and 
SCHH at 4, 8, 12 and 24 hours following exposure to physiological rat and human serum 
concentrations of T4. In medium of SCRH, T4G increased over time (Figure 2.4A). In rat 2, 
T4G peaked at 12 hours while in rat 1, T4G levels increased in a linear manner (p < 0.001; 
r2=0.98) with a slope of 0.5 ± 0.05 pmol/hr/mg cellular protein.  T4G appearance in the 
medium of SCHH was only detected at 12 and 24 hours for Hu1362 and at 24 hours in the 
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medium of Hu1364.  The amounts of T4G were much higher (13 times) in medium of SCRH 
as compared to SCHH. In SCRH medium, T4S was only detected at 24 hours (Figure 2.4B). 
In medium of Hu1362, T4S was first detected by 8 hours but there was no consistent time 
related trend.  In Hu1364, T4S increased linearly (p < 0.05; r2= 0.90) with time starting at 4 
hours at a rate of 0.6 ± 0.2 pmol/hr/mg cellular protein.   
In the medium of SCRH, there were no consistent time related trends for T3+rT3 
concentrations for either rat culture (p >0.05; r2=0.18).  In medium of Hu1362, T3+rT3 
concentrations decreased significantly in a linear manner (p < 0.03; r2=0.94) between 4 to 24 
hours. T3+rT3 concentrations decreased over time, but not in a linear manner (p >0.08) in 
Hu1364 (Figure 2.4C).   
The percent of [125I] radioactivity for T4 decreased over time as metabolites increased 
in the media of SCRH and SCHH. T4 was consistently detectable in SCHH (Table 2.4) and 
SCRH (Table 2.5) at all time points tested.  By 24 hours, a larger (2 times) percentage of T4 
accumulated in SCHH compared to SCRH. The percentage of T4 increased over time in 
SCHH, but not in a linear manner (p>0.14). T4 in the medium of SCHH decreased; however, 
not in a linear manner (p >0.09). T4G and T4S were not detectable in SCRH or SCHH. 
Initially at 4 hours, T3+rT3 were detectable in SCRH but not in SCHH.  At 24 hours, T3+rT3 
were detectable in SCHH and not detectable in SCRH.   
 
Intrinsic clearance of T4 from the media of SCRH and SCHH. 
The clearance of T4 from the media of SCRH and SCHH was evaluated between 4 
and 24 hours.  T4 depletion profiles are shown in Figure 2.5, where the percent of T4 
remaining in media over time is shown for SCRH (A) and SCHH (B). A one-phase decay 
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model was used to estimate CLint in both SCRH and SCHH.  In SCRHs, T4 concentrations 
significantly decreased from 4-24 hours.  CLint in the hepatocytes of rat 1 and rat 2 were 1.08 
and 0.75 µl/min/106 cells, respectively. In humans, T4 concentrations also significantly 
decreased from 4-24 hours.  CLint for Hu1362 and 1364 were 0.56 and 0.62 µl/min/106 cells, 
respectively. 
 
Effects of T4 concentration on metabolite levels 
 T4 metabolite levels in media of SCRH (Figure 2.6A) or SCHH (Figure 2.6B) were 
examined following a 24 h incubation with increasing concentrations of [125I]-T4 on culture 
day 6. Metabolites levels increased with increasing [125I]-T4 concentrations in the media of 
SCRH and SCHH. At all concentrations, the rank order of metabolites in the medium of 
SCRH was: T4G>T3+rT3>T4S.  T4G was undetectable at lower concentrations of [125I]-T4 in 
medium of SCHH. The rank order of metabolites in the medium of SCHH was T3+rT3>T4G 
≈T4S. 
 
Effects of PCB 153 on T4 metabolite levels and clearance 
To study the effects of hepatic enzyme inducers on T4 metabolism in hepatocytes, 
PCB 153 was used as a prototype environmental chemical. Following exposure to PCB 153 
(72 hours), SCRH and SCHH were treated with physiological rat and human serum 
concentrations of T4 for 24 hours. Treatment of SCRH with 30µM PCB 153 increased T4G 
2.9-fold (Figure 2.7A). T4G in media of Hu8092 and Hu8096 was only detectable following 
PCB 153 treatment. Following PCB 153 treatment, T4G levels increased in the media of 
Hu1362 and Hu1364 9.3- and 3.2-fold, respectively. T4S levels did not change significantly 
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in the media of SCRH, Hu8092, Hu8096, Hu1362, and Hu1364 (Figure 2.7B). T3+rT3 levels 
following PCB 153 treatment were unchanged in the media of SCRH, Hu8092, Hu8096, 
Hu1362, and Hu1364 (Figure 2.7C). Increases in T4G levels in media of rat and human 
hepatocytes were a more consistent response to PCB 153 treatment as compared to T4S and 
T3+rT3 appearance.  
 
Effect of PCB 153 on the intrinsic clearance of T4 from the media of SCRH and SCHH. 
 Following 72 hours treatment with 30uM of PCB 153, T4 clearance was evaluated 
between 4 and 24 hours for SCRH and SCHH (Table 2.6).  A one-phase decay model was 
used to estimate the clearance rate in both SCRH and SCHH. CLint in the hepatocytes of rat1 
and rat 2 following PCB 153 treatment were 1.34 and 1.53 µl/min/106 cells, respectively. 
This represents between a 1.24- and 2.06-fold change in the clearance of T4 in the rat 
hepatocytes compared to the control.  CLint for Hu1362 and Hu1364 were 0.47 and 0.61 
µl/min/106 cells. This represents a 0.86-fold change for Hu1362 and no change in the 
clearance of T4 in Hu1364 compared to the control.  
 
D. DISCUSSION 
 
Much of the studies examining thyroxine metabolism use either microsomal or 
cytosolic fractions of various tissues. Using isolated liver fractions such as microsomes and 
cytosols has limitations in understanding the overall metabolism of endogenous substances 
and xenobiotics.   SCHs provide more in vivo-like metabolism, particularly when there are 
multiple enzymes involved with different intracellular locations. Differences in 
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glucuronidation and metabolism of THs between rats and humans were studied using liver 
and intestinal microsomal and liver cytosolic preparations and sandwich cultured 
hepatocytes. T4G activity varied by a factor of 5 in human microsomes and varied by a less 
than a factor of two in the SCHH.   The variation in human liver microsomal T4G activity is 
similar to that observed by Yamanaka et al (2007) and Kato et al (2008).  The rat liver 
microsomal T4G activity was higher than the human microsomal activity by 2- to 17.5-fold.  
In the SCH, the basal T4G activity was 2- to more than 13-fold greater in SCRH compared to 
SCHH, depending on the day in culture.  The concordance between the microsomal and SCH 
results on species differences provides confidence that the culture conditions are 
representative of in vivo metabolism. 
Pooled rat intestinal microsomes had greater T4G activity than the pooled rat liver 
microsomes.  Similar differences in T4G activity were observed with the pooled human 
intestinal microsomes compared to the human liver microsomes.  Yamanaka et al (2007) also 
demonstrated T4 glucuronidation in human liver and intestinal microsomes and suggested 
that in humans, intestinal clearance of T4 is half that of liver and that intestinal 
glucuronidation may play an important role in enterohepatic circulation.  This is the first 
report to demonstrate that, similar to humans, rat intestinal microsomes have higher T4G 
glucurondiation activity compared to liver microsomes and also suggests an important role of 
intestinal glucuronidation in the enterohepatic circulation of thyroxine in rats.   
In contrast to glucuronidation, sulfation of T4 in rat and human liver cytosols were 
similar and the variation in T4 sulfation was less than 1.5-fold in the various human samples.  
In the SCRH, <1% of the T4 is sulfated.  In comparison, almost 25% of the T4 is 
glucuronidated after 24 hours in culture.  In SCHH, <1% of the T4 is sulfated or 
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glucuronidated.  While previous studies have examined T3 sulfation in rat hepatocytes, this is 
the first study to examine T4 sulfation in both SCRH and SCHH.   The relative importance of 
T4 metabolic pathways did not vary with substrate concentration (0.1 to 100 µM T4) in either 
SCRH or SCHH.   The similar proportions of metabolites produced as concentration 
increases is consistent with the similar Km values ranging between 20-100 µM that various 
UGT and SULT isoforms exhibit towards T4 (Li and Anderson, 1999;  Yamanaka, et al., 
2007).   
Results of the [125I]-T4 incubation time course studies show that T4G does not appear 
in the medium of SCHH and T4S does not appear in the medium of SCRH at early time 
points, but were measurable at the 24 hour time point.  This is consistent with the intrinsic 
clearance of T4 from media in the present study.  T3+rT3 were detectable at each time point in 
the media of SCRH and SCHH.  While T3+rT3 contaminants were found in stock solutions, 
they were determined to be less than 0.1% of the [125I]-T4. Data were then corrected for this 
contaminant, so it is unlikely that the appearance of T3+rT3 were due to impurities. Despite 
the appearance of T3+rT3 at all time points examined, we did not detect further conversion 
metabolites like T2, T3-glucuronide or T3-sulfate in either medium or cells, but this may be 
due to detection limits for these metabolites. 
In the present study, physiologically relevant concentrations of T4 for rat (0.05μM) 
and human (0.1μM) were used to examine T4 metabolite levels in media and cells of SCH.  
T4G appearance in medium from SCRH is detectable on day 3 in culture and plateaus on 
days 4 through 6. In contrast, T4G appearance diminished until undetectable in the medium 
of SCHH by as soon as the fourth day in culture. Amounts of T4G in medium of SCRH were 
about 13-fold greater than in medium of SCHH.  T3+rT3 levels increase from day 3 to day 4 
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in culture and plateaus between days 4 and 6 for SCRH and Hu8092. In medium of Hu8096, 
T3+rT3 levels remained constant over days in culture. In contrast, we found that T4S amounts 
in the media of SCRH and SCHH were similar by culture days 5 and 6. Except for T4G in the 
media of Hu8092 and Hu8096, metabolite levels were maintained out to culture day 6. In a 
study using monolayer cultures of rat hepatocytes, T4G activity decreased over culture days 
(Viollon-Abadie et al., 2000). This does not agree with the present study, however, the 
difference in culture systems between the studies suggests that the effects observed are 
related to culture conditions. 
Transmembrane movement of thyroid hormones was thought to be a passive process; 
however, there is evidence that translocation occurs through active transport mechanisms 
(Blondeau et al., 1988;  De Jong et al., 1992;  de Jong, et al., 1993). Specifically, members of 
the MCT and OATP family have been shown to facilitate TH transport (Pizzagalli et al., 
2002;  Friesema et al., 2003;  Friesema et al., 2008;  van der Deure et al., 2008). Active 
transport is likely the rate-limiting step for TH metabolism; therefore, SCRH and SCHH 
were used to examine T4 accumulation over time. The rate of T4 accumulation has been 
shown to be slower in human hepatocytes than rat hepatocytes (Krenning et al., 1981;  de 
Jong, et al., 1993). In the present study, the rate of T4 accumulation is similar between SCRH 
and SCHH up to 5 minutes.  At the later time points in the accumulation studies, [125I]-T4 
accumulation plateaued at lower concentrations in SCRH than SCHH. The lower 
accumulation of T4 in SCRH compared to the SCHH is consistent with the greater T4G 
activity of the SCRH compared to the SCHH.  Transthyretin (TTR) and thyroid binding 
globulin (TBG) are major TH serum binding proteins and are thought to modulate the 
delivery of TH from blood to cells (Hennemann et al., 2001;  Choksi et al., 2003). In 
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humans, the majority of T4 is bound to TBG (Benvenga, 2005).  In rats, TBG expression is 
not detectable in adults; therefore, the major carrier protein for T4 is TTR (Savu, et al., 1991).  
This difference in serum binding proteins between rat and human may be of important to T4 
accumulation due to the differences in T4 affinity, where T4 has approximately 140-times 
greater affinity for TBG (Ka=1x10-10 M) than for TTR (Ka=7x10 -7 M) (Robbins, 1991). The 
T4 concentrations used in the present study do not take into account the binding of T4 to TTR 
or TBG; therefore, the species difference in TH binding proteins in vivo may indicate species 
differences in hepatic T4 accumulation. 
PCBs are environmental contaminates that were once used in capacitors and other 
industrial processes.  In rats, PCBs decrease thyroid hormones and this effect is thought to be 
due to increased hepatic accumulation and glucuronidation (Bastomsky, 1974;  Hood and 
Klaassen, 2000a;  Klaassen and Hood, 2001;  Craft, et al., 2002;  Crofton et al., 2005;  
Martin et al., 2012).  PCB 153 is one of the predominate congeners found in the environment 
as well as in humans.  It has been described as a phenobarbital-like PCB and decreases 
thyroid hormones in rats (Craft, et al., 2002;  Crofton, et al., 2005).  The current study shows 
that PCB 153 induced T4 glucuronidation in both SCRH and SCHH.  In comparison, T4S and 
T3+rT3 production were unaffected by PCB 153 treatment in both SCRH and SCHH. T4G in 
control media from Hu8092 and Hu8096 was not detectable; however, following PCB-153 
treatment, T4G accumulated in the media. In SCRH, T4G accumulation in the medium from 
control and PCB153 treatment was greater than in SCHH.  In vivo studies using the PCB 
mixture, Aroclor 1254, showed decreases in hepatic deiodinase I activity in rats (Hood and 
Klaassen, 2000b).  In the present study, no change in T3+rT3 production following PCB 153 
treatment of SCRH and SCHH was observed.  The difference between the in vivo studies and 
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the in vitro studies may be that in vivo, reductions in hepatic deiodinase activity may not be 
due to direct effects of the chemical on hepatocytes, but a physiological response to 
decreased serum T4 concentrations (Davies et al., 1996). Therefore, if deiodinase activity 
reductions are a physiological response in vivo, it is likely that T3+rT3 production would not 
change in hepatocyte cultures at the concentrations of T4 used in this study. 
The present study assessed the utility of SCH for evaluating the species differences in 
TH metabolism changes following exposure to environmental chemicals.  This is the first 
report, to our knowledge, characterizing inducibility, metabolism, and clearance of T4 in an 
in vitro model system in both SCRH and SCHH.  T4 metabolism was measurable in untreated 
SCRH and SCHH.  Exposure to PCB 153 increased metabolism of T4, consistent with the 
effects observed in vivo in rats. This model is also consistent with other in vivo and in vitro 
data indicating that glucuronidation may be a predominant pathway for hepatic TH 
metabolism in rats. Previous studies have suggested that sulfation is the preferred pathway 
for TH metabolism in humans (Kester, et al., 1999;  Kester, et al., 2003); however we find 
that deiodination of T4 is the favored pathway in this model system.  This in vitro system 
may be useful in evaluating a chemical’s ability to increase hepatic T4 metabolism in vivo.  
However, while the present model can be used to qualitatively assess whether a chemical can 
alter TH metabolism, quantitative extrapolation of this data to in vivo exposures requires 
further development. 
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Table 2.1  
 
Donor information for human hepatocytes 
 
     Donor              Sex        Age    Smoke/Alcohol        Medications        Experimental Use 
 UKN=unknown  
 
  
Hu1191 Male 19 No/No UKN T4 Accumulation/ 
T4 Clearance 
Hu1193 Male 68 Yes/No Aspirin 
Zolpidem 
Simvastatin 
Ranitidine 
 
T4 Accumulation/ 
T4 Clearance 
Hu1197 Female 29 No/Yes Amphetamine 
Bupropion 
Cetirizine 
Clonazepam 
Lamotrigine 
 
T4 Accumulation/ 
T4 Clearance 
Hu1362 Female 57 No/No Atenolol and 
Chlorthalidone 
Lorazepam 
Oxycodone 
 
Time course/ 
PCB 153 
Hu1364 Male 51 No/No Cyanocobalamin 
Diltiazem 
Ferrous Sulfate 
Folic Acid 
Metoprolol 
Omeprazole 
Potassium Chloride 
Prednisone 
 
Time course/ 
PCB 153 
Hu8092 
(non-
transplantable) 
 
Male 
 
59 
 
No/No 
 
UKN T4 dose response/ 
culture days/ 
PCB 153 
 
Hu8096 
(non-
transplantable) 
Male 52 No/Yes UKN T4 dose response/ 
culture days/ 
PCB 153 
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Table 2.2  
 
Liver microsomes and cytosol 
 
  
Species Tissue Fraction Lot Sex Supplier Number of 
subjects 
Human Liver 
Cytosolic/ 
Microsomal 
 
SD114 Male CellzDirect 1 
Human Liver 
Cytosolic/ 
Microsomal 
 
SD119 Male CellzDirect 1 
Human Liver 
Cytosolic/ 
Microsomal 
 
SD120 Female CellzDirect 1 
Human Liver 
Cytosolic/ 
Microsomal 
 
SD122 Male CellzDirect 1 
Human Liver 
Cytosolic/ 
Microsomal 
 
SD123 Female CellzDirect 1 
Human Liver Cytosolic/ Microsomal SD129 Male CellzDirect 1 
Human Liver Microsomal PL050 Mixed CellzDirect 50 
Human Liver Cytosolic PL024 Mixed CellzDirect 28 
Rat Liver Cytosolic RT042 Male CellzDirect 50 
Rat Liver Microsomal RT046 Male CellzDirect 50 
Human Liver Microsomal 0710091 Mixed XenoTech 50 
Human Intestine Microsomal 0610108 Mixed XenoTech 10 
Rat Liver Microsomal 0710387 Male XenoTech 400 
Rat Intestine Microsomal 0410063 Male XenoTech 148 
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Table 2.3  
 
Comparison of hepatic and intestinal T4G formation rates in microsomes and hepatic 
T4S formation rates in cytosols from rats and humansa. 
 
Species Tissues Donor T4G 
pmol/mg/min 
T4S 
pmol/mg/min 
Ratb 
 
Liver Pooled 2.0 4.4 
Ratc 
 
Liver Pooled 3.5 ND 
Ratc 
 
Intestine Pooled 7.2  NDd 
Humanc 
 
Liver Pooled 1.0 ND 
Humanb 
 
Liver Pooled 0.3 4.0 
Humanc 
 
Intestine Pooled 3.4  NDd 
Humanb 
 
Liver SD114 0.2 4.4 
Humanb 
 
Liver SD119 0.4 4.2 
Humanb 
 
Liver SD120 0.3 4.1 
Humanb 
 
Liver SD122 0.3 4.4 
Humanb 
 
Liver SD123 0.3 4.3 
Humanb Liver SD129 0.5 4.8 
aData are expressed as pmol/mg protein/min (mean). Data represent the average of duplicate 
experiments with variability of <30%. ND=not determined; T4 conjugates were generated 
following an incubation with 4uM [125I]-T4 
bSamples obtained from Invitrogen 
cSamples obtained from Xenotech 
dCytosol not available 
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Table 2.4  
 
Mass balance of T4 and T4 metabolites after exposure of human hepatocytes on culture 
day 6 to 0.1µM [125I]-T4 
aData are expressed as percent of total [125I] activity (mean); Data represent the average of 
duplicate experiments;  Limits of detection=0.4 pmol/mg cellular protein; BLQ=below limits 
of quantitation; n=2 (Hu1362 and Hu1364) 
  
Time 
(hours) T4
a
 T4Ga T4Sa T3+rT3a 
 
4 
8 
12 
24 
Cells     Media 
12.9      85.5 
14.2      84.2 
17.4      80.7 
17.8      79.5 
Cells     Media 
BLQ       BLQ  
BLQ       BLQ 
BLQ      BLQ 
BLQ      BLQ 
Cells     Media 
  BLQ       BLQ  
  BLQ         0.4 
  BLQ         0.4 
  BLQ         0.6  
Cells       Media 
     BLQ        1.5 
BLQ        1.4 
BLQ        1.7 
0.3          1.3 
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Table 2.5  
 
Mass balance of T4 and T4 metabolites after exposure of rat hepatocytes on culture day 
6 to 0.05µM [125I]-T4 
Percentages of total metabolites, T4G, T4S and T3+rT3, in media and hepatocytes following 
exposure to [125I]-T4 for 4, 8, 12, or 24 hours. 
aData are expressed as percent of total [125I] activity (mean); Data represent the average of 
duplicate from experiments; Limits of detection=0.5 pmol/mg cellular protein; BLQ=below 
limits of quantitation.; n=2. 
  
Time 
(hours) T4
a
 T4Ga T4Sa T3+rT3a 
 
4 
8 
12 
24 
Cells      Media 
  10.5         83.8 
    7.6         77.6 
  10.8         70.6 
    8.4         65.3 
Cells       Media 
BLQ        3.4 
BLQ      12.7 
BLQ      16.8 
BLQ      23.7 
Cells       Media 
BLQ       BLQ 
BLQ       BLQ 
BLQ       BLQ 
BLQ         0.4 
Cells         Media 
0.2             2.1 
BLQ           2.1 
BLQ           1.9 
BLQ           2.3 
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Table 2.6 
 
Intrinsic clearance of [125I]-T4 following treatment with PCB 153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data represent the average of duplicates from a single experiment.  
SCH were incubated with 0.05µM [125I]-T4 (rat) or 0.1µM [125I]-T4 (human) for up to 
24 hours.  
 
  
  Control PCB 153 Fold 
change 
Rat 1 Rate constant K (1/min) 
 
Clint (µl/min/106 cells) 
 
Scaled Clint (ml/min/kg body weight) 
 
0.00075 
 
1.08 
 
5.16 
 
0.00094 
 
1.34 
 
6.41 
 
1.25 
 
1.24 
 
1.24 
Rat 2 Rate constant K (1/min) 
 
Clint (µl/min/106 cells) 
 
Scaled Clint (ml/min/kg body weight) 
 
0.00052 
 
0.75 
 
3.58 
 
0.00107 
 
1.53 
 
7.33 
 
2.06 
 
2.04 
 
2.05 
Hu 1362 Rate constant K (1/min) 
 
Clint (µl/min/106 cells) 
 
Scaled Clint (ml/min/kg body weight) 
 
0.00039 
 
0.56 
 
1.60 
 
0.00033 
 
0.47 
 
1.37 
 
0.84 
 
0.86 
 
0.85 
Hu 1364 Rate constant K (1/min) 
 
Clint (µl/min/106 cells) 
 
Scaled Clint (ml/min/kg body weight) 
 
0.00043 
 
0.61 
 
1.78 
 
0.00043 
 
0.61 
 
1.77 
 
0.98 
 
1.00 
 
0.99 
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Figure 2.1 Representative chromatogram of T4 and its metabolites in medium.   
The graph shows metabolites [iodide (-I), T4-glucuronide (T4G), T4-sulfate (T4S), 3,3’,5-
triiodothyronine (T3) and 3,3’,5’-triiodothyronine (rT3)] in medium of SCRH following a 24 
hour incubation with 5.0µM [125I]-T4 on culture day 6. Peaks were separated using UPLC. 
Fractions of eluent were collected and analyzed by gamma spectroscopy. 
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Figure 2.2 T4 metabolite levels in media during time in culture.SCH arrive on culture day 
2 and are untreated. SCH were incubated with 0.05µM [125I]-T4 (rat) or 0.1µM [125I]-T4 
(human) for 24 hours on culture days 3, 4, 5, or 6. Metabolites were separated using the 
established UPLC method. Metabolites analyzed are (A) T4G, (B) T4S, and (C) T3+rT3. Data 
are expressed as pmol/mg cellular protein [mean (human hepatocytes)] or [mean±SD (rat 
hepatocytes)]. Human hepatocyte data represent the average of duplicates in a single 
experiment. Human hepatocytes are from two donors (Hu8092 and Hu8096). Rat hepatocytes 
are from 3 donors (n=3) 
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Figure 2.3. Accumulation of [125I]-derived radioactivity in rat and human hepatocytes. 
Sandwich-cultured hepatocytes were incubated with 0.0005µM (5000 cpm) per well [125I]-T4 
on culture day 6. The accumulation of [125I]-T4 was determined over time (1-5 min).  Data 
represent the average of duplicates in a single experiment. Individual hepatocyte donor 
values are presented. Data are expressed as percentage of dose. The lines represent the linear 
regression of the data (1-5 min). The curved lines are the nonlinear regression of the data (1-
30 min). Rat hepatocytes are from 2 donors (n=2) and human hepatocytes are from 3 donors 
(n=3).    
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Figure 2.4. T4 metabolite levels in media during incubation time. SCH were incubated 
with 0.05µM [125I]-T4 (rat) or 0.1µM [125I]-T4 (human) for on culture day 6. Metabolite 
appearance were determined over time (4-24).Metabolites were separated using the 
established UPLC method. Metabolites analyzed are (A) T4G, (B) T4S, and (C) T3+rT3. Data 
are expressed as pmol/mg cellular protein (mean). Data represent the average of duplicates in 
a single experiment. Limits of detection=0.5 pmol/mg cellular protein. BLQ=below limits of 
quantitation.  
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Figure 2.5. [125I]-T4 clearance in the media of rat (A) and human (B) hepatocytes. SCH 
were incubated with 0.05µM [125I]-T4 (rat) or 0.1µM [125I]-T4 (human) on culture day 6. The 
accumulation of [125I]-T4 was determined over time (4-24 hours). Data represent the average 
of duplicates in a single experiment. Data are expressed as percentage of T4 remaining in 
media. The lines represent the linear regression of the data. 
 
73 
 
A. 
0 20 40 60 80 100
0
10000
20000
30000
40000
T4G
T4S
T3+rT3
T4 concentration (µM)
pm
ol
/m
g
 
B. 
 
0 20 40 60 80 100
0
500
1000
1500
2000
2500
T4G
T4S
T3+rT3
T4 concentration (µM)
pm
ol
/m
g
 
Figure 2.6. Metabolite levels in media of hepatocytes exposed to [125I]-T4 on culture day 
6 for 24 hours. (A) Rat hepatocytes were incubated with 0.05-100µM [125I]-T4 and (B) 
human hepatocytes were incubated with 0.1-100µM [125I]-T4 for 24. Data are expressed as 
pmol/mg cellular protein (mean). Data represent the average of duplicate experiments. The 
lines represent the linear regression of the data. Limits of detection=0.5 pmol/mg cellular 
protein; BLQ=below limits of quantitation. n=2 for rat hepatocytes and human hepatocytes 
(Hu8092 and Hu8096). 
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Figure 2.7. Comparison of metabolites in the media of SCRH and SCHH following 
treatment with PCB 153. Hepatocytes were incubated with 0.1% DMSO (control) or 30µM 
PCB 153 for 72 hours starting on culture day 3. Hepatocytes are then incubated for 24 hours 
on culture day 6 with 0.05µM (rat) or 0.1µM (human) [125I]-T4. Metabolites were separated 
using the established UPLC method. Metabolites analyzed are (A) T4G, (B) T4S, and (C) 
T3+rT3. Data represent the average of duplicate experiments. Data are expressed as pmol/mg 
cellular protein (mean±SD for rat hepatocytes and mean for human hepatocytes); Limits of 
detection= 0.5 pmol/mg cellular protein; BLQ=below limits of quantitation. n=3 for rat 
hepatocytes. Human hepatocytes are from 4 donors (Hu8092, Hu8096, Hu1362, and 
Hu1364). *Significantly different than control in rat hepatocytes; p<0.05.  
 
 
CHAPTER 3 
 
EFFECTS OF NUCLEAR RECEPTOR AGONISTS ON THYROXINE 
METABOLISM IN RAT AND HUMAN HEPATOCYTES 
 
A. INTRODUCTION 
 
Thyroid hormones (TH) are critical modulators of development in vertebrates.  In 
humans, developmental hypothyroidism is associated with increased risk of neurological 
impairment and decreases in stature and hearing loss.  The magnitude of these changes is 
dependent upon the magnitude of the developmental hypothyroidism. In amphibians and fish, 
metamorphosis occurs during peak plasma TH concentrations; therefore, decreases in TH 
delay metamorphosis.  Because of its importance in development, chemicals that alter thyroid 
hormone concentrations are potential developmental toxicants.   
Circulating TH concentrations are regulated, in part, by hepatic metabolism through 
pathways including: deiodination, glucuronidation and sulfation.  In TH responsive tissues, 
thyroxine (T4) is converted to triiodothyronine (T3), the active hormone, by deiodinases.  
Deiodinases also convert T4 and T3 to 3, 3’, 5’-triiodothyronine (rT3) and 3, 3’-
diiodothyronine (3, 3’-T2), respectively.  TH can be deactivated in the liver by, uridine 
diphosphate glucuronosyltransferase (UGT) and sulfotransferase (SULT) and these 
conjugates are then excreted through the bile into the intestines. There are significant species 
differences in thyroid hormone metabolism.  For example, human SULT1A1 catalyzes TH
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sulfation unlike the rat homolog (Visser, et al., 1998;  Kester, et al., 1999). Although 
SULT1A1 is expressed in human and rat liver (Ozawa et al., 1993;  Runge-Morris et al., 
1998), the divergence of catalytic activity toward TH suggests SULT1A1 is important to TH 
sulfation in the human liver and not in rat liver.  Primary rat hepatocytes produce 
approximately 13 times more T4-glucuronide (T4G) than T4-sulfate (T4S) when incubated 
with T4 (Richardson et al., submitted).  In contrast, primary human hepatocytes produced 
more T4S and deiodination products, T3 and rT3 (Richardson et al; submitted).  This suggests 
that T4 glucuronidation is the predominate pathway of deactivation in rats, while humans 
utilize sulfation and to a greater extent deiodination to deactivate T4.   
There are multiple sites within the thyroid axis in which xenobiotics alter TH 
homeostasis. Although SULTs are involved in T4 metabolism, most hypotheses on TH 
disruption focus on the increase in T4 metabolism though the induction of hepatic UGTs. 
Many agents that decrease serum T4 concentrations and induce hepatic UGTs activate 
nuclear receptors, such as constitutive androstane receptor (CAR), pregnane X receptor 
(PXR), and aryl hydrocarbon receptor (AhR) (Barter and Klaassen, 1992;  Kretschmer and 
Baldwin, 2005;  Qatanani, et al., 2005).  Phenobarbital (PB), a prototype activator of 
constitutive androstane receptor (CAR), decreases serum TH concentrations, increases 
hepatic T4 glucuronidation (Hood and Klaassen, 2000a;  Vansell and Klaassen, 2001;  
Vansell and Klaassen, 2002a;  Hood, et al., 2003;  Kato, et al., 2010) and increases the 
biliary elimination of T4G in rodents (Oppenheimer, et al., 1968;  McClain, et al., 1989;  
Wong, et al., 2005). PB has been shown to decrease serum T4 concentrations in humans 
(Tanaka et al., 1987;  Eiris-Punal, et al., 1999); however, it is unclear by what mechanism the 
T4 decrease occurs. Pregnenolone-16α-carbonitrile (PCN) and 3-methylcholanthrene (3MC), 
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prototype activators of PXR and AhR, respectively, also decrease serum T4 concentrations 
and induce hepatic T4-UGT activity in rats (Hood and Klaassen, 2000a;  Hood, et al., 2003;  
Richardson and Klaassen, 2010). While UGTs may play a role in decreasing circulating TH, 
it is not certain that the induction of hepatic T4 glucuronidation alone is responsible for the 
effects on serum TH concentration following xenobiotic exposure. Research shows that 
serum T4 decreases may not be dependent on increases in T4 glucuronidation. For example, 
decreases in serum T4 concentrations by phenobarbital (PB), pregnenolone-16α-carbonitrile 
(PCN), 3-methylcholanthrene (3MC) and polychlorinated biphenyls (PCBs) occur even in 
Ugt1a-deficient Gunn rats (Kato, et al., 2004;  Kato, et al., 2005;  Richardson and Klaassen, 
2010). The experimental compound 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-
methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (DMP 904) and the PCB mixture, Kanechlor-
500 (KC500) decrease serum T4 in rats, by increasing biliary elimination of unconjugated T4, 
(Wong, et al., 2005;  Kato, et al., 2007;  Lecureux, et al., 2009). Additionally, PB, DMP 904, 
and KC500 increase the accumulation of T4 in the liver (Wong, et al., 2005;  Kato, et al., 
2007;  Lecureux, et al., 2009;  Kato, et al., 2010).  This further suggests that serum T4 
decreases occur through a liver-selective accumulation and biliary elimination of T4, rather 
than through the induction of hepatic UGT. This also indicates that the process for 
xenobiotic-mediated decreases in serum T4 is controlled by uptake and efflux transporters in 
the liver. 
In addition to UGTs, AhR, PXR and CAR regulate transporter proteins (Maglich, et 
al., 2002;  Bock and Kohle, 2004;  Wagner, et al., 2005;  Jigorel et al., 2006). Though much 
focus has been placed on the metabolism of TH by UGTs, it is not exactly clear what role 
hepatic transporters play in the decrease in serum TH.  Multidrug resistance–associated 
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protein-2 (MRP2) and multidrug resistance protein-1 (MDR1) contribute to the excretion of a 
broad spectrum of substrates (Mitchell, et al., 2005;  Lecureux, et al., 2009;  Miyawaki et al., 
2012). Decreases in serum TH concentrations have been associated with increases in hepatic 
MRP2 mRNA and protein expression in rats treated with clobazam (CLB) (Miyawaki, et al., 
2012).   
A potential difference between rodents and humans with respect to thyroid disruptors 
is the slight difference in the structure activity relationship for the activation of nuclear 
receptors across species.  For example, in humans the PXR activator, rifampicin, does not 
activate PXR in rodents (Moore, et al., 2000;  Tirona et al., 2004).  Similarly, there are 
rodent and human specific activators of CAR.  Activators of CAR and PXR affect TH 
homeostasis in rodents (Chen et al., 2003;  Kretschmer and Baldwin, 2005;  Qatanani, et al., 
2005); thus, extrapolating xenobiotic-induced thyroid disruption by activators of hepatic 
nuclear receptors in rodents to humans is challenging due to the species differences in 
metabolism of the hormones and differences in the structure activity relationships for hepatic 
nuclear receptors across species. 
To our knowledge, this is the first report to examine differences in rat and human 
hepatic T4 metabolism as it relates to nuclear receptor activation. This study examines how 
prototype nuclear receptor agonists PB (human and rat CAR), PCN (rat PXR), Rif (human 
PXR), 3MC (human and rat AhR) change T4 metabolism in rat and human sandwich-cultured 
hepatocytes (SCH). The PB-like inducer, PCB 153 was also used as a prototype environment 
contaminant to assess the effects on T4 disposition in rat and human hepatocytes.  In addition, 
mRNA expression for cytochrome P450s (CYPs) UGTs, SULTs, deiodinase 1 (D1), and 
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transporters, were also examined to determine other possible genes involved in TH 
disruption. 
 
B. MATERIALS AND METHODS 
 
Chemicals 
L-thyroxine (T4), phenobarbital (PB), 3-methylcholanthrene (3MC), pregnenolone-
16α-carbonitrile (PCN), and rifampicin (Rif) were purchased from Sigma-Aldrich Co. (St. 
Louis, MO).  2, 2’, 4, 4’, 5, 5’-hexachlorobiphenyl (PCB 153) was purchased from Radian 
Corporation (Austin, TX). [125I]-T4, (116 Ci/mmol) was purchased from Perkin Elmer Life 
Sciences Inc. (Waltham, MA) and was purified to >98%) immediately before use with 
Sephadex LH-20 (Sigma-Aldrich) as described by Rutgers et al. (1989). All other reagents 
were of the highest grade commercially available. 
 
Hepatocyte culture  
Fresh primary male Sprague-Dawley sandwich-cultured rat hepatocytes (SCRH) and 
sandwich-cultured human hepatocytes (SCHH) in 24-well plates were received on culture 
day 2 from Life Technologies (Durham, NC). Hepatocytes were maintained for up to 6 days 
in culture with daily medium replacement. The maintenance medium consists of: Williams’ 
E medium with 0.1% dimethyl sulfoxide (DMSO) including Hepatocyte Maintenance 
Supplement (Life Technologies), which contains 0.1 µM dexamethasone and proprietary 
concentrations of penicillin-streptomycin, ITS+ (insulin, transferrin, selenium complex, BSA 
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and linoleic acid), GlutaMAX™ and HEPES]. Human donor demographics can be found in 
Table 3.1.  
 
T4 and T4 metabolite separation and quantitation  
Samples were dried at 40°C under N2 gas and then reconstituted with 40µl mobile 
phase consisting of 18% acetonitrile in 0.02M ammonium acetate (pH=4). After addition of 
mobile phase, samples were centrifuged at 10,000 x g for 5 minutes at room temperature and 
the supernatants were placed in vials for UPLC analysis. UPLC equipped with a C18 – 2.1 x 
50mm x 1.7 µm (Waters Corp.; Milford, MA) resolution column and a fraction collector 
were used for identification of T4 and T4 metabolites. Gradient elution was performed using a 
method modified version of a previously established method by Rutgers et al. (1987) with a 
16 minute gradient of 18-40% acetonitrile in 0.02M ammonium acetate (pH=4). Solvent flow 
rate was 0.4ml/min and 15 second fractions were collected in test tubes. Peaks were then 
identified by analyzing collected fractions for radioactivity by gamma spectroscopy. 
Retention times for T4, T3, rT3, T4-glucuronide (T4G), and T4-sulfate (T4S) were determined 
using synthetic and biosynthetic compounds as described by Richardson et al. (submitted). 
Peaks for T3 and rT3 were often inseparable; as a result, these peaks were added together and 
are presented as T3+rT3. Hepatocyte protein content was determined using a protein assay kit 
with bovine serum albumin as a standard (Bio-Rad Laboratories, Hercules, CA). 
 
T4 accumulation in hepatocytes following treatment with nuclear receptor agonists  
Stock solutions of each chemical were diluted in DMSO and added to maintenance 
medium to a final DMSO concentration of 0.1%. SCRH and SCHH were treated with species 
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appropriate prototypical nuclear receptor agonist starting on culture day 3.  SCRH were 
treated for 72 hours with the DMSO vehicle (0.1%), PB (1000 µM), PCN (10 µM), 3MC (5 
µM), or PCB 153 (30 µM) in maintenance medium for 72 hours. SCHH were treated for 72 
hours with the DMSO vehicle (0.1%) or PB (1000 µM), Rif (10 µM), 3MC (5 µM), or PCB 
153 (30 µM) in maintenance medium. Following the 72 hour incubation, medium was 
removed and replaced with maintenance medium containing 0.0005µM (5000 CPM) of 
[125I]-T4 for 1, 2, 5, 10, 20, or 30 minutes. After incubation, medium was collected and cells 
were washed twice with 0.5 ml/well of ice-cold PBS buffer. After washing, hepatocytes were 
collected by adding 0.5ml/well 0.1M NaOH. 125I-derived radioactivity in collected medium 
and hepatocytes were analyzed by gamma spectroscopy.  
 
Effects of hepatic enzyme inducers on T4 metabolite levels 
Stock solutions of PB, PCN, Rif, 3MC, and PCB 153 were diluted in dimethyl 
sulfoxide (DMSO) and added to Williams’ E medium at a final DMSO concentration of 
0.1%. On culture day 3, fresh SCRH were exposed for 72 hours to the DMSO vehicle 
(0.1%), PB (10, 100, 1000 µM), PCN (0.1, 1, 10 µM), 3MC (0.05, 0.5, 5 µM), or PCB 153 
(0.3, 3, 30 µM). SCHH were treated for 72 hours to the DMSO vehicle (0.1%) or PB (10, 
100, 1000 µM), Rif (0.1, 1, 10 µM), 3MC (0.05, 0.5, 5 µM), or PCB 153 (0.3, 3, 30 µM).  
After 72 hours, medium was removed and replaced with Williams’ E medium containing 
0.05 µM (rat) or 0.1 µM (human) [125I]-T4 (500,000 CPM) for 24 hours. Medium was 
collected and stored at 4°C until analysis. Hepatocytes were washed twice with 0.5 ml/well 
ice-cold PBS and collected by adding 0.5 ml/well of NaOH. Medium was prepared and 
analyzed for T4 metabolites as the method describes above.  
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RNA isolation and real-time RT-PCR analysis. 
Upon termination of the treatment period (72 hours), cells were washed once with 
ice-cold PBS (0.5ml/well), lysed by the addition of 0.7ml of RLT Buffer (Qiagen, Hilden, 
Germany) containing 1.0% β-mercaptoethanol (final concentration) and stored at -70° C until 
use. Lysates were thawed on ice and total RNA was isolated using the RNeasy Midi Kit with 
DNase I digestion performed during column purification (Qiagen, Hilden, Germany). The 
integrity of RNA samples were assessed using the 2100 Bioanalyzer was used (Agilent 
Technologies, Palo Alto, CA). RNA Integrity Numbers (RINs) greater than 8.0 are seen as 
acceptable for real-time RT-PCR analysis.  Real-time RT-PCR was performed using the ABI 
Prism 7700 Sequence Detection System (ABI, Foster City, CA). Total RNA (100ng) was 
converted to cDNA using High Capacity cDNA Reverse Transcription Kits (ABI, Foster 
City, CA). PCR reactions were then performed on all cDNAs using TaqMan Universal PCR 
Master Mix and custom TaqMan Low Density Arrays (ABI, Foster City, CA) preloaded with 
target gene expression assays. Gene expression assay identifications are listed in Tables 3.2 
and 3.3.   
All RT-PCR data were quantified by the relative quantitation method ΔΔCt (Applied 
Biosystems User Bulletin 2). These data were quantified relative to a control sample and an 
endogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The control 
group is used as a reference point for all other dose groups; therefore, all samples are 
expressed as fold difference as compared with control. 
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Data analysis 
The statistical intergroup comparisons were determined by using one-way analysis of 
variance (ANOVA) followed by Dunnet’s Multiple Comparison and linear trend post tests. 
Nonlinear regression analysis was used to assess the relationship between [125I]-T4 
accumulation and chemical treatments. A one-phase association exponential equation  
Y=Y0 + (Plateau-Y0)*(1-exp(-K*x)), 
was fit to the [125I]-T4 accumulation data where plateau is the Y value at infinite times and 
half time is the time (minutes) it takes to reach half the plateau and is computed as ln(2)/K. 
GraphPad Prism 5.0 was used to analyze all data (GraphPad Software San Diego, CA). The 
level of probability of statistical significance was p < 0.05.  
 
C. RESULTS 
 
T4 metabolite levels following treatment with nuclear receptor activators 
To study the effects of hepatic enzyme inducers on T4 metabolism in hepatocytes, PB 
(CAR), and 3MC (AhR) were used as prototype nuclear receptor agonists for SCRH and 
SCHH. PCN and Rif were used as prototype PXR agonists for SCRH and SCHH, 
respectively. PCB 153 was used as a prototype environmental contaminant for SCRH and 
SCHH. T4G in the medium of SCRH significantly increased with treatment of 1000 µM PB 
(1.7-fold), 1 and 10 µM PCN (1.7- and 2.0-fold), 0.05, 0.5, and 5 µM 3MC (1.6-, 2.2-, and 
4.4-fold), and 0.3, 3, and 30 µM PCB 153 (1.6-, 2.3-, 4.8-fold) (Figure 3.1A). T4G in 
medium of SCHH significantly increased following Rif (10 µM) and PCB 153 (30 µM) 
treatment 2.9- and 3.6-fold, respectively (Figure 3.2A). T4G levels in the medium of SCHH 
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did not change with PB and 3MC treatment.  T4S (Figures 3.1B and 3.2B) and T3+rT3 
(Figures 3.1C and 3.2C) levels in the medium of SCRH and SCHH were not significantly 
changed with chemical treatment compared to control.    
 
Cytochrome P450 mRNA expression 
To determine if chemical treatments effectively activated specific nuclear receptors, 
mRNA expression levels of target cytochrome P450s were measured by RT-PCR. CYP1A 
mRNA expression was used as a marker for Ah receptor activation in SCRH (Table 3.4) and 
SCHH (Table 3.5).  3MC significantly increased CYP1A1 mRNA in SCRH 270.2-fold (5 
µM) and in SCHH 154.6-fold (0.5 µM) and 178.0 (5 µM). As markers for CAR activation, 
Cyp2b2 and CYP2B6 mRNA expression was used for SCRH and SCHH, respectively.  PB 
(1000 µM) treatment significantly increased Cyp2b2 mRNA expression 197-fold in SCRH. 
CYP2B6 significantly increased following PCB 153 (3 and 30 µM) treatment in SCHH 21.7- 
and 31.4-fold. CYP3A mRNA expression was used as a marker for PXR activation.  In 
SCRH, Cyp3a1 mRNA expression significantly increased 660.1-fold following treatment 
with PCN (10 µM). CYP3A4 mRNA expression significantly increased following PB (1000 
µM) and Rif (1 and 10 µM) 20.0- 15.7- and 24.9-fold, respectively. 
 
UGT, SULT and D1 mRNA expression 
There was a significant 25.7-fold increase in Ugt1a6 mRNA expression with 3MC (5 
µM) treatment of SCRH (Table 3.6). Ugt1a1, Ugt1a5, and Ugt2b mRNA expression in 
SCRH was not significantly altered with treatment. In SCHH, 1000 µM PB significantly 
increased UGT1A1, UGT1A4, UGT1A6, and UGT2B4 by approximately 6.4-, 9.6, 2.2-, and 
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2.0-fold (Table 3.7).  SCHH treated with 1 and 10 µM Rif significantly increased UGT1A1 
(4.7- and 6.6-fold) and UGT2B (2.1- and 2.4-fold) mRNA expression. UGT1A4 and 
UGT2B15 increased significantly in SCHH with Rif (10 µM) treatment by 7.2-fold and 3.1-
fold, respectively. Expression levels for the UGT genes examined were not significantly 
changed in SCHH with 3MC or PCB 153 treatment. PB (1000 µM) significantly increased 
Sult1e1 mRNA expression in SCRH by 6.8-fold (Table 3.8). Sult1c1 mRNA expression in 
SCRH significantly decreased with 10 µM PCN by 80%.  3MC and PCB 153 treatment did 
not alter Sult mRNA expression in SCRH. In SCHH, SULT1A3, SULT1E1, and SULT2A1 
were not significantly changed with chemical treatment (Table 3.9). Deiodinase 1 mRNA 
expression in SCRH was not significantly changed with chemical treatment (Table 3.10). In 
SCHH, deiodinase I mRNA expression increased 2.4-fold following treatment with 0.3 µM 
PCB 153, but was unchanged at the 2 higher doses of 3 and 30 µM PCB 153 (Table 3.11). 
 
Cell-associated radioactivity of [125I]-T4 in fresh rat and human hepatocytes following 
xenobiotics treatment 
Hepatocyte accumulation of T4 following xenobiotic treatment (72 hours) was 
evaluated by measuring the amount of radioactivity in the hepatocytes after incubation with 
[125I]-T4 for 1 to 30 minutes (Figure 3.3). Preliminary studies showed [125I]-T4 did not 
significantly bind to BD Matrigel® (BD Biosciences) or plastic ware (data not shown). An 
exponential one-phase association model was used to fit accumulation data for control and 
treated hepatocytes. The data for SCRH fit one curve indicating no significant difference in 
[125I]-T4 accumulation between all treatment groups (Figure 3.3A). In SCRH, [125I]-T4 
association plateau equaled 4.8% and half time was 4.0 minutes for all treatment groups.  
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[125I]-T4 accumulation was different between treatment groups in SCHH (Figure 3.3B). The 
model showed that [125I]-T4 accumulation into SCHH plateaued at 11.7, 11.5, 14.2, 11.7, and 
10.9% for control, PB, Rif, 3MC, and PCB 153, respectively. Half times were determined to 
be 16.0, 13.9, 15.7, 14.2, and 20.6 minutes for control, PB, Rif, 3MC, and PCB 153, 
respectively.  A linear model was used to fit the data from 1 to 10 minutes to analyze 
accumulation at early time points. The data for SCRH and SCHH fit one curve indicating no 
significant difference in [125I]-T4 accumulation between all treatment groups (SCRH: F=0.19 
(4,76); p=0.9413 and SCHH: F=1.60 (4,110); p=0.1792).  
 
Efflux and uptake transporter mRNA expression 
Mdr1a mRNA expression increased significantly in SCRH with PB (1000 µM), 3MC 
(5 µM), and PCB 153 (30 µM) by 1.4-, 1.7-, and 1.6-fold (Table 3.12). PCN treatment did 
not significantly change Mdr1a mRNA expression in SCRH. In SCRH, Mdr1b, Mrp2, and 
Mrp3 were not significantly altered with chemical treatment.  PB (1000 µM) treatment 
increased MDR1 and MRP2 mRNA expression in SCHH by 2.3- and 2.5-fold, respectively 
(Table 3.13). 1 µM and 10 µM Rif significantly increased MDR1 (2.0- and 2.0-fold, 
respectively) and MRP2 (2.0- and 2.1-fold, respectively) mRNA expression. MRP3 mRNA 
expression was not significantly altered with chemical treatment. Neither 3MC nor PCB 153 
significantly changed MDR1, MRP2, and MRP3 mRNA expression in SCHH. Only 1000 
µM PB significantly increased Oat2 mRNA expression in SCRH by 1.9-fold (Table 3.12). 
Ntcp1 mRNA expression in SCRH was unchanged with chemical treatment. In SCHH, 
NTCP1 and OAT2 were not significantly altered with chemical treatment (Table 3.13).  
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D. DISCUSSION  
 
Through the activation of nuclear receptors such as AhR, CAR, and PXR, xenobiotics 
are thought to lower serum T4 concentrations by increasing T4 glucuronidation and biliary 
elimination (Barter and Klaassen, 1994;  Klaassen and Hood, 2001;  Kato et al., 2011;  
Martin, et al., 2012). However, xenobiotic-mediated increases in T4 glucuronidation do not 
necessarily correlate with a change in serum T4 concentrations in rodents (de Sandro, et al., 
1992;  Hood and Klaassen, 2000a;  Craft, et al., 2002) and decreases in serum T4 may occur 
independent of hepatic T4 glucuronidation (Kato, et al., 2004;  Kato, et al., 2005;  Kato, et 
al., 2007;  Kato, et al., 2010;  Richardson and Klaassen, 2010).  Previous studies also 
demonstrate that decreases in serum T4 may occur as a result of increases in T4 accumulation 
in the liver (Kato, et al., 2011;  Martin, et al., 2012). The present study questions the 
importance of hepatic T4 glucuronidation and nuclear receptor activation on T4 clearance in 
rat and human hepatocytes. Prototype nuclear receptor agonists known to decrease serum T4 
concentrations and increase hepatic UGTs in rats were chosen for this study (Hood and 
Klaassen, 2000a;  Craft, et al., 2002). To examine the effects of nuclear receptor agonists on 
T4 metabolism, sandwich-cultured Sprague-Dawley male rat (SCRH) and human (SCHH) 
hepatocytes were treated with PB and 3MC, the prototype agonists for CAR and AhR, 
respectively. Due to the species differences in PXR activation, SCRH were treated with PCN 
and SCHH were treated with Rif. PCB 153, often described as a PB-like inducer (Parkinson 
et al., 1983;  McFarland and Clarke, 1989), was used as a prototype persistent organic 
pollutant. PCB 153 mediates decreases in serum T4 concentrations in rats and is found in 
high concentrations in human serum (NHANES, 2012) (Crofton, et al., 2005;  Liu et al., 
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2012). The results of this study show that increases in T4 glucuronidation are agonist- and 
species-specific. To our knowledge the present experiments were the first to examine species 
differences in xenobiotic-mediated increases in T4 metabolism using rat and human 
hepatocytes.  
To determine the functional integrity of the SCH used in this study, CYP1A, CYP2B, 
and CYP3A mRNA expression were measured, as classic targets for AhR, CAR, and PXR 
activation, respectively. As expected, the prototypical nuclear receptor agonists PB, PCN, 
and 3MC increased target P450 mRNA expression in SCRH. Consistent with previous 
studies, PB activates CAR to increase Cyp2b2 (CAR) and to a lesser degree Cyp3a1 (PXR) 
in SCRH (Frueh et al., 1997;  Meyer and Hoffmann, 1999;  de Longueville et al., 2003). In 
SCRH, PCN increased Cyp3a1 and to a much lesser degree Cyp2b2 (Smirlis et al., 2001) and 
3MC increased Cyp1a1 (AhR) (Hartley and Klaassen, 2000;  Surry et al., 2000). As 
previously reported, PB acted as a mixed activator of CAR and PXR through the induction of 
CYP2B6 and CYP3A4 in SCRH (Faucette et al., 2007;  Rotroff et al., 2010). PXR activation 
by Rif resulted in the induction of both CYP3A4 and CYP2B6 in SCHH (Faucette et al., 
2006). An overlap in genes regulated by PXR and CAR has been previously demonstrated, 
where PXR regulates CYP2B genes and CAR regulates CYP3A genes and this crosstalk 
between receptors may explain the overlapping induction of CYP2B and CYP3A in this 
study (Maglich, et al., 2002;  Pascussi et al., 2008).  As expected, 3MC proved to be a strong 
activator of AhR through the increase of CYP1A1 in SCHH. The prototype environmental 
pollutant, PCB 153, is described as PB-like based on its ability to induce CYP2B (Parkinson, 
et al., 1983;  McFarland and Clarke, 1989). In the present study, PCB 153 was a potent 
inducer of Cyp2b2 in SCRH.  In SCHH, PCB 153 was a more potent inducer of CYP2B6 and 
89 
 
CYP1A1, than CYP3A4, but the increase in CYP1A1 suggests the presence of a possible 
dioxin-like contaminant. However, the lack of a dose-dependent increase in Cyp1a1 in SCRH 
indicates the CYP1A1 increase in SCHH may be due to the overlapping regulation by CAR 
(Auyeung et al., 2003;  Nishimura et al., 2005).  
T4G, T4S, rT3 and T3 were all measured in the medium of SCRH and SCHH and only 
T4G was altered by chemical treatment. T4G increased in the medium of SCRH treated with 
PB, PCN, 3MC, and PCB 153 by as much as 1.7- , 2.0- , 4.4- , and 4.8-fold, respectively.  
These results are consistent with previous studies in which rat hepatocytes treated with PB 
(Viollon-Abadie, et al., 2000) and 3MC (Jemnitz et al., 2000) increased T4-UGT activity.  In 
vivo studies show that rats treated with PB, PCN, or 3MC resulted in increased hepatic T4-
UGT activity; however similar to the present study, PB-mediated increases in T4-UGT 
activity were small compared to the other nuclear receptor agonists (Barter and Klaassen, 
1992;  Barter and Klaassen, 1994;  Hood and Klaassen, 2000a). Kato et al. (2005) found that 
decreases in serum T4 in Gunn rats treated with PB were independent of T4 glucuronidation. 
In the present study, the small changes in T4G levels in the medium of SCRH following PB 
treatment is consistent with studies using Gunn rats and suggests that hepatic T4 
glucuronidation may play a smaller role in serum T4 decreases in rats treated with PB 
compared to PCN and 3MC. In contrast to SCRH, SCHH treated with Rif and PCB 153 
increased T4G levels in the medium; however, PB and 3MC did not increase T4G production. 
Studies by Ohnhaus et al (1981;  1983) showed that PB did not decrease serum T4 in humans, 
but parameters for liver microsomal enzyme activity, antipyrene and 6-β-hydroxycortisol 
clearance were increased in humans. Compared to PB, Rif decreased serum T4 and increased 
the metabolic clearance of antipyrene and 6-β-hydroxycortisol, but to a much greater extent 
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in humans. Although not exact evidence of T4 metabolism, the data suggest that the decrease 
in serum T4 followed by treatment with Rif may occur through mechanisms other than 
glucuronidation in humans.  
In rat liver, Ugt1a1 and Ugt1a6 are thought to be the major isoforms responsible for 
T4 glucuronidation (Vansell and Klaassen, 2002b) and UGT1A1, UGT1A3 and UGT1A9 are 
thought to be responsible for T4 glucuronidation in human liver (Findlay et al., 2000;  Yoder 
Graber et al., 2007). The differential induction of UGTs by AhR, CAR, and PXR is more 
apparent in rats, but not in humans. For example, AhR regulates Ugt1a6 in rats and to a lesser 
extent in humans (Auyeung, et al., 2003;  Bock, 2011). In rats, Ugt1a1 is regulated by CAR 
and PXR. In humans, UGT1A1 and UGT1A6 are regulated by AhR, CAR and PXR; 
however, UGT1A6 is not as inducible as UGT1A1 In the present study, not all of the 
agonists that increased T4G levels in the medium of SCRH and SCHH increased UGT 
mRNA expression. The lack of UGT mRNA expression induction in rat hepatocytes treated 
with PB agrees with studies by Shelby and Klaassen (2006), which show hepatic 
Ugt1a1,Ugt1a5, and Ugt1a6 mRNA expression did not change in rats treated with PB. In 
contrast to the present study, hepatic Ugt1a1 and Ugt1a5 mRNA expression have been shown 
to increase in rats treated with PCN (Shelby and Klaassen, 2006). In the present study, the 
25.7-fold increase in Ugt1a6 mRNA expression coincided with the 4.4-fold increase in T4G 
levels in medium of SCRH treated with 3MC. Rat Ugt1a6 induction is dependent on AhR 
activation (Auyeung, et al., 2003;  Bock, 2011) and the lack of significant increases in 
Ugt1a6 mRNA expression confirms that PCB 153 is not activating AhR in this model 
system. In SCHH, UGT mRNA expression increased with PB treatment, although T4G levels 
did not increase in the medium.  Rif increased mRNA expression, which coincides with 
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increases in T4G levels in the medium of SCHH. UGT mRNA expression levels were 
induced in SCHH treated with 3MC and PCB 153.  Despite the increased UGT1A1 mRNA 
expression by 3MC, there was no increase in T4G levels.  PCB 153 increased T4G levels by 
3.6-fold, which coincided with increases in UGT1A1 (p<0.01) and UGT1A4 (p<0.001).  
These results show that UGT mRNA expression may not be a reliable indicator for the 
increase in T4G levels in this system.  However in SCRH, 3MC increased T4G levels, which 
matched the increase in Ugt1a6 mRNA expression suggesting that potent activators of AhR 
may increase T4G levels through the induction of UGTs to a greater extent than other nuclear 
receptor activators.  
AhR, CAR and PXR also have been implicated in the regulation of SULTs (Saini, et 
al., 2004;  Yanagiba et al., 2009;  Aleksunes and Klaassen, 2012) and it has been proposed 
that SULTs may be more important in the metabolism of TH in humans than in rats (Kester, 
et al., 1999;  Kester, et al., 2003). In the present study, there were no significant changes in 
T4S levels following treatment of SCRH and SCHH with each nuclear receptor agonist. 
Because SULTs have a low affinity for T4 and the evidence that T4G is the major metabolite 
found in the bile in rats, it is not surprising that T4 sulfation did not change in the medium of 
SCRH and SCHH (Rutgers, et al., 1989;  Visser, 1996). In addition, the lack of effect on T4 
sulfation may be partly due to the instability and poor capacity of the SULT cofactor, PAPS 
(Koster et al., 1981;  Kim et al., 1995;  Novakova et al., 2004).  Impaired hepatic DI activity 
is associated with hypothyroidism in rats treated with dioxin or dioxin-like chemicals (Hood 
and Klaassen, 2000b;  Viluksela et al., 2004;  Szabo, et al., 2009); however, in the present 
study, there was no change in T3+rT3 levels and no change in DI mRNA expression in both 
species of hepatocytes. This agrees with the premise that a reduction in deiodinase activity is 
92 
 
a physiological response and is not due to direct effects of microsomal enzyme inducers; 
therefore, changes in T3+rT3 production and DI mRNA expression may not be observed in an 
in vitro system (Davies, et al., 1996). 
 Hepatic transporters are important in facilitating the absorption, distribution, and 
elimination of a variety of nutrients, drugs, and metabolites and are coordinately induced 
through the activation of nuclear receptors (Bock and Kohle, 2004;  Kohle and Bock, 2009;  
Aleksunes and Klaassen, 2012). Furthermore, reports show that TH are actively transported 
into and out of cells (De Jong, et al., 1992;  de Jong, et al., 1993;  Friesema, et al., 1999;  
Visser et al., 2008;  Lecureux, et al., 2009). Kato et al. (2010;  2011) demonstrated that PB 
and PCB 153 increased [125I]-T4 liver accumulation in rodents. The increase [125I]-T4 
accumulation in the liver resulted in increases in the biliary elimination of [125I]-T4 and [125I]-
T4G, suggesting that hepatic transporters are involved in the xenobiotic-mediated cellular 
uptake and biliary excretion of 125I]-T4 and [125I]-T4G. Differences between rats and mice in 
the biliary elimination of [125I]-T4 and [125I]-T4G following treatment with PB and PCB 153 
indicates a possible difference in the activity of transporters responsible for excretion into the 
bile duct (Kato, et al., 2010;  Kato, et al., 2011).  As a potential rate-limiting step for TH 
metabolism, we examined the species differences in accumulation of [125I]-T4 following 
treatment with different nuclear receptor agonists. In untreated hepatocytes, the rate of [125I]-
T4 accumulation is slower in human hepatocytes than rat hepatocytes (Krenning, et al., 1981;  
de Jong, et al., 1993). Previous work in our laboratory (Richardson et al; submitted) showed 
that at early time points (1-5 minutes) [125I]-T4 accumulation in untreated SCRH and SCHH 
were not significantly different. In the present study, [125I]-T4 accumulation following 
treatment with each agonist was not significantly different in SCRH and SCHH; however, 
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mRNA expression for MDR1, an efflux transporter, increased significantly with PB, 3MC 
and PCB 153 in SCRH and with PB and Rif treatment in SCHH. MRP2 is also an efflux 
transporter and it increased in SCHH treated with PB and Rif. Oat2 mRNA expression, an 
uptake transporter, increased in SCRH treated with PB; however, no significant changes were 
found in SCHH.  Collectively, the differences in transporter mRNA expression did not 
necessarily coincide with [125I]-T4 accumulation in SCRH and SCHH nor was it consistent 
with the differences in T4G levels in the medium of SCRH and SCHH following treatment 
with nuclear receptor agonists.  The main goal of the present study was to examine nuclear 
receptor-mediated increases in UGTs and T4 metabolism; therefore our system was 
optimized for nuclear receptor activation (72 hours incubation with activator) and T4 
metabolism (24 hours incubation with T4). Opposing expression profiles for uptake and 
efflux transporters were found over culture days in SCRH, suggesting optimal culture 
conditions for uptake transporters may not be optimal for efflux transporters (Tchaparian et 
al., 2011). Because the system was optimized for induction and metabolism and not 
optimized for transporter activity, it is difficult to make assertions about T4 transport in our 
system. In addition, mRNA expression is not a reliable indicator of transporter expression 
and therefore may explain the lack of consistency in the data (Johnson et al., 2002b;  Johnson 
and Klaassen, 2002;  Kipp and Arias, 2002;  Tchaparian, et al., 2011). The in vitro system 
used in the present study may not be able to discriminate between T4 accumulation and 
excretion; therefore, the use of transporter vesicles may be more suitable for the further 
exploration of all aspects of T4 transport. 
In the present study, PCB 153 increased T4G levels in the medium of both SCRH and 
SCHH, whereas PB treatment caused a small increase in T4G only in medium of SCRH. 
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Based on P450 induction, PB appears to be a CAR agonist at lower and possibly more 
physiologically relevant concentrations; PCB 153 appears to be a more potent CAR agonist 
in SCRH. In SCHH, PB is a mixed activator of CAR and PXR however; PCB 153 appears to 
be more of a potent CAR agonist. Overall, the data suggests that PCB 153 is not PB-like, due 
to the large increases in T4G levels in medium of SCRH and SCHH; however, based on P450 
induction PB and PCB 153 are similar. This suggests PCB 153 is a more potent inducer of T4 
glucuronidation than PB in SCRH and SCHH.  
Species differences have been previously described in P450 induction and may 
explain species differences in T4 metabolism found in the current study. For example, PB 
does not directly interact with CAR; however, human CYP2B6 is inducible by PB, although 
to a much lesser extent than rodent CYP2B.  Since PB does not bind to CAR, this difference 
in induction may be due to differences in the proximal promoter for the CYP2B gene in 
rodents and humans (Faucette, et al., 2006).  In the current study, the species-specific 
differences in T4 glucuronidation following treatment with nuclear receptor agonists may be 
due to alternative splicing, phosphorylation of the receptor, or through crosstalk from other 
signaling systems (Weigel, 1996;  Crofts et al., 1998;  Fasco, 1998;  Shao and Lazar, 1999). 
While it appears that UGT metabolism and nuclear receptor regulation may not explain 
decreases in serum T4, further exploration of the role of transporters in this issue would be 
warranted. 
The present study further supports previous findings, which propose that serum T4 
decreases may occur independent of glucuronidation. It has been suggested that increases in 
transporter-mediated accumulation of T4 in the liver is a mechanism by which serum T4 is 
metabolized or eliminated through the bile; however, we were unable to confirm that 
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differences in T4 accumulation are linked to differences in T4 metabolism in this system. 
Data from this study are in accordance with previous studies which show increases in T4 
glucuronidation are species- and agonist-specific and further confirms that PB mediated 
decreases in serum T4 may be independent of hepatic T4 glucuronidation in rats (Kato, et al., 
2005;  Kato, et al., 2010). This study shows that PCB 153 was PB-like in its ability to induce 
CYP2B in SCRH and SCHH; however, PCB 153 and PB are not similar in their ability to 
induce T4 glucuronidation.  Overall, we demonstrate that SCH are an appropriate tool for 
assessing TH disruption and human risk, although further exploration of the role of 
transporters in T4 disposition is needed.    
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Table 3.1 
 
Donor information for human hepatocytes  
  Donor       Gender    Age      Smoke/Alcohol          Medications          Experimental Use 
UKN=unknown 
  
Hu1191 
 
Male 19 No/No UKN T4 accumulation 
Hu1193 Male 68 Yes/No Aspirin 
Zolpidem 
Simvastatin 
Ranitidine 
 
T4 accumulation 
Hu1197 
 
 
 
 
 
Hu1236 
 
 
Hu1248 
 
Female 
 
 
 
 
 
Female 
 
 
Male 
29 
 
 
 
 
 
68 
 
 
63 
No/Yes 
 
 
 
 
 
No/No 
 
 
Yes/Yes 
Amphetamine 
Bupropion 
Cetirizine 
Clonazepam 
Lamotrigine 
 
Multivitamin 
Vitamin D 
 
Sertraline 
Vicodin 
Docusate Sodium 
 
T4 accumulation 
 
 
 
 
 
Dose response 
 
 
Dose response 
Hu1362 Female 57 No/No Atenolol and 
Chlorthalidone 
Lorazepam 
Oxycodone 
 
Dose response 
Hu1364 Male 51 No/No Cyanocobalamin 
Diltiazem 
Ferrous Sulfate 
Folic Acid 
Metoprolol 
Omeprazole 
Potassium Chloride 
Prednisone 
Dose response 
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Table 3.2 
 
TaqMan rat gene expression assays  
Group Gene TaqMan Gene 
Expression Assay ID 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Endogenous control Gapdh Rn99999916_s1 
Nuclear receptor activation  Cyp1a1 
Cyp2b2 
Cyp3a1 
 
Rn00487218_m1 
Rn02786833_m1 
Rn01640761_gH 
Phase II metabolism 
 
Ugt1a1 
Ugt1a5 
Ugt1a6 
Ugt2b 
Sult1a1 
Sult1b1 
Sult1c1 
Sult1e1 
 
Rn00754947_m1 
Rn01427785_m1 
Rn00756113_mH 
Rn02349650_m1 
Rn00582915_m1 
Rn00673872_m1 
Rn00581955_m1 
Rn00820646_g1 
Transporter 
 
 
Mdr1a 
Mdr1b 
Mrp2 
Mrp3 
Ntcp1 
Oat2 
 
Rn00591394_m1 
Rn00561753_m1 
Rn00563231_m1 
Rn00589786_m1 
Rn00566894_m1 
Rn00585513_m1 
Thyroid hormone responsive D1 
 
Rn00572183_m1 
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Table 3.3 
 
TaqMan human gene expression assays   
Group Gene TaqMan Gene 
Expression Assay ID 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Endogenous control GAPDH 
 
Hs99999905_m1 
 
Nuclear receptor activation CYP1A1 
CYP2B6 
CYP3A4 
 
Hs00153120_m1 
Hs03044634_m1 
Hs00430021_m1 
 
Phase II metabolism 
 
UGT1A1 
UGT1A4 
UGT1A6 
UGT1A9 
 
SULT1A3 
SULT1E1 
SULT2A1 
 
Hs02511055_s1 
Hs01592480_m1 
Hs01592477_m1 
Hs02516855_sH 
 
Hs00413970_m1 
Hs00193690_m1 
Hs00234219_m1 
 
Transporter 
 
 
MDR1B 
MRP2 
MRP3 
NTCP1 
OAT2 
 
Hs00184500_m1 
Hs00166123_m1 
Hs00358656_m1 
Hs00161820_m1 
Hs00185140_m1 
 
Thyroid hormone responsive D1 
 
Hs01554724_m1 
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Figure 3.1. Comparison of appearance of metabolites in medium of SCRH following 
treatment with nuclear receptor agonists. Hepatocytes were incubated with 0.1% DMSO 
(control), PB, PCN, 3MC, or PCB 153 for 72 hours. Hepatocytes are then incubated for 24 
hour with 0.05 µM [125I]-T4. Metabolites were separated using the established UPLC method. 
Metabolites analyzed are T4G (A), T4S (B), and T3+rT3 (C). Experiments were performed in 
duplicate Data are expressed as mean±standard deviation. n=4/group. *Significantly different 
than control; p<0.05. **Significantly different than control; p<0.01. ***Significantly 
different than control; p<0.001. 
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Figure 3.2. Comparison of appearance of metabolites in medium of SCHH following 
treatment with nuclear receptor agonists. Hepatocytes were incubated with 0.1% DMSO 
(control), PB, Rif, 3MC, or PCB 153 for 72 hours. Hepatocytes are then incubated for 24 
hour with 0.1 µM [125I]-T4. Metabolites were separated using the established UPLC method. 
Metabolites analyzed are T4G (A), T4S (B), and T3+rT3 (C). Experiments were performed in 
duplicate Data are expressed as mean±standard deviation. n=4/group. ***Significantly 
different than control; p<0.001. 
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Table 3.4 
 
Fold change in rat hepatic P450 mRNA expression 
Chemical 
 
Dose 
(µM) 
Cyp1a1a Cyp2b2a Cyp3a1a 
PB  
 
0 
10 
100 
1000 
1.0±0.0 
1.8±0.8 
1.8±1.4 
4.7±2.4 
1.0±0.0 
10.1±14.9 
28.3±19.9 
197.0±78.6b 
1.0±0.0 
11.2±18.2 
18.2±28.7 
60.4±51.8 
 
PCN 
 
0 
0.1 
1 
10 
 
1.0±0.0 
2.8±3.8 
1.7±1.8 
2.8±2.3 
 
1.0±0.0 
0.8±0.6 
4.2±2.9 
7.4±2.9 
 
1.0±0.0 
17.9±27.6 
213.9±347.2 
660.7±489.1b 
 
3MC 
 
0 
0.05 
0.5 
5 
 
1.0±0.0 
33.8±52.8 
30.9±24.6 
270.2±204.9b 
 
1.0±0.0 
0.9±0.9 
0.8±0.9 
1.0±0.4 
 
1.0±0.0 
7.8±12.2 
5.3±7.2 
4.4±4.2 
 
PCB 153 
 
0 
0.3 
3 
30 
 
1.0±0.0 
2.1±1.2 
4.2±2.8 
3.6±0.5 
 
1.0±0.0 
20.9±12.2 
27.4±19.4 
19.0±18.7 
 
1.0±0.0 
7.2±10.8 
21.1±34.0 
78.6±94.0 
aData are expressed as fold change mean±standard deviation (n=3/group)  
relative to control.  
bSignificantly different from control group (p<0.001). 
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Table 3.5 
 
Fold change in human hepatic P450 mRNA expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 aData are expressed as fold change mean±standard deviation (n=4/group)  
              relative to control. 
bSignificantly different from control group (p<0.05). 
cSignificantly different from  control group (p<0.01).  
dSignificantly different from control group (p<0.001). 
  
Chemical 
 
Dose 
(µM) 
CYP1A1a CYP2B6 a CYP3A4 a 
PB  
 
0 
10 
100 
1000 
 
1.0±0.0 
0.5±0.3 
0.8±0.5 
1.3±0.5 
1.0±0.0 
1.3±0.2 
5.7±2.1 
     17.1±7.4 
1.0±0.0 
1.0±0.4 
3.7±2.4 
  20.0±10.8d 
 
Rif 0 
0.1 
1 
10 
 
1.0±0.0 
0.6±0.4 
1.0±0.5 
0.7±0.4 
1.00±0.01 
2.34±1.61 
6.80±5.56 
15.29±9.46 
1.00±0.00 
5.10±4.20 
15.65±9.33c 
  24.87±12.09d 
3MC 0 
0.05 
0.5 
5 
 
1.0±0.0 
9.8±6.4 
     154.6±132.8c 
  178.0±162.4c 
1.0±0.0 
1.3±0.3 
1.2±0.4 
1.0±0.1 
1.0±0.0 
1.0±0.3 
0.7±0.5 
0.9±0.3 
PCB 153 0 
0.3 
3 
30 
1.0±0.0 
0.8±0.3 
5.2±5.6 
19.6±22.5 
1.0±0.0 
4.6±2.5 
  21.7±11.0b 
  31.4±24.1d 
1.0±0.0 
1.4±0.8 
2.9±0.7 
 5.3±2.4 
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Table 3.6 
 
Fold change in rat hepatic UGT mRNA expression 
aData are expressed as fold change mean±standard deviation (n=3/group) relative 
to control. 
bSignificantly different from control group (p<0.001). 
 
 
 
Chemical 
 
Dose 
(µM) 
Ugt1a1a Ugt1a5a Ugt1a6a Ugt2ba 
PB  
 
0 
10 
100 
1000 
 
1.0±0.0 
1.2±0.8 
1.9±1.7 
2.4±0.6 
1.0±0.0 
2.0±1.0 
2.0±0.7 
1.4±0.1 
1.0±0.0 
1.4±0.3 
2.0±1.2 
1.9±0.4 
1.0±0.0 
2.8±2.9 
3.1±2.7 
2.3±1.1 
PCN 0 
0.1 
1 
10 
 
1.0±0.0 
1.4±0.8 
2.5±1.9 
2.3±0.8 
1.0±0.0 
1.4±0.8 
2.6±2.6 
2.4±1.0 
1.0±0.0 
1.6±0.2 
1.8±0.8 
0.9±0.1 
1.0±0.0 
2.0±1.5 
3.1±2.9 
1.3±0.4 
3MC 0 
0.05 
0.5 
5 
 
1.0±0.0 
1.5±1.0 
1.0±0.2 
0.5±0.2 
1.0±0.0 
1.3±0.6 
1.2±0.3 
0.5±0.3 
1.0±0.0 
2.3±0.9 
8.2±1.7 
  25.7±21.2b 
1.0±0.0 
3.1±2.9 
2.7±1.8 
1.1±0.3 
PCB 153 0 
0.3 
3 
30 
1.0±0.0 
1.3±0.5 
1.8±1.1 
1.5±0.3 
1.0±0.0 
1.5±1.1 
1.6±1.2 
2.1±0.4 
1.0±0.0 
1.7±0.4 
2.1±0.1 
1.9±0.9 
1.0±0.0 
2.7±2.5 
2.7±2.7 
0.9±0.3 
 
 
Table 3.7 
 
Fold change in human hepatic UGT mRNA expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    aData are expressed as fold change mean±standard deviation (n=4/group) relative to control. 
bSignificantly different from control group (p<0.05).  
  cSignificantly different from control group (p<0.01). 
   dSignificantly different from control group (p<0.001). 
Chemical 
 
Dose 
(µM) 
UGT1A1a UGT1A4a UGT1A6a UGT1A9 a UGT2B15 UGT2B4 
PB 
 
0 
10 
100 
1000 
 
1.0±0.0 
0.9±0.1 
2.2±0.7 
  6.4±2.6d 
1.0±0.1 
1.2±0.3 
1.7±0.3 
  9.6±6.2d 
1.0±0.0 
1.1±0.1 
1.6±0.7 
 2.2±0.3d 
 
1.0±0.0 
0.9±0.1 
1.0±0.3 
1.0±0.2 
1.0±0.0 
0.9±0.1 
1.6±0.5 
1.9±0.8 
1.0±0.0 
1.3±0.0 
1.5±0.4 
 2.0±0.5b 
 
Rif 0 
0.1 
1 
10 
 
1.0±0.0 
1.5±0.3 
4.7±2.2b 
6.6±3.6d 
1.0±0.1 
1.5±0.4 
3.3±0.5 
7.2±0.7d 
1.0±0.0 
1.2±0.1 
1.2±0.0 
1.6±0.2 
 
1.0±0.0 
1.1±0.3 
0.8±0.3 
0.9±0.3 
1.0±0.0 
1.5±0.3 
2.7±0.6 
 3.1±1.3d 
 
1.0±0.0 
1.5±0.3 
 2.1±0.5c 
 2.4±0.9d 
 
3MC 0 
0.05 
0.5 
5 
 
1.0±0.0 
1.5±0.2 
3.3±0.6 
2.9±1.1 
1.0±0.1 
1.7±0.7 
2.8±1.6 
1.8±0.6 
1.0±0.0 
1.2±0.3 
1.3±0.4 
1.1±0.3 
1.0±0.0 
1.0±0.2 
0.7±0.0 
1.0±0.3 
1.0±0.0 
1.2±0.6 
1.1±0.7 
0.9±0.3 
 
1.0±0.0 
1.3±0.3 
1.2±0.4 
1.1±0.3 
PCB 153 0 
0.3 
3 
30 
1.0±0.0 
1.3±0.2 
2.8±1.3 
3.5±1.5 
1.0±0.1 
1.3±0.5 
1.4±0.6 
2.1±0.1 
1.0±0.0 
1.1±0.3 
0.9±0.1 
1.3±0.2 
1.0±0.0 
1.1±0.3 
1.3±0.1 
1.0±0.1 
1.0±0.0 
1.3±0.6 
1.2±0.2 
1.2±0.3 
1.0±0.0 
1.3±0.3 
1.4±0.4 
1.4±0.2 
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Table 3.8 
 
Fold change in rat hepatic SULT mRNA expression 
Chemical 
 
Dose 
(µM) 
Sult1a1a Sult1b1a Sult1c1a Sult1e1a 
PB  
 
0 
10 
100 
1000 
 
1.0±0.0 
1.7±1.7 
1.8±1.2 
2.1±0.6 
1.0±0.0 
1.5±1.2 
1.7±0.6 
1.4±1.3 
1.0±0.0 
0.9±0.3 
1.7±0.2 
0.9±0.1 
1.0±0.0 
0.8±0.6 
2.5±1.3 
6.8±4.2c 
PCN 0 
0.1 
1 
10 
 
1.0±0.0 
1.7±0.8 
2.2±1.7 
0.9±0.3 
1.0±0.0 
1.3±0.5 
2.3±1.0 
1.5±0.5 
1.0±0.0 
1.1±0.2 
0.7±0.1 
0.2±0.1b 
1.0±0.0 
1.3±0.3 
1.7±1.1 
1.1±0.5 
3MC 0 
0.05 
0.5 
5 
 
1.0±0.0 
1.7±1.5 
1.9±0.5 
1.1±0.6 
1.0±0.0 
1.4±1.0 
2.0±0.7 
1.0±0.0 
1.0±0.0 
0.6±0.2 
1.3±0.8 
1.2±0.5 
1.0±0.0 
0.9±0.4 
1.5±0.3 
1.2±0.4 
PCB 153 0 
0.3 
3 
30 
1.0±0.0 
1.7±0.5 
1.9±0.9 
0.7±0.2 
1.0±0.0 
1.7±0.9 
1.7±0.9 
0.9±0.2 
1.0±0.0 
1.2±0.3 
0.9±0.2 
0.8±0.8 
1.0±0.0 
2.4±1.0 
1.7±0.6 
0.8±0.4 
aData are expressed as fold change mean±standard deviation (n=3/group)  
 relative to control.  
bSignificantly different from control group (p<0.05). 
cSignificantly different from control group (p<0.001). 
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Table 3.9 
 
Fold change in human hepatic SULT mRNA expression 
 
 
 
 
 
 
 
 
 
 
 
                      
aData are expressed as fold change mean±standard deviation (n=4/group) 
relative to control. 
 
 
  
Chemical 
 
Dose 
(µM) 
SULT1A3a SULT1E1a SULT2A1 a 
PB  
 
0 
10 
100 
1000 
 
1.0±0.0 
0.9±0.4 
1.1±0.3 
1.3±0.4 
1.0±0.0 
1.0±0.3 
0.5±0.1 
0.3±0.2 
1.0±0.0 
0.9±0.0 
1.0±0.7 
1.0±0.4 
 
Rif 0 
0.1 
1 
10 
 
1.0±0.0 
0.9±0.5 
1.1±0.5 
1.0±0.4 
1.0±0.0 
1.1±0.7 
0.7±0.5 
0.7±0.7 
1.0±0.0 
1.1±0.7 
0.9±0.3 
0.9 ±0.7 
 
3MC 0 
0.05 
0.5 
5 
 
1.0±0.0 
0.8±0.3 
0.9±0.4 
0.7±0.3 
1.0±0.0 
1.1±0.3 
0.7±0.2 
0.9±0.1 
1.0±0.0 
1.0±0.2 
1.0±0.2 
1.0±0.2 
PCB 153 0 
0.3 
3 
30 
1.0±0.0 
0.8±0.2 
0.9±0.3 
1.4±0.9 
1.0±0.0 
1.0±0.3 
1.0±0.3 
0.6±0.3 
1.0±0.0 
0.9±0.3 
1.2±0.4 
0.8±0.4 
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Table 3.10 
 
Fold change in rat hepatic deiodinase I mRNA expression 
 
 
 
 
 
 
 
 
 
 
 
 
    aData are expressed as fold change mean±standard deviation (n=4/group) 
 relative to control. 
 
  
Chemical 
 
Dose 
(µM) 
D1a 
PB  
 
0 
10 
100 
1000 
 
1.0±0.0 
0.8±0.2 
1.1±0.0 
1.4±0.2 
PCN 0 
0.1 
1 
10 
 
1.0±0.0 
0.9±0.3 
1.1±0.3 
0.8±0.2 
3MC 0 
0.05 
0.5 
5 
 
1.0±0.0 
0.8±0.3 
1.2±0.6 
1.3±1.0 
PCB 153 0 
0.3 
3 
30 
1.0±0.0 
0.9±0.3 
1.3±0.1 
0.8±0.1 
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Table 3.11 
 
Fold change in human hepatic deiodinase I mRNA expression 
 
 
 
 
 
 
 
 
 
 
 
 
                                         aData are expressed as fold change mean±standard deviation (n=4/group). 
 
Chemical 
 
Dose 
(µM) 
D1a 
PB  
 
0 
10 
100 
1000 
 
1.0±0.0 
1.0±0.2 
1.6±1.0 
2.0±0.5 
Rif 0 
0.1 
1 
10 
 
1.0±0.0 
1.7±0.7 
1.9±0.4 
1.6±0.1 
3MC 0 
0.05 
0.5 
5 
 
1.0±0.0 
1.1±0.4 
0.9±0.0 
1.2±0.7 
PCB 153 0 
0.3 
3 
30 
1.0±0.0 
2.4±1.3b 
1.9±1.1 
1.5±0.3 
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Figure 3.3. Accumulation of [125I]-derived radioactivity in rat (A) and human (B) 
hepatocytes following treatment with nuclear receptor agonists..Sandwich-cultured 
hepatocytes were plated at 3.5x105 cells per well and incubated with 0.0005µM (5000 CPM) 
[125I]-T4. The accumulation of [125I]-T4 was determined over time (1-30 min) following 
treatment. Data are expressed as percentage of dose mean ± standard deviation. The lines 
represent the linear regression of the data. The curved lines represent the nonlinear regression 
of the data. n=3/group.  
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Table 3.12 
 
Fold change in rat hepatic efflux and uptake transporter mRNA expression 
Chemical 
 
Dose 
(µM) 
Mdr1aa Mdr1ba Mrp2a Mrp3a Ntcp1a Oat2a 
PB  
 
0 
10 
100 
1000 
1.0±0.0 
0.9±0.1 
0.9±0.2 
1.4±0.5d 
1.0±0.0 
0.9±0.4 
0.8±0.5 
1.3±0.7 
1.0±0.0 
2.0±1.8 
2.2±1.7 
2.4±0.8 
1.0±0.0 
1.1±0.4 
1.1±0.3 
1.5±0.5 
1.0±0.0 
1.2±1.1 
1.5±0.8 
1.6±0.6 
1.0±0.0 
1.2±0.5 
1.4±0.2 
1.9±0.7b 
 
PCN 
 
0 
0.1 
1 
10 
 
1.0±0.0 
0.7±0.3 
1.2±0.2 
1.2±0.1 
 
1.0±0.0 
0.7±0.3 
1.1±0.4 
1.3±0.2 
 
1.0±0.0 
2.2±1.4 
3.9±4.3 
4.0±1.8 
 
1.0±0.0 
1.1±0.3 
1.4±0.1 
1.2±0.1 
 
1.0±0.0 
1.3±0.7 
1.9±1.6 
0.8±0.2 
 
1.0±0.0 
1.1±0.3 
1.5±0.5 
0.8±0.2 
 
3MC 
 
0 
0.05 
0.5 
5 
 
1.0±0.0 
0.9±0.1 
0.9±0.4 
1.7±0.2c 
 
1.0±0.0 
0.9±0.1 
0.8±0.4 
1.0±0.4 
 
1.0±0.0 
2.1±1.8 
1.7±0.1 
1.8±0.3 
 
1.0±0.0 
0.9±0.1 
1.6±0.9 
2.0±0.7 
 
1.0±0.0 
1.3±1.4 
1.4±0.4 
1.2±0.9 
 
1.0±0.0 
1.0±0.4 
1.4±0.4 
1.4±0.2 
 
PCB 153 
 
0 
0.3 
3 
30 
 
1.0±0.0 
0.9±0.4 
1.1±0.2 
  1.6±0.1b 
 
1.0±0.0 
0.7±0.5 
0.8±0.4 
1.1±0.1 
 
1.0±0.0 
1.9±0.9 
2.5±1.6 
2.8±1.4 
 
1.0±0.0 
1.1±0.5 
1.3±0.5 
1.3±0.1 
 
1.0±0.0 
1.5±0.9 
1.2±0.7 
0.7±0.1 
 
1.0±0.0 
1.3±0.3 
1.3±0.1 
1.0±0.3 
aData are expressed as fold change mean±standard deviation (n=3/group) relative to     
control. 
               bSignificantly different from control group (p<0.05). 
               cSignificantly different from control group (p<0.01). 
               dSignificantly different from control group (p<0.001). 
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Table 3.13 
 
Fold change in human hepatic efflux and uptake transporter mRNA expression  
aData are expressed as fold change mean±standard deviation (n=4/group) relative to 
control. 
      bSignificantly different from control group (p<0.01). 
     cSignificantly different from control group (p<0.001). 
  
Chemical 
 
Dose 
(µM) 
MDR1a MRP2a MRP3 a    NTCP1a    OAT2a 
PB  
 
0 
10 
100 
1000 
 
1.0±0.1 
0.9±0.2 
1.2±0.3 
 2.3±0.6c 
1.0±0.0 
1.0±0.1 
1.3±0.4 
 2.5±0.0c 
1.0±0.0 
0.7±0.2 
0.7±0.2 
0.9±0.3 
1.0±0.0 
0.9±0.3 
0.8±0.5 
0.6±0.1 
1.0±0.0 
0.9±0.4 
1.0±0.30 
0.7±0.4 
Rif 0 
0.1 
1 
10 
 
1.0±0.1 
1.1±0.2 
 2.0±0.7b 
 2.0±0.7b 
1.0±0.0 
1.2±0.3 
 1.8±0.3c 
 2.1±0.3c 
1.0±0.0 
0.9±0.1 
1.0±0.3 
0.8±0.2 
1.0±0.0 
0.8±0.1 
1.3±0.9 
1.1±0.5 
1.0±0.0 
1.4±0.4 
1.1±0.1 
1.3±0.2 
3MC 0 
0.05 
0.5 
5 
 
1.0±0.1 
0.9±0.3 
0.8±0.2 
0.8±0.1 
1.0±0.0 
1.0±0.2 
0.9±0.2 
0.9±0.2 
1.0±0.0 
0.7±0.1 
0.7±0.2 
0.7±0.3 
1.0±0.0 
1.0±0.5 
0.6±0.1 
0.8±0.2 
1.0±0.0 
1.0±0.5 
0.7±0.4 
0.7±0.3 
PCB 153 0 
0.3 
3 
30 
1.0±0.1 
1.1±0.1 
1.1±0.3 
1.4±0.6 
1.0±0.0 
1.1±0.0 
1.1±0.2 
1.4±0.3 
1.0±0.0 
0.9±0.2 
0.9±0.3 
0.9±0.3 
1.0±0.03 
0.9±0.3 
1.1±0.0 
0.7±0.2 
1.0±0.0 
1.0±0.2 
1.2±0.3 
0.8±0.2 
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 CHAPTER 4 
 
EFFECTS OF BDE 47 ON THYROXINE METABOLISM 
 
A. INTRODUCTION 
 
Polybrominated diphenyl ethers (PBDEs) are a class of flame retardants used in 
various consumer products including polyurethane foam, electronics, and textile coating. Due 
to their persistence and lipophilicity, PBDEs bioaccumulate and have been detected in biota, 
environmental samples and human biological samples (Focant et al., 2004a;  Schecter et al., 
2010;  Krol et al., 2012). Pentabromodiphenyl ether (DE-71), is a commercial mixture of 
tribromodiphenyl ether to hexabromodiphenyl ether congeners, of which approximately 30% 
consists of 2,2′,4,4′-tetrabromodiphenyl ether (BDE 47).   BDE 47 is the predominant 
congener found in most environmental and human samples and usually accounts for half of 
the total PBDEs measured (Hites, 2004;  Lorber, 2008). Although found in human tissues, 
the health risks from exposure to PDBEs are uncertain.   
Similar to polychlorinated biphenyls (PCBs) and dioxins, PBDEs disrupt thyroid 
hormone (TH) homeostasis (Zhou, et al., 2001;  Hallgren and Darnerud, 2002;  Richardson, 
et al., 2008;  Szabo, et al., 2009).  Although there are many sites within the thyroid axis in 
which xenobiotics such as PBDEs can interrupt TH homeostasis, the literature focuses on 
two possible mechanisms: (1) the increase in hepatic TH metabolism and (2) the competitive
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binding of PBDEs with TH binding proteins. In rodents, decreases in thyroxine (T4) are often 
associated with xenobiotic-mediated increases in T4 glucuronidation and the subsequent 
elimination of T4-glucuronide (T4G) into bile (Vansell and Klaassen, 2002b;  Hood, et al., 
2003;  Martin, et al., 2012). Decreases in serum T4 in rodents treated with PBDEs often have 
been linked to inductions of hepatic uridinediphosphate glucuronosyltransferases (UGTs). In 
rat pups, gestational and lactational exposures to PBDEs result in decreased serum T4 
concentrations and inductions in hepatic UGT activity (Zhou, et al., 2002;  Szabo, et al., 
2009). Exposure to BDE 47 resulted in a 50% decrease in serum T4 concentrations and 
increases in hepatic Ugt1a1 and Ugt1a7 mRNA expression in female mice; however liver T4-
UGT activity did not increase (Richardson, et al., 2008). Although it appears that serum T4 
decreases are associated with increases in hepatic UGTs, there is evidence that T4 decreases 
may be independent of UGT induction. Ugt1a-deficient Gunn rats fed, 3-methylcholanthrene 
(3MC), pregnenolone-16α-carbonitrile (PCN), or Arochlor 1254 resulted in decreases in 
serum T4 concentrations 19, 38, and 91%, respectively; however, hepatic T4-UGT activity 
was unchanged and the magnitude of the decrease in serum T4 was similar to that observed in 
the Wistar rat (Richardson and Klaassen, 2010). Kenechlor-500 administered to Wistar and 
Gunn rats decreased serum T4 and increased the accumulation of [125I]-T4 in several tissues 
including the liver, but only increased T4 glucuronidation in the Wistar rat (Kato, et al., 
2007). In Wistar rats treated with phenobarbital (PB), decreases in serum T4 is associated 
with increased hepatic T4-UGT activity and increased biliary elimination of [125I]-T4 and 
[125I]-T4G, but in the Gunn rat, PB decreases serum T4 concentrations without a concomitant 
increase in T4 glucuronidation or biliary elimination (Kato, et al., 2010).  
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In addition to UGTs, Sulfotransferases (SULTs) are a pathway for TH metabolism. 
SULTs are inducible in rat liver following xenobiotics treatment and may be linked to 
enhanced TH metabolism in the liver and biliary elimination (Szabo, et al., 2009;  Paul et al., 
2010). Sulfation of TH facilitates their further degradation by deiodinase I (DI) (Visser et al., 
1990;  Visser, 1994). Deiodinases also are involved in TH metabolism in their conversion of 
T4 and T3 to 3, 3’, 5’-triiodothyronine (rT3) and 3, 3’-diiodothyronine (3, 3’-T2), respectively. 
Together these studies show that decreases in serum T4 are not completely associated with 
hepatic T4 glucuronidation, but also may involve sulfation, deiodination, serum-to-liver 
accumulation and biliary elimination of T4.  
Transthyretin (TTR), is a major plasma TH binding protein found in all vertebrates.  
Hydroxylated PBDEs have been shown to competitively interact with TTR and it is 
hypothesized that this interaction displaces T4 from binding to TTR (Meerts et al., 2000;  
Hallgren and Darnerud, 2002;  Hamers et al., 2008). Hydroxylated metabolites of BDE 47, -
51, -51, -75, and -77 displaced more than 60% of [125I]-T4 from TTR in vitro (Meerts, et al., 
2000). Hamers et al. (2008) reported that six different hydroxylated metabolites of BDE 47 
had TTR-binding potencies 160–1600 times higher than the parent compound (BDE 47). 
This suggests that decreases in serum T4 may result from the displacement of T4 from TTR 
by BDE 47 metabolites.  
Aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) and 
pregnane X receptor (PXR) regulate genes such as cytochrome P450s (CYPs), UGTs, SULTs 
and transporters which are all involved in the metabolism and elimination of xenobiotics 
(Bock and Kohle, 2004;  Wagner, et al., 2005;  Kohle and Bock, 2009;  Tolson and Wang, 
2010). Correlations between inductions in hepatic UGTs and multidrug resistance protein-
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associated protein (MRP) with decreases in serum T4 have been observed. In mice, BDE 47 
induces CAR regulated genes such as Cyp2b10 mRNA expression (Richardson, et al., 2008). 
BDE 47 also increased CAR regulated genes possibly involved in the metabolism and 
transport of THs.  For example, hepatic Ugt1a1 and Ugt1a7 mRNA expression increases 
correlated with serum T4 decreases in mice treated with BDE 47. There is evidence that 
transporters regulated by nuclear receptors are responsible for transporting T4 or conjugated 
compounds such as T4G.  Multidrug resistance proteins (MDRs) are important in TH efflux 
(Mitchell, et al., 2005).  Several studies report a correlation between the induction of hepatic 
UGT (Ugt1a1 and Ugt1a6), multidrug resistance protein-associated protein (Mrp2), and 
organic anion transporting proteins (Oatp1 and Oatp2) mRNA expression levels with 
decreases in serum TH concentrations in rodents following chemical exposure (Ribeiro, et 
al., 1996;  Mitchell, et al., 2005;  Wong, et al., 2005;  Miyawaki, et al., 2012). Friesema et al 
(2005) used Xenopus laevis oocytes to identify Na(+) taurocholate cotransporting 
polypeptide (NTCP) and organic anion transporting polypeptide (OATP) as TH uptake 
transporters.  In mice, BDE 47 increases Mdr1a and Mrp3 mRNA expression (Richardson, et 
al., 2008). These results suggest that the upregulation of hepatic UGTs in concert with the 
upregulation in hepatic transporters may enhance the elimination of TH by BDE 47. 
Collectively, these studies show that hepatic T4 metabolism, displaced T4-TTR binding, and 
the active transport of THs may play a part in disrupting TH homeostasis. 
The use of in vitro approaches to predict aspects of human drug metabolism has been 
of great interest. Hepatocytes are used in the in vitro-in vivo extrapolation of metabolic 
activity toward a number of drugs. As biologically relevant tools in the study of metabolism, 
hepatocytes are a dependable model for predicting the induction of xenobiotics metabolizing 
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enzymes (LeCluyse, 2001;  Hewitt, et al., 2007). Using primary rat and human sandwich-
cultured hepatocytes this study makes comparisons of T4 metabolism in response to nuclear 
receptor activation by BDE 47. The present study also compares the effects of BDE 47 on the 
genes involved in TH homeostasis in rat liver and hepatocytes.   
 
B. MATERIALS AND METHODS 
 
Chemicals 
2, 2', 4, 4'-Tetrabromodiphenyl ether (BDE 47) was provided by Battelle Memorial 
Institute (Columbus, OH). Purity was >98% as determined by reverse-phase-performance 
liquid chromatography (HPLC). L-thyroxine (T4) was purchased from Sigma-Aldrich Co. 
(St. Louis, MO). [125I]-T4, (116 Ci/mmol) was purchased from Perkin Elmer Life Sciences 
Inc. (Waltham, MA) and was purified to >98%) immediately before use with Sephadex LH-
20 (Sigma-Aldrich) as described by Rutgers et al. (1989). All other chemicals used were of 
the highest grade commercially available. 
 
Animals and Treatment  
Adult (7 -9 week old) male Sprague-Dawley rats were purchased from Harlan 
Laboratories (Dublin, VA).Animals were maintained on a 12h light/dark cycle at ambient 
temperature (22ºC) and relative humidity (55 ± 5%), and were provided with NTP 2000 
(Zeigler Bros. Inc., Gardner, PA) and tap water ad libitum..  All procedures comply with the 
Animal Welfare Act Regulations, 9 CFR 1-4 and animals will be handled and treated 
according to the Guide for the Care and Use of Laboratory Animals (ILAR, 1996). Animals 
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were treated with a single daily dose for 4 consecutive days.  Rats were randomly selected 
for each treatment group (n=6/group).  Rats were administered BDE 47 in corn oil (0, 3, 30, 
or 100 mg/kg/day for 4 days) by oral gavage (5 ml/kg).  Dosing solutions were prepared by 
dissolving BDE 47 in acetone followed by the addition of corn oil.   The acetone was 
removed from the dosing solutions by evaporation with a speed vacuum device  
 
Serum and Tissue Collection 
24 Hours after the final dose, mice were euthanized by CO2 asphyxiation followed by 
exsanguinations via cardiac puncture; and blood and livers were collected.  Blood was 
allowed to clot for 1 hour on ice in serum separator tubes (Becton Dickinson, Franklin Lakes, 
NJ).  Blood was centrifuged at 1300 x g for 30 min to obtain serum.  Serum was frozen and 
held at -80°C until analyzed.  Livers were removed and weighed.  Approximately 200 mg of 
liver was placed in a separate tube and frozen at -80°C for subsequent RNA purification.  
The remaining liver was frozen at -80°C for further enzyme activity analysis. 
 
Serum T4 concentration  
Serum T4, was measured in duplicate using Coat-a-Count radioimmunoassay kits 
(Diagnostic Products Corporation, Los Angeles, CA) according to the method of Craft et 
al.,(2002)  
 
T4-UGT Activity Assay  
Liver microsomal fractions were prepared (Zhou, et al., 2001) and protein 
concentrations were measured using a protein assay kit with bovine serum albumin as a 
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standard (Bio-Rad Laboratories, Hercules, CA). Hepatic T4-UGT activity was determined by 
using a modified assay (Zhou, et al., 2001;  Zhou, et al., 2002) based on a previously 
published method (Visser et al., 1993a). All data are expressed as fold change compared to 
control, where controls for T4-UGT are expressed as pMol T4-UGT/min/mg protein.  
 
T4-SULT activity assay 
Liver cytosol was collected at the same time the microsomes were collected. SULT 
activities were assayed by incubation of 4µM of T4, and 100,000 cpm of 125I-labeled T4 
(Perkin-Elmer) for 30 min at 37°C with 20 ug protein/ml of liver cytosol in the presence or 
absence (blank) of 50µM 3’-phosphoadenosine 5’-phosphosulfate (PAPS; Sigma) in 0.2 ml 
of 0.1M phosphate (pH 7.2) and 2mM EDTA (Sigma) (Kaptein, et al., 1997). The mixtures 
were applied to 1 ml of lipophilic sephadex (Sigma) LH-20 minicolumns (Superlco), and 
equilibrated in 0.1M HCl. Iodine, and sulfated T4 were successively eluted with 2 X 1 ml of 
0.1M HCl, and 6 X 1 ml of ethanol/water (20/80, vol/vol), respectively. Fractions were 
collected and 1 ml of the T4 sulfate (T4S) fraction was quantitated for radioactivity. 
 
Hepatocyte culture and BDE 47 treatment 
Fresh primary male Sprague-Dawley sandwich-cultured rat hepatocytes (SCRH) and 
sandwich-cultured human hepatocytes (SCHH) in 24-well plates were received on culture 
day 2 from Life Technologies (Durham, NC). Hepatocytes were maintained for up to 6 days 
in culture with medium replaced daily. The maintenance medium consists of: Williams’ E 
medium with 0.1% dimethyl sulfoxide (DMSO) including Hepatocyte Maintenance 
Supplement (Life Technologies) which contains 0.1µM dexamethasone and proprietary 
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concentrations of penicillin-streptomycin, ITS+ (insulin, transferrin, selenium complex, BSA 
and linoleic acid), GlutaMAX™ and HEPES].  
Stock solutions of BDE 47 were diluted to 0.3, 3, and 30µM in DMSO and added to 
maintenance medium at a final DMSO concentration of 0.1%. On culture day 3, fresh SCRH 
and SCHH were exposed for 72 hours to the DMSO vehicle (0.1%) or BDE 47 (0.3, 3 
30µM). After 72 hours, medium was removed and replaced with maintenance medium 
containing physiological concentrations [0.05µM (rat) or 0.1µM (human)] of [125I]-T4 
(500,000 cpm/well) for 24 hours. Medium was collected, prepared and analyzed for T4 
metabolites by the method described below. Hepatocytes were collected and analyzed for 
protein content or frozen at -70°C for RNA isolation. Human donor demographics can be 
found in Table 4.1.  
 
T4 and T4 metabolite separation and quantitation  
All media samples were dried at 40°C under N2 gas and then reconstituted with 40µl 
mobile phase consisting of 18% acetonitrile in 0.02M ammonium acetate (pH=4). After 
addition of mobile phase, samples were centrifuged at 10,000 x g for 5 minutes at room 
temperature and the supernatants were placed in vials for UPLC analysis. UPLC equipped 
with a C18 – 2.1 x 50mm x 1.7µm (Waters Corp.; Milford, MA) resolution column and 
fraction collector were used for identification of T4 and T4 metabolites. Gradient elution was 
performed using a method modified version of a previously established method by Rutgers et 
al. (1987) with a 16 minute gradient of 18-40% acetonitrile in 0.02M ammonium acetate 
(pH=4). Solvent flow rate was 0.4ml/min and 15 second fractions were collected in test 
tubes. Peaks were then identified by analyzing collected fractions for radioactivity by gamma 
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spectroscopy. Retention times for T4, T3, rT3, T4-glucuronide (T4G), and T4 sulfate (T4S) 
were determined using synthetic and biosynthetic compounds as described by Richardson et 
al.(submitted). Peaks for T3 and rT3 were often inseparable; as a result, these peaks were 
added together and are presented as T3+rT3. Hepatocyte protein content was determined 
using a protein assay kit with bovine serum albumin as a standard (Bio-Rad Laboratories, 
Hercules, CA). 
 
RNA Isolation and relative real-time RT-PCR  
Total RNA was isolated using the RNeasy Mini Plus Kit with gDNA eliminator 
columns. (Qiagen, Hilden, Germany). To assess the integrity of the RNA samples, the 2100 
Bioanalyzer was used (Agilent Technologies, Palo Alto, CA). RNA with RNA Integrity 
Numbers (RINs) greater than 8.1 were used for RT-PCR.  Real-time RT-PCR was performed 
using the ABI Prism 7700 Sequence Detection System (ABI, Foster City, CA). 100 ng of 
total RNA was used for each reaction. cDNA was synthesized using the High Capacity RNA-
to-cDNA Kit (ABI, Foster City, CA). PCR was then performed on all cDNAs using TaqMan 
Universal PCR Master Mix and Custom TaqMan Array Micro Fluidic Cards (ABI, Foster 
City, CA). TaqMan gene expression assays are listed in Tables 4.2 and 4.3.  
 
Physiologically Based Pharmacokinetic Modeling 
 In order to compare media concentrations to peak blood concentrations, a 
physiologically based pharmacokinetic model was used to estimate peak blood 
concentrations in the in vivo studies.  Using the PBPK model of Emond et al. (2010), peak 
blood and liver concentrations were estimated for each dose of BDE 47 administered to the 
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rats.  The Emond et al. (2010) model was developed based on data from male and female 
Sprague-Dawley rats following single and multiple dose exposures.   
 
Data Analysis  
All data are presented as the mean ± standard deviation. The statistical intergroup 
comparisons were determined by using one-way analysis of variance (ANOVA) followed by 
Dunnet's Multiple Comparison post-hoc test (GraphPad Prism 5.0, GraphPad Software San 
Diego, CA). The levels of probability of statistical significance are p < 0.05. A one-phase 
decay exponential equation, 
Y= (Y0-Plateau)*exp (-K*X) +Plateau, 
was fit to the [125I]-T4 disappearance data where the depletion rate constant (K) was 
determined. The half-life (t1/2) of all reactions was then determined as ln(2)/K. Using the rate 
of [125I]-T4 depletion, intrinsic clearance (CLint) estimates were determined as described by 
Obach (1997) using the equation,  
 CLint, in vitro=KV/N, 
expressed as μl/min/106 cells, where K is ln(2)/ t1/2, V is the incubation volume and N is the 
number of hepatocytes used.  Human hepatocyte CLint (µl/min/106 cells) was scaled to in 
vivo CLint (ml/min/kg body weight) using the physiological parameters, human liver weight 
22 g/kg body weight and hepatocellularity 120 X 106 cells/g of liver (Bayliss, et al., 1999;  
Soars, et al., 2002). Rat hepatocyte CLint (µl/min/106 cells) was scaled to in vivo CLint 
(ml/min/kg body weight) using the physiological parameters, rat liver weight 40 g/kg body 
weight and hepatocellularity 120 X 106 cells/g of liver (Bayliss, et al., 1999) 
 
131 
 
C. RESULTS 
 
Rat body weight, liver weight and serum total T4 
No obvious signs of toxicity and no treatment effect on body weight were noted 
between treatment groups of BDE 47. Liver weights increased 11%, 19%, and 21% at 10, 30, 
and 100 mg/kg/day BDE 47, respectively (Table 4.5). Similarly, liver-to-body weight ratios 
increased 9%, 17%, and 22% at 10, 30, and 100 mg/kg/day BDE 47, respectively. Decreases 
in serum total T4 of 76% and 96% were observed at 30 and 100 mg/kg/day of BDE 47 
(Figure 4.1).  There were no significant effects on serum total T4 at the lowest dose tested (10 
mg/kg/day BDE 47)  
 
Intrinsic clearance of T4 from the media of SCRH and SCHH 
The clearance of T4 from the media of SCRH and SCHH treated with 30µM BDE 47 
was evaluated between 4 and 24 hours (Table 4.4).  A one-phase decay model was used to 
estimate intrinsic clearance (CLint) in both SCRH and SCHH. BDE 47 did not significantly 
change Clint of T4 in the media of SCRH and SCHH. CLint in the untreated hepatocytes of 
rat1 and rat 2 was 1.08 and 0.75 µl/min/106 cells, respectively. In BDE 47 treated SCRH, 
CLint was 0.93 and 0.86 µl/min/106 cells for rat 1 and rat 2, respectively. In untreated SCHH, 
CLint for Hu1362 and 1364 was 0.56 and 0.62 µl/min/106 cells, respectively. Following BDE 
47 treatment, CLint was 0.56 and 0.52 µl/min/106 cells for Hu1362 and Hu1364, respectively. 
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CYPs: P450 mRNA expression   
Rats treated with BDE 47 (100 mg/kg/day) resulted in increased hepatic Cyp1a1 
mRNA expression by 44.9-fold (Table 4.6). Cyp1a1 did not change with 10 or 30 mg/kg/day 
BDE 47. At 30 and 100 mg/kg/day BDE 47, Cyp2b2 increased 16.4- and 21.0-fold and 
increased Cyp3a1 6.2-and 8.9-fold, respectively. In rat liver, Cyp2b2 and Cyp3a1 did not 
change at the lowest dose (10 mg/kg/day).  
BDE 47 did not change Cyp1a1 mRNA expression in SCRH (Table 4.7). In SCRH, 
Cyp2b2 increased 45.1- and 40.6-fold following treatment with 3 and 30µM BDE 47. 0.3µM 
BDE 47 did not change Cyp2b2. Cyp3a1 mRNA expression increased in SCRH 7.2-fold only 
at 30 µM BDE 47 and not at the lower concentrations. BDE 47 did not change CYP1A1 in 
SCHH (Table 4.8). BDE 47 (30µM) increased CYP2B6 and CYP3A4 in SCHH by 15.7- and 
10.9-fold, respectively. CYP2B6 and CYP3A4 mRNA expression did not change with 0.3 or 
3µM BDE 47. 
 
UGTs: T4G levels, enzyme activity and mRNA expression   
BDE 47 increased hepatic microsomal T4-UGT activity by 60%, 50%, and 50% at 10, 
30, and 100 mg/kg/day (Table 4.9). In rat liver, Ugt1a1 mRNA expression increased 
approximately 1.7- and 1.7-fold at 30 and 100 mg/kg/day, respectively.  Hepatic Ugt1a5and 
Ugt1a6 mRNA expression increased 1.5- and 2.0-fold, respectively in rats treated with 100 
mg/kg/day BDE 47.   
In the medium of SCRH, T4G levels were unchanged (Figure 4.2A) and UGT mRNA 
expression in rat hepatocytes was unchanged following BDE 47 treatment (Table 4.10).  In 
the medium of SCHH, T4G increased 2.0-fold at 30µM BDE 47 (Figure 4.3A). UGT1A1 
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increased 3.6-fold in human hepatocytes exposed to 30µM BDE 47 (Table 4.11). UGT1A4, 
UGT1A6, and UGT1A9 mRNA expression did not change with BDE 47 treatment. 
 
SULTs: T4S levels, enzyme activity and mRNA expression  
BDE 47 did not change T4-SULT activity or Sult mRNA expression in rat liver 
(Table 4.12).  T4S levels in the media of SCRH and SCHH did not change following 
treatment with BDE 47 treatment (Figure 4.2B and Figure 4.3B).  SULT mRNA expression 
also did not change in SCRH and SCHH with BDE 47 (Table 4.13 and 4.14). 
 
Transporters: mRNA expression 
In rat liver, Mdr1a and Mdr1b mRNA expression increased following treatment with 
100 mg/kg/day BDE 47 1.6- and 2.5-fold, respectively (Table 4.15).  BDE 47 increased 
Mrp3 mRNA expression 10.4- and 15.0-fold at 30 and 100mg/kg/day BDE 47 in rat liver. 
BDE 47 did not change Mrp2, Ntcp1, and organic anion transporter (Oat2) in rat liver.Mrp2 
increased 1.6-fold mRNA expression in SCRH treated with 30µM BDE 47 (Table 4.16). 
BDE 47 did not change mRNA expression for Mdr1a, Mdr1b, Mrp3, Ntcp1, and Oat2 in 
SCRH. In SCHH, MRP2 mRNA expression increased 1.6-fold with 30µM BDE 47 (Table 
4.17). MRP3 mRNA expression in human hepatocytes decreased 31% with 3 and 30µM 
BDE 47.  OAT2 mRNA expression in human hepatocytes decreased 54% and 63% with 3 
and 30µM BDE 47, respectively. MDR1 and NTCP1 mRNA expression in SCHH did not 
increase with BDE 47. 
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Thyroid responsive genes.  
In rat liver and SCRH, Dio1 and Ttr mRNA expression did not change with BDE 47 
treatment (Table 4.18 and Table 4.19). In SCHH DIO1 did not change with BDE 47 
treatment, but decreased 56% with 30uM BDE 47 (Table 4.20). 
 
Physiologically Based Pharmacokinetic Modeling. 
A physiologically based pharmacokinetic model was used to estimate peak blood 
concentrations in the in vivo studies.  Using the PBPK model of Emond et al. (2010), peak 
blood and liver concentrations were estimated for each dose of BDE 47 administered to the 
rats.  The model predicts that the range of peak blood concentrations of BDE 47 in rats 
treated with 10-100 mg/kg of BDE 47 is similar to the range of media concentrations used in 
the in vitro studies (Figure 4.4).   
 
D. DISCUSSION  
 
It has been hypothesized that in rodents, PBDEs disrupt TH homeostasis by the 
induction of hepatic T4-glucuronidation and the competition between PBDE metabolites and 
T4 for binding to the serum transport protein, TTR. The effects of PBDEs on TH homeostasis 
in humans are limited and it is unclear if the mechanisms underlying the decrease in serum T4 
in rodents is the same for humans. This study further investigates the alteration of thyroid 
hormone homeostasis of BDE 47. In particular, this study aims to identify nuclear receptor 
regulated genes altered by BDE 47, which may help understand the mechanisms by which 
BDE 47 decreases serum T4 in rats. Using rat and human hepatocytes, we also make species 
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comparisons on the effects of BDE 47 on hepatic T4 metabolism and the genes involved. In 
this study, BDE 47 decreased serum T4 in rats and increased T4G in the medium of SCHH.  
In addition, BDE 47 altered the mRNA expression of recognized hepatic UGTs and 
transporters of TH or glucuronides.   
After a 4-day treatment, BDE 47 decreased circulating total serum T4 concentration in 
rats by as much as 96% at the highest dose of 100 mg/kg/day. This observation supports our 
recent findings in which mice treated with 100mg/kg/day BDE 47 for 4 days decreased 
serum T4, although to a smaller degree in mice with a 43% decrease (Richardson, et al., 
2008). Decreases in serum T4 in rats treated with BDE 47 have previously been associated 
with moderate increases in hepatic T4-UGT activity (Hallgren et al., 2001;  Hallgren and 
Darnerud, 2002).  In the present study, BDE 47 increased T4-UGT activity by approximately 
50% from controls.  It seems unlikely that a small increase in T4-UGT activity could, by 
itself, result in over a 90% decrease in hormone concentrations.  In SCRH, BDE 47 did not 
increase T4G in the medium nor Ugt mRNA. In contrast, T4G levels increased in the medium 
of SCHH as was UGT1A1 mRNA expression.  
The present in vivo and in vitro data in rats is inconsistent with the hypothesis that the 
large decrease in serum T4 in rats are due solely to increases in Ugt mRNA expression and 
T4-UGT activity in liver. The lack of change in T4G levels in the medium or Ugt mRNA 
expression in SCRH following BDE 47 treatment supports the findings in the in vivo study 
and suggests that T4 glucuronidation has only a small effect, if any on the observed decreases 
in serum T4 in rats.  In SCHH, the increase in T4G levels in the medium may be due to the 
nearly 4-fold increase in UGT1A1. This also suggests that BDE 47 may have a greater effect 
on human UGTs compared to rat UGTs. 
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It is hypothesized that SULTs may be more important in the metabolism of THs in 
humans than rats, because SULT1E1 conjugates THs in humans, but not in rats (Kester, et 
al., 1999;  Kester, et al., 2003). Rutgers et al. (1989) reports that in untreated rats, 7 times 
more T4G was excreted into the bile than T4S. In this study, T4G levels were about 25 times 
greater in the medium of SCHH compared to T4S. In contrast, T4G and T4S levels in the 
medium of untreated SCHH were similar. BDE 47 had no effect on T4-SULT activity and 
SULT mRNA expression in rat liver. There also was no effect on T4S medium levels and 
SULT mRNA expression in SCRH and SCHH. SULT mRNA expression agreed with the T4-
SULT activity and T4S levels and confirms that BDE 47 has no effect on T4 sulfation.  
DI is responsible for most T3 production peripherally. However, when serum T4 
decreases, DI also decreases in an attempt to preserve serum T3 concentrations suggesting 
that the decrease in DI is mediated by a feedback mechanism through the thyroid axis 
(Zavacki et al., 2005). Hypothyroidism in rats treated with dioxin or dioxin-like chemicals is 
often associated with inhibited hepatic DI activity (Hood and Klaassen, 2000b;  Viluksela, et 
al., 2004;  Szabo, et al., 2009). In this study, DI mRNA expression and T3+rT3 levels in 
media did not change in SCRH and SCHH treated with BDE 47.  This agrees with the idea 
that decreases in DI are a physiological response to decreases in serum T4 and therefore may 
not be detected in an in vitro system. DI mRNA expression also did not change in rat liver 
which did not agree with the hypothesized association between decreases in DI and serum T4.   
CYP1A, CYP2B and CYP3A are classic targets for AhR, CAR, and PXR activation.  
In rats and mice, BDE 47 does not increase CYP1A mRNA, suggesting it is not an AhR 
agonist in rodents (Pacyniak et al., 2007;  Richardson, et al., 2008). HepG2 cells treated with 
BDE 47 also showed no AhR activation (Peters et al., 2006). Liver from F344 rats BDE 47 
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had a significant effect on the level of Cyp1a1 mRNA expression (2.4-fold) only at the 
highest dose, (100 μmol/kg-day for 3 days) indicating an activation of the Ah receptor 
(Sanders et al., 2005). In the present study, BDE 47 induced Cyp1a1 mRNA expression in rat 
liver, but not in SCRH and SCHH. The effect of BDE 47 on CYP1A1 in SCRH and SCHH 
agrees with previous studies showing BDE 47 is not an AhR agonist. In contrast, increases in 
Cyp1a1 in rat liver suggest that the AhR is activated. Ugt1a6 expression is regulated, in part 
by the AhR (Auyeung, et al., 2003;  Nishimura, et al., 2005). In this study, Cyp1a1 mRNA 
expression increase 44.8-fold while Ugt1a6 mRNA expression increased only 2.0-fold in the 
liver of rats treated with 100 mg/kg/day. The increase in Cyp1a1 and Ugt1A6 mRNA 
indicates the activation of AhR may come from an unidentified contaminant in the BDE 47 
(Wahl et al., 2008).  
BDE 47 increased CYP2B2 and CYP3A1 in rat liver and SCRH and SCHH which 
agrees with previous studies in mice and rats (Sanders, et al., 2005;  Pacyniak, et al., 2007;  
Richardson, et al., 2008). As common targets of CAR and PXR, the increases in CYP2B2 
and CYP3A1 indicate BDE 47 is a mixed inducer in rats, SCRH and SCHH. In particular, the 
increases in P450 mRNA expression support the idea that the hepatocytes used in this study 
are functional and viable. 
In general, it is hypothesized that hydroxylated PBDEs bind to TTR may decrease 
serum T4 concentrations by increase the hepatic uptake and biliary elimination of T4 in 
rodents (Hallgren and Darnerud, 2002).  The present study showed no change in TTR mRNA 
expression in rat liver and SCHR.  This does not agree with previous studies in which Ttr 
mRNA expression in mouse liver decreases with BDE 47 (Richardson, et al., 2008). TTR 
mRNA expression decreased in SCHH treated with BDE 47 (30µM), which agrees with 
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previous studies in mice (Richardson, et al., 2008).  Thyroxine-binding globulin (TBG) is the 
major T4 binding protein in humans; therefore it is unclear how significant a decrease in 
hepatic TTR mRNA would be to TH homeostasis in humans.  
Like other xenobiotic metabolizing enzymes, transporters are also regulated by 
nuclear receptor activation. In this study, we examined the effects of BDE 47 on hepatic 
uptake and efflux transporters and the role they may play in TH disruption. MDR1, MRP2, 
and MRP3 are efflux transporters and are regulated by AhR, CAR, and PXR (Cherrington et 
al., 2002;  Maglich, et al., 2002;  Kohle and Bock, 2009).  MDR1 encodes for the efflux 
transporter P-glycoprotein (P-gp) involved in the transport of hormones, steroids and a wide 
range of xenobiotics. Cells transfected with Mdr1 cDNA increased the efflux of T3 compared 
to cells without Mdr1 (Mitchell, et al., 2005). In mice, glucuronidated compounds are 
substrates for Mdr1. Like MDR1, MRP2, is a canalicular efflux transporter and is responsible 
for the transport of conjugated organic anions into bile (Leslie et al., 2005;  Nies and 
Keppler, 2007). Increases in MRP2 in rodents have been linked to UGT induction andT4 
elimination following treatment with PB or PCN (Johnson et al., 2002a;  Miyawaki, et al., 
2012). Szabo et al. (2009) demonstrated that rat pups exposed to DE-71 decreased serum T4 
and increased hepatic Mrp2 and UGTs.  MRP3, a sinusoidal efflux transporter, exports 
glucuronides from the liver to the blood.  NTCP, a sinusoidal uptake transporter, is known as 
a transporter of T4 and T4S (Friesema, et al., 1999;  Visser, et al., 2011). OAT2 is a 
basolateral uptake transporter and mediates the transport of exogenous and endogenous 
compounds from blood to liver.   
Mdr1a and Mdr1b encode P-gp in rodents.  In mice treated with BDE 47, hepatic 
Mdr1a decreased and Mdr1b mRNA expression did not change (Richardson, et al., 2008). In 
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the present study, hepatic Mdr1a and Mdr1b increased in rats treated with 100mg/kg/day 
BDE 47. In SCRH, Mdr1a and Mdr1b mRNA expression did not change.  MDR1 encodes P-
gp in humans and was unchanged in SCHH treated with BDE 47. This suggests MDR1 in 
rats may mediate the biliary elimination of T4 or T4G.   
BDE 47 did not change Mrp2 mRNA expression in rat liver. Mrp2 increased in 
SCRH. Although linked with T4 biliary elimination; our results suggest that Mrp2 mRNA 
expression may not be responsible for the observed decrease in serum T4 in rats. In contrast, 
MRP2 increased in hepatocytes from rats and humans following BDE 47 treatment. In 
response to BDE 47 treatment, MRP2 in rat liver may play a different role in the transport of 
T4, T4G and xenobiotics when compared to MRP2 in the hepatocytes.  
NTCP1 did not change with BDE 47 treatment of rats, SCRH and SCHH.  OAT2 did 
not change in rat liver and SCRH. OAT2 mRNA expression in SCHH decreased at 3 and 
30µM BDE 47. These results suggest BDE 47 did not induce a NTCP1- or OAT2-mediated 
increase in hepatic T4 uptake. In general, the effects of BDE 47 on transporter mRNA 
expression are inconsistent between rat and human hepatocytes and between rat liver and rat 
hepatocytes.  There are inconsistencies between transporter mRNA expression and T4G 
levels in media. Tchaparian et al.(2011) found a lack of concordance in the expression 
profiles for uptake and efflux transporters in SCRH over days in culture, indicating there may 
be different culture conditions for uptake transporters and efflux transporters .The aim of the 
present study was to examine increases in UGTs and T4 metabolism in response to BDE 47; 
as a result, our goal was to optimize our system for nuclear receptor activation by BDE 47 
and T4 metabolism. To optimize our system we determined that it was best to use an 
induction phase (BDE 47 incubation) of 72 hours followed by a metabolism phase (T4 
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incubation) of 24 hours. Transporter activity or expression was not optimized in this study 
and may explain the contrasting results observed in this study. Overall, transporter function 
were not confirmed; therefore, conclusions about the effect of BDE 47 on T4 uptake or 
biliary excretion.  
A PBPK model was used to estimate the peak blood concentrations of BDE 47 from 
animals treated with 10, 30, or 100 mg/kg of BDE 47 for 4 consecutive days.  Model 
predictions of blood concentrations were within the range of the in vitro medium 
concentrations evaluated in the in vitro component of this study.  The modest effects on the 
induction of T4 glucuronidation occurred both in vitro and in vivo and at similar exposure 
concentrations.  In contrast, in vivo BDE 47 induced over a 90% decrease in serum T4 
concentrations.  These data suggest that the in vitro model recapitulates the in vivo response 
at similar concentrations and that it is unlikely that T4 glucuronidation plays a large part of 
this effect.  In the latest NHANES survey, the mean human serum concentrations of BDE 47 
are 2.1 nM with the 95th percentile at 17.8 nM.  These concentrations are approximately 1000 
fold lower than the exposures examined in these studies and suggest that effects on hepatic 
enzyme induction or changes in serum TH concentrations are unlikely to occur at 
background human exposure. 
The present study investigated the effects of BDE 47 on T4 serum concentrations and 
hepatic genes involved in T4 metabolism and transport in rats.  Species differences in T4 
metabolism also were examined using SCRH and SCHH treated with BDE 47. The TH 
disrupting effects of BDE 47 in rats is likely due to multiple mechanisms in the liver; 
including T4 glucuronidation and/or biliary efflux of T4 and is mediated through CAR/PXR 
pathways. In SCRH, BDE 47 appears to activate the CAR/PXR pathway and the mechanism 
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may be different than that of rats, because T4 glucuronidation appears not to be involved. In 
SCHH, T4 glucuronidation, biliary efflux and decreases in T4-TTR binding may be involved 
and is mediated through a CAR/PXR pathway. The effects observed in rats may be a result of 
a furan contaminant, which makes it difficult to attribute all of the observed effects to BDE 
47 alone. There were some inconsistencies in some of the transporter mRNA expression 
levels in the hepatocytes. This may be due to the culture days chosen for sample collection 
which may affect transporter mRNA expression or activity; therefore, transport efflux and 
uptake should not be ruled out as a mechanism of action. Overall, this study shows the utility 
of SCH in the continuing investigation of TH disruption and human relevance.   
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Table 4.1   
 
Donor information for human hepatocytes 
                Donor      Gender   Age       Smoke/Alcohol    Medications    Experimental Use  
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Hu1236 
 
 
Hu1248 
 
 
 
 
Hu1362 
 
 
 
 
Hu1364 
 
Female 
 
 
Male 
 
 
 
 
Female 
 
 
 
 
Male 
 
68 
 
 
63 
 
 
 
 
57 
 
 
 
 
51 
 
No/No 
 
 
Yes/Yes 
 
 
 
 
No/No 
 
 
 
 
No/No 
 
Multivitamin 
Vitamin D 
 
Sertraline 
Vicodin 
Docusate  
 
 
Atenolol and 
Chlorthalidone 
Lorazepam 
Oxycodone 
 
Cyanocobalamin 
Diltiazem 
Ferrous Sulfate 
Folic Acid 
Metoprolol 
Omeprazole 
Potassium 
Chloride 
Prednisone 
BDE 47 
Treatment 
 
BDE 47 
Treatment 
 
 
 
BDE 47 
Treatment/ 
T4 Clearance 
 
 
BDE 47 
Treatment/ 
T4 Clearance 
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Table 4.2 
 
Taqman rat gene expression assays  
Group Gene Taqman Gene 
Expression Assay ID 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Endogenous control Gapdh Rn99999916_s1 
Nuclear receptor activation  Cyp1a1 
Cyp2b2 
Cyp3a1 
 
Rn00487218_m1 
Rn02786833_m1 
Rn01640761_gH 
Phase II metabolism 
 
Ugt1a1 
Ugt1a5 
Ugt1a6 
Ugt2b 
Sult1a1 
Sult1b1 
Sult1c1 
Sult1e1 
 
Rn00754947_m1 
Rn01427785_m1 
Rn00756113_mH 
Rn02349650_m1 
Rn00582915_m1 
Rn00673872_m1 
Rn00581955_m1 
Rn00820646_g1 
Transporter 
 
 
Mdr1a 
Mdr1b 
Mrp2 
Mrp3 
Ntcp1 
Oat2 
 
Rn00591394_m1 
Rn00561753_m1 
Rn00563231_m1 
Rn00589786_m1 
Rn00566894_m1 
Rn00585513_m1 
Thyroid hormone responsive Dio1 
Ttr 
Rn00572183_m1 
Rn00562124_m1 
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Table 4.3 
 
Taqman human gene expression assays   
Group Gene Taqman Gene   
Expression Assay ID 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Endogenous control GAPDH 
 
Hs99999905_m1 
 
Nuclear receptor activation CYP1A1 
CYP2B6 
CYP3A4 
 
Hs00153120_m1 
Hs03044634_m1 
Hs00430021_m1 
 
Phase II metabolism 
 
UGT1A1 
UGT1A4 
UGT1A6 
UGT1A7 
UGT1A9 
UGT1A10 
 
 
SULT1A3 
SULT1E1 
SULT2A1 
 
Hs02511055_s1 
Hs01592480_m1 
Hs01592477_m1 
Hs02517015_s1 
Hs02516855_sH 
Hs02516990_s1 
 
Hs00413970_m1 
Hs00193690_m1 
Hs00234219_m1 
 
Transporter 
 
 
MDR1B 
MRP2 
MRP3 
NTCP1 
OAT2 
 
Hs00184500_m1 
Hs00166123_m1 
Hs00358656_m1 
Hs00161820_m1 
Hs00185140_m1 
 
Thyroid hormone responsive D1 
TTR 
Hs01554724_m1 
Hs00174914_m1 
145 
 
0 10 30 100
0
2
4
6
***
***
BDE 47 (mg/kg/day)
T 4
(u
g/
dl
)
 
Figure 4.1. Total serum T4 concentrations in rats treated with BDE 47. 
Data are expressed as mean ± standard deviation (n=6/group).  
           ***Significantly different from control group (p< 0.001). 
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Figure 4.2. Comparison of metabolites in the medium of SCRH treated with BDE 47. 
Hepatocytes were incubated with 0.1% DMSO (control), 0.3, 3, or 30µM BDE 47 for 72 
hours starting on culture day 3.Hepatocytes are then incubated for 24 hours on culture day 6 
with 0.05µM [125I]-T4. Metabolites were separated using the established UPLC method. 
Metabolites analyzed are (A) T4G, (B) T4S, and (C) T3+rT3. Data represent the average of 
duplicate experiments. Data are expressed as pmol/mg cellular protein (mean±SD). Limits of 
detection= 0.5 pmol/mg cellular protein. n=4 for rat hepatocytes.  
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Figure 4.3. Comparison of metabolites in the medium of SCHH treated with BDE 47. 
Hepatocytes were incubated with 0.1% DMSO (control), 0.3, 3, or 30µM BDE 47 for 72 
hours starting on culture day 3.Hepatocytes are then incubated for 24 hours on culture day 6 
with 0.1µM [125I]-T4. Metabolites were separated using the established UPLC method. 
Metabolites analyzed are (A) T4G, (B) T4S, and (C) T3+rT3. Data represent the average of 
duplicate experiments. Data are expressed as pmol/mg cellular protein (mean±SD) Limits of 
detection= 0.5 pmol/mg cellular protein. n=4 human donors. Human hepatocytes are from 4 
donors (Hu1236, Hu1248, Hu1362, and Hu1364). **Significantly different than control; 
p<0.01.  
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Figure 4.4.  Comparison of in vivo and in vitro responses based on either medium 
concentrations (in vitro) or estimated blood concentrations (in vivo).  T4G activity is 
presented as either T4G accumulation in medium (T4G pmol/mg protein) or T4G activity in 
hepatic microsomal fractions (T4G pmol/min/mg protein) 
 
 
  
151 
 
Table 4.4  
 
Intrinsic clearance of [125I]-T4 following treatment with BDE 47  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  Control BDE 47 Fold 
Change 
     
Rat 1 Rate constant K (1/min) 
 
Clint (µl/min/106 cells) 
 
Scaled Clint (ml/min/kg body 
weight) 
 
0.00075 
 
1.08 
 
5.16 
 
0.00065 
 
0.93 
 
4.47 
 
0.86 
 
0.86 
 
0.87 
Rat 2 Rate constant K (1/min) 
 
Clint (µl/min/106 cells) 
 
Scaled Clint (ml/min/kg body 
weight) 
 
0.00052 
 
0.75 
 
3.58 
 
0.00060 
 
0.86 
 
4.11 
 
1.15 
 
1.15 
 
1.15 
Hu 1362 Rate constant K (1/min) 
 
Clint (µl/min/106 cells) 
 
Scaled Clint (ml/min/kg body 
weight) 
 
0.00039 
 
0.56 
 
1.60 
 
0.00039 
 
0.56 
 
1.61 
 
1.00 
 
1.00 
 
1.00 
Hu 1364 Rate constant K (1/min) 
 
Clint (µl/min/106 cells) 
 
Scaled Clint (ml/min/kg body 
weight) 
 
0.00043 
 
0.62 
 
1.78 
 
0.00037 
 
0.52 
 
1.50 
 
0.86 
 
0.86 
 
0.84 
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Table 4.5 
 
Effects of BDE 47 on rat body weight, organ weights, and liver-to-body weight ratio 
Treatment  Body (g) a   Liver (g) a  Liver-to-body wt. ratio a 
(mg/kg/day)          
0   234.7±8.0  10.0±0.5  0.04±0.0  
10   238.5±9.5   11.2±0.8b  0.05±0.0c  
30   237.8±7.3  12.3±0.6d  0.05±0.0d  
100   232.1±10.7  12.7±0.9d  0.06±0.0d  
aData are expressed as mean ± standard deviation (n=6/group) 
bSignificantly different from control group (p< 0.05) 
cSignificantly different from control group (p< 0.01) 
dSignificantly different from control group (p< 0.001) 
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Table 4.6 
 
Effects of BDE 47 on P450s in rat liver  
Treatment  Cyp1a1a   Cyp2b2a  Cyp3a1a 
(mg/kg/day)          
0   1.1±0.6  1.2±0.8  1.0±0.3  
10            13.5±12.5   4.7±1.5  2.2±0.7  
30            24.1±27.0           16.4±6.7d  6.2±2.8c  
100            44.8±45.4b           21.0±7.1d  8.9±3.1d  
aData are expressed as mean ± standard deviation (n=6/group) 
bSignificantly different from control group (p< 0.05) 
cSignificantly different from control group (p< 0.01) 
dSignificantly different from control group (p< 0.01) 
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Table 4.7 
 
Effects of BDE 47 on P450s in rat hepatocytes 
Treatment  Cyp1a1a   Cyp2b2 a  Cyp3a1 a 
(µM)          
0   1.0±0.0  1.0±0.0  1.0±0.0  
0.3   1.6±1.7   7.3±4.7  1.7±1.5  
3   1.2±1.4           45.1±36.5b  1.3±0.1  
30   0.6±0.4           40.6±25.7b  7.2±4.7c  
aData are expressed as mean ± standard deviation (n=5/group) 
bSignificantly different from control group (p< 0.05) 
cSignificantly different from control group (p< 0.01) 
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Table 4.8 
 
Effects of BDE 47 on P450s in human hepatocytes 
Treatment  CYP1A1a   CYP2B6 a  CYP3A4 a 
(µM)          
0   1.0±0.0  1.0±0.0  1.0±0.0  
0.3   1.0±0.6   4.1±4.7  1.4±1.1  
3   1.0±1.2  5.0±3.3  2.1±1.2  
30   2.4±1.7           15.7±12.1b           11.0±8.4b  
aData are expressed as mean ± standard deviation (n=4/group) 
bSignificantly different from control group (p< 0.05) 
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Table 4.9 
 
Effects of BDE 47 on T4-UGT activity and Ugt mRNA expression in rat liver 
Treatment T4-UGTa   Ugt1a1a  Ugt1a5a  Ugt1a6a 
(mg/kg/day) 
0  1.0±0.1  1.1±0.4  1.0±0.3  1.0±0.3 
10  1.6±0.1c  1.3±0.2  1.0±0.3  1.3±0.2 
30  1.5±0.2c  1.7±0.4b  1.2±0.0  1.6±0.3 
100  1.5±0.1c  1.6±0.4b  1.5±0.3b  2.0±0.6c 
aData are expressed as fold change mean ± standard deviation (n=5-6/group) 
bSignificantly different from control group (p< 0.05) 
cSignificantly different from control group (p< 0.001) 
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Table 4.10 
 
Effects of BDE 47 on Ugt mRNA expression in rat hepatocytes 
Treatment    Ugt1a1a  Ugt1a5a  Ugt1a6a 
(µM) 
0    1.0±0.0  1.0±0.0  1.0±0.0 
0.3    1.3±0.5  1.3±0.5  1.2±0.5 
3    0.9±0.1  1.3±0.5  1.1±0.1 
30    1.1±0.4  1.8±0.8  1.7±0.8 
aData are expressed as fold change mean ± standard deviation (n=5/group) 
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Table 4.11 
 
Effects of BDE 47 on UGT mRNA expression in human hepatocytes 
Treatment UGT1A1a  UGT1A4a  UGT1A6a  UGT1A9a 
(µM) 
0  1.0±0.0  1.0±0.0  1.0±0.0   1.0±0.00     
0.3  1.2±0.4  1.4±0.3  1.1±0.3  1.0±0.2     
3  1.7±0.7  1.6±1.3  1.2±0.5  1.0±0.2      
30  3.6±1.6b  2.3±0.6  1.5±0.6  1.0±0.2      
aData are expressed as fold change mean ± standard deviation (n=4/group) 
bSignificantly different from control group (p< 0.01) 
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Table 4.12 
 
Effects of BDE 47 on T4-SULT activity and SULT mRNA expression in rat liver 
Treatment T4-SULTa      Sult1a1a      Sult1b1a      Sult1c1a      Sult1e1a 
(mg/kg/day)  
0  1.0±0.3    1.0±0.2    1.0±0.1    1.0±0.2    1.0±0.2 
10  1.0±0.3    0.9±0.1    1.1±0.3    1.0±0.2    1.0±0.2 
30  1.0±0.5    0.8±0.1    1.0±0.2    1.0±0.2    0.9±0.1 
100  0.8±0.3    0.8±0.3    1.0±0.2    1.0±0.2    0.9±0.1 
aData are expressed as fold change mean ± standard deviation (n=5-6/group) 
aSignificantly different from control group (p< 0.05) 
bSignificantly different from control group (p< 0.01) 
  
160 
 
Table 4.13 
 
Effects of BDE 47 on and SULT mRNA expression in rat hepatocytes 
Treatment  Sult1a1a Sult1b1a Sult1c1a Sult1e1a 
(µM)  
0   1.0±0.0 1.0±0.0 1.0±0.0 1.0±0.0 
0.3   1.2±0.5 1.2±0.2 1.0±0.5 1.4±1.0 
3   0.9±0.3 1.0±0.2 0.9±0.2 1.1±0.5 
30   0.7±0.3 1.0±0.3 1.0±1.0 1.4±0.5 
aData are expressed as fold change mean ± standard deviation (n=5/group) 
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Table 4.14 
 
Effects of BDE 47 on SULT mRNA expression in human hepatocytes 
Treatment  SULT1A3a  SULT1E1a  SULT 2A1a   
(µM)  
0   1.0±0.0  1.0±0.0  1.0±0.0  
0.3   1.6±1.0  2.0±1.7  1.0±0.4  
3   1.1±0.6  0.9±0.6  1.1±0.8  
30   0.6±0.2  0.4±0.5  1.1±0.6  
aData are expressed as fold change mean ± standard deviation (n=4/group) 
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Table 4.15 
 
Effects of BDE 47 on efflux and uptake transporter mRNA expression in rat liver 
Treatment Mdr1aa         Mdr1ba           Mrp2a            Mrp3a            Ntcp1a            Oat2a 
(mg/kg/day) 
0            1.0±0.1         1.1±0.5         1.0±0.2          1.0±0.4           1.0±0.3           1.0±0.2 
10            1.3±0.3         1.2±0.4         1.1±0.3          4.2±2.5           1.2±0.4           0.9±0.2 
30            1.3±0.3         1.8±0.6         1.2±0.2        10.4±3.2d          1.1±0.3           0.9±0.1 
100            1.6±0.4b        2.5±0.9c        1.4±0.5        15.0±2.8d         1.1±0.4            0.9±0.2 
aData are expressed as fold change mean ± standard deviation (n=6/group) 
bSignificantly different from control group (p< 0.05) 
cSignificantly different from control group (p< 0.01) 
dSignificantly different from control group (p< 0.001) 
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Table 4.16 
 
Effects of BDE 47 on efflux and uptake transporter mRNA expression in rat 
hepatocytes 
Treatment Mdr1aa          Mdr1ba          Mrp2a          Mrp3a           Ntcp1a          Oat2a 
(µM) 
0           1.0±0.00         1.0±0.0         1.0±0.0        1.0±0.0         1.0±0.0         1.0±0.0 
0.3           1.4±0.6           1.4±0.5         1.3±0.5        1.3±0.4         1.2±0.5         1.3±0.5 
3           1.0±0.3           0.9±0.3         1.1±0.3        0.9±0.1         0.7±0.2         1.0±0.2 
30                  1.5±0.6           1.3±0.7         1.6±0.5b       1.3±0.5         0.7±0.4         1.1±0.3 
aData are expressed as fold change mean ± standard deviation (n=5/group) 
bSignificantly different from control group (p< 0.05) 
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Table 4.17 
 
Effects of BDE 47 on efflux and uptake transporter mRNA expression in human 
hepatocytes 
Treatment  MDR1a MRP2a MRP3a NTCP1a OAT2a 
(uM) 
0   1.0±0.0 1.0±0.0 1.0±0.0 1.0±0.0 1.0±0.0 
0.3   1.1±0.3 0.9±0.6 0.9±0.3 1.3±0.6 0.9±0.4 
3   1.1±0.0 1.0±0.2 0.7±0.1b 1.0±0.5 0.5±0.1b 
30   1.5±0.6 1.6±0.3c 0.7±0.1b 0.4±0.2 0.4±0.2b 
aData are expressed as fold change mean ± standard deviation (n=4/group) 
bSignificantly different from control group (p< 0.05) 
cSignificantly different from control group (p< 0.01) 
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Table 4.18 
 
Effects of BDE 47 on thyroid hormone responsive genes in rat liver 
Treatment       Dio1a      Ttra  
(mg/kg/day)  
0    1.0±0.2   1.0±0.3   
10    1.1±0.2    1.0±0.4   
30    1.1±0.1   1.0±0.2   
100    1.1±0.4   0.9±0.4   
aData are expressed as mean ± standard deviation (n=6/group) 
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Table 4.19 
 
Effects of BDE 47 on thyroid hormone responsive genes in rat hepatocytes 
Treatment       Dio1a                 Ttra 
(µM)  
0    1.0±0.0   1.0±0.0   
0.3    1.2±0.6   1.2±0.6   
3    0.9±0.4   1.0±0.5   
30    0.7±0.2   1.1±0.9 
aData are expressed as mean ± standard deviation (n=5/group) 
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Table 4.20 
 
Effects of BDE 47 on thyroid hormone responsive genes in human hepatocytes 
Treatment      DIO1a        TTRa  
(µM)  
0    1.0±0.0    1.0±0.0   
0.3    1.5±0.5    1.1±0.4   
3    1.3±0.3    0.8±0.0   
30    1.7±0.6    0.4±0.1b   
aData are expressed as mean ± standard deviation (n=4/group) 
bSignificantly different from control group (p< 0.01) 
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CHAPTER 5 
 
CONCLUSIONS 
 
This study builds upon previous investigations into the mechanism of T4 disruption. It 
is hypothesized that through the activation of nuclear receptors such as, AhR, CAR, and 
PXR, hepatic UGTs are induced resulting in the enhancement in hepatic T4 glucuronidation 
and T4 clearance from the serum. There are findings that show that the magnitude of serum 
T4 decreases does not correlate with the magnitude of inductions in hepatic T4-UGT activity. 
Further reports indicate that the inconsistencies in serum T4 concentrations may be due the 
increased hepatic accumulation and elimination of T4 instead of increases in T4 
glucuronidation. Overall, this work shows that the induction of T4 glucuronidation is species-
and agonist-specific.  In addition, because of the small changes in T4 glucuronidation, the 
role of hepatic T4 glucuronidation in the disruption of T4 homeostasis is uncertain.  
The liver is a major site of xenobiotic and TH metabolism; therefore, hepatocytes 
were used because of their biological relevance. Hepatocytes also offered a direct 
comparison of hepatic T4 metabolism between rats and humans.  Sandwich cultured 
hepatocytes (SCH) were specifically chosen because hepatocytes in a sandwich configuration 
have been shown to extend the metabolism and transport functions of the cells. To achieve 
the goals set forth in this study, an analytical method for the detection of THs and their 
metabolites was developed.  Most importantly, the radiometric detection method developed
175 
 
for these studies simultaneously detect and quantify radiolabelled THs and metabolites in 
media and in hepatocytes.  To my knowledge, these are the first in vitro experiments to use 
physiologically relevant concentrations of T4 for rat (0.05µM) and human (0.1µM) to 
examine T4 metabolite levels in media. In an effort to create a straightforward method for 
measuring T4 metabolism TH serum binding proteins were not added to the media.  To make 
the experiments more relevant, future studies should use serum binding proteins (TTR and 
TBG) in the media, at species relevant concentrations would be helpful in examining the 
influence of T4 binding on metabolism.  TTR and TBG are produced in the liver and are 
presumed to be produced in hepatocytes; therefore, by adding TTR and TBG to the media in 
addition to what is produced by the hepatocytes may result in serum protein concentrations 
greater than those found in rat and human serum.  
With the knowledge that TH translocation occurs through active transport 
mechanisms (Blondeau, et al., 1988;  De Jong, et al., 1992;  de Jong, et al., 1993), it is 
reasonable to assume that active transport is likely the rate-limiting step for TH metabolism 
in hepatocytes. T4 uptake has been shown to be slower in human hepatocytes than rat 
hepatocytes (Krenning, et al., 1981;  de Jong, et al., 1993). In agreement with previous 
studies, I found that [125I]-T4 accumulation was a slower process in SCHH than in SCRH at 
longer time points; however at shorter time points accumulation did not change. Hepatic 
elimination may be rate-limiting due to the interplay of metabolic and transport processes; 
therefore, the greater T4 metabolite production of SCRH in comparison to SCHH may be 
partially explained by the more rapid uptake of T4 into SCRH.  
Agonists of hepatic nuclear receptors CAR, PXR, and AhR, consistently cause 
decreases in circulating TH concentrations in rodents (Barter and Klaassen 1992; Kretschmer 
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and Baldwin 2005; Qatanani et al. 2005). Prototypical agonists were used to examine the 
effects of nuclear receptor agonists on T4 metabolism. SCRH and SCHH hepatocytes were 
treated with PB and 3MC, the prototypical agonists for CAR and AhR, respectively. Due to 
the species differences in PXR activation, rat hepatocytes were treated with PCN and human 
hepatocytes were treated with Rif. The prototypical persistent organic pollutant, PCB 153 
was used in these studies because as a PB-like PCB, it induces the CAR P450 target, CYP2B.  
SCRH and SCHH were treated with PCB 153 to compare with the effects of PB treatment on 
T4 metabolism.  T4G in the media of SCRH increased with all of the nuclear receptor 
activators; however T4G only increased in the media of SCHH following treatment with Rif 
and PCB 153. Only PCB 153 increased T4G levels in the media of both SCRH and SCHH. 
This suggests that PCB 153 may be similar to PB in its ability to increase CYP2B; however 
PCB 153 is not PB-like when comparing T4G levels in the media of SCRH and SCHH. The 
results in SCRH are similar to results in vivo which show increases in hepatic T4-UGT 
activity or biliary T4G elimination (McClain, et al., 1989;  Hood and Klaassen, 2000a;  Craft, 
et al., 2002;  Kato, et al., 2004;  Kato, et al., 2011). Data on xenobiotic-mediated increases in 
T4 metabolism in humans is limited; however, the results in SCRH are similar to previous 
human in vivo studies, in which Rif decreased serum T4 and increased liver metabolic 
activity to a greater extent than PB (Ohnhaus, et al., 1981;  Ohnhaus and Studer, 1983).  
There is some consensus with the results from previous in vivo studies; however, it was 
difficult to correlate the UGT mRNA expression with T4G levels in media of SCRH and 
SCHH.  The most important finding from these data is that while PCB 153 is PB-like in its 
ability to induce CYP2B, PCB 153 is different from PB as it is a more efficacious inducer of 
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T4 glucuronidation than PB. Future studies should focus on the differences in UGT induction 
between PB and PCB 153.  
AhR, CAR and PXR have been shown to regulate SULTs (Saini, et al., 2004;  
Yanagiba, et al., 2009;  Aleksunes and Klaassen, 2012); however, T4S levels in the media of 
SCRH and SCHH did not change with treatment of each agonist. MRNA expression of 
SULTs involved with T4 sulfation also did not change. The lack of change in T4S levels is 
not exactly surprising, because T4G is the major metabolite found in the bile of rats. Also, 
SULTs have a low affinity for T4 so it is reasonable that T4S levels do not change whereas 
T4G levels increase (Rutgers, et al., 1989;  Visser, 1996). In this study, there was no change 
in T3+rT3 levels and no change in DI mRNA expression in both species of hepatocytes. 
Hepatic deiodinase I activity often decreases with hypothyroidism in rats treated with AhR 
agonists (Hood and Klaassen, 2000b;  Viluksela, et al., 2004;  Szabo, et al., 2009). 
Reductions in deiodinase activity is thought to be a physiological response to decreases in 
serum T4 and is not mediated by nuclear receptor agonist; therefore, changes in T3+rT3 
production and DI mRNA expression may not be observed in an in vitro system(Davies, et 
al., 1996). 
Increases in [125I]-T4 liver accumulation and biliary elimination of [125I]-T4 and [125I]-
T4G occurs in rodents treated with PB or PCB 153 (Kato, et al., 2010;  2011). I found that 
[125I]-T4 accumulation is slower in SCHH than in SCRH. This shows that uptake and efflux 
transporter may play an important part in the metabolism of T4. The effects of nuclear 
receptor agonists on uptake and efflux transporter mRNA expression were mixed. mRNA 
expression for efflux transporters MDR1, an efflux transporter, increased with PB, 3MC and 
PCB 153 in SCRH and with PB and Rif in SCHH. MRP2, also an efflux transporter 
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increased in SCHH treated with PB and Rif. The only change in uptake transporters was with 
the increase in Oat2 mRNA expression, in SCRH treated with PB.  These results indicate that 
treatment with nuclear receptor agonists may alter efflux and uptake transporter activity; 
however, it is difficult to correlate T4G changes with transporter mRNA expression in SCRH 
and SCHH.  It could be explained that the lack of consistency between transporter mRNA 
expression and treatment with nuclear receptor agonist is due to the culture day in which the 
cells were collected for mRNA analysis. Hepatocytes were treated for 72 with an agonist; 
however, it is possible that treating the hepatocytes for 48 hours would result in more 
consistency in transport mRNA expression. Tchaparian, et al.(2011) demonstrated that in 
SCRH, expression profiles for uptake and efflux transporters do not predict transport activity. 
This suggests that optimal culture conditions for uptake transporters are not necessarily 
optimal for efflux transporters. The in vitro method described in this report was optimized for 
T4 metabolism and not for transporter activity; therefore, it is difficult to make conclusions 
about T4 transport in our system. Further work describing the uptake and efflux of T4 by 
transporters is needed.  
BDE 47 is a major congener in the PBDE class of brominated flame retardants. It is 
also the predominant congener found in most environmental and human samples (Hites, 
2004;  Lorber, 2008). BDE 47 has been shown to be an agonist for CAR and to a lesser 
extent PXR in rodents (Pacyniak, et al., 2007;  Richardson, et al., 2008). Previous studies, 
show BDE 47 decreases serum T4 in rodents and increases T4-UGT activity or UGT mRNA 
expression (Hallgren, et al., 2001;  Hallgren and Darnerud, 2002;  Richardson, et al., 2008). 
To my knowledge this is the first time in vivo-in vitro comparisons have been made 
concerning BDE 47 and its effect on T4 metabolism.  Using SCRH and SCHH, we also 
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investigated the changes in T4G levels in response to BDE 47. To examine effects on T4 
glucuronidation, T4-UGT activity and UGT mRNA expression were analyzed in the liver of 
rats treated with BDE 47. T4-UGT activity did not change; however, UGT mRNA expression 
increased. BDE 47 also did not change T4G levels or UGT mRNA expression in SCRH. The 
increase in hepatic UGT mRNA expression did not coincide with the lack of T4-UGT activity 
increase in rat liver or T4G levels in the media of rat hepatocytes.  This discrepancy could be 
due to an inability of the T4-UGT enzyme assay to accurately measure T4 glucuronidation. It 
is possible that the T4-UGT assay was not optimized for different UGT isoforms; therefore, 
changes in T4 glucuronidation may not be measured accurately (Visser, et al., 1993a;  Hood 
and Klaassen, 2000a). Also, certain UGT isoforms may be necessary to adequately measure 
increases in T4-UGT activity or in T4G levels in the media. The rat and SCRH data is 
inconsistent with the large decrease (96%) in serum. In SCRH, BDE 47 did not change T4G 
levels or UGT mRNA expression which supports the findings in the in vivo rat study. This 
suggests that hepatic T4 glucuronidation has only a minor effect on the decrease in serum T4 
in rats.  In contrast, BDE 47 increased T4G levels in the media of SCHH and increased 
UGT1A1 mRNA expression which shows a potential species difference in the BDE 47 effect 
on T4 metabolism in rodents and humans.  
The response of transport mRNA expression to BDE 47 was mixed. Overall, the 
results suggests MDR1 in rats may mediate the biliary elimination of T4 or T4G following 
BDE 47 treatment; however, this same result may not be observed in SCRH or SCHH. Mrp2 
mRNA expression did not change with BDE 47; therefore, it may not be responsible for the 
decrease in serum T4 observed in rats. In general, transporter mRNA expressions following 
treatment with BDE 47 are mixed between the species of hepatocytes and rat liver which 
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makes it difficult to make conclusions about BDE 47 and T4 transport. To better answerer 
questions concerning transporters, further studies on the elimination or accumulation of T4 in 
rats should be conducted.  
In conclusion, there were consistent differences in the levels of T4G in the media of 
untreated SCRH and SCHH. Species differences were also observed for [125I]-T4 uptake and 
T4G levels in treated hepatocytes which may give insight into the effects of nuclear receptor 
agonists on TH disruption. It is understood that there are species differences in nuclear 
receptor activation and ligand binding and these species difference were apparent in this 
study. There were some inconsistencies in some of the UGT, SULT and transporter mRNA 
expression levels which are difficult to explain; but they should not be ruled out as a method 
to describe increases in T4 metabolism or biliary elimination. Future studies may be able to 
resolve these inconsistencies by confirming the gene expression data with protein analysis. 
To my knowledge this is the first study to examine multiple T4 metabolites and induction by 
AhR, CAR, and PXR agonist in rat and human hepatocytes. While there are limitations in the 
quantitation of T4 uptake, further work is warranted. Overall, these studies show the utility of 
SCH in the study of hepatic T4 metabolism in the continuing investigation of thyroid 
hormone disruption and human relevance.  
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 APPENDIX 
POSSIBLE MECHANISMS OF THYROID HORMONE DISRUPTION IN MICE BY 
BDE 47, A MAJOR POLYBROMINATED DIPHENYL ETHER CONGENER2 
 
A. INTRODUCTION 
 
Polybrominated diphenyl ethers (PBDEs) have been commercially used as fire 
retardants in consumer products such as polyurethane foam, electronics, and textile coating.  
PBDEs are lipophilic compounds that have been detected in human serum and breast milk as 
well as in various types of environmental media around the world (Petreas et al., 2003;  
Schecter et al., 2003;  Focant et al., 2004b).  2, 2', 4, 4'-Tetrabromodiphenyl ether (BDE 47) 
is the predominant congener found in most wildlife and human samples and generally 
accounts for half of the total PBDEs measured (Birnbaum and Staskal, 2004;  Hites, 2004).  
Although health risks to humans following PBDE exposure are unknown, several studies in 
rodents report potential developmental, reproductive, neurological, and endocrine toxicity 
(Zhou, et al., 2001;  de Wit, 2002;  Zhou, et al., 2002;  Birnbaum and Staskal, 2004). 
Due to their structural similarity to polychlorinated biphenyls (PCBs) and thyroid 
hormones (THs), PBDEs may act as TH disruptors.  Developmental exposures to commercial  
_____________________ 
2Richardson, V.M., Staskal, D.F., Ross, D.G., Dilliberto, J.J., DeVito, M.J., and Birnbaum, 
L.S. Toxicol Appl Pharmacol 226(3), 244-50. 2008
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PBDE mixtures decreased circulating TH concentrations in rat pups (Zhou, et al., 2002;  
Ellis-Hutchings et al., 2006).  Additionally, short term exposures to PBDEs during puberty 
resulted in decreases in TH in rats (Zhou, et al., 2001;  Stoker et al., 2004).  While there is 
sufficient evidence that PBDEs decrease circulating TH concentrations, the mechanisms 
involved are unclear.   
There are multiple sites within the thyroid axis in which xenobiotics can alter the 
hormonal balance, such as changes in binding proteins and hormone metabolism.  In rodents, 
decreases in TH concentrations are often associated with induced hepatic thyroxine (T4)-
glucuronidation followed by increased biliary elimination of the conjugated hormone (Barter 
and Klaassen, 1992;  Vansell and Klaassen, 2002a).  Rats exposed to PBDEs have decreased 
concentrations of circulating T4 which are linked to moderate induction in hepatic 
uridinediphosphate glucuronosyltransferases (UGTs) (Hallgren and Darnerud, 2002;  Zhou, 
et al., 2002).  While UGTs play a role in decreasing circulating TH, it is not certain that the 
induction of hepatic T4-glucuronidation alone is responsible for the effects on TH 
concentration following PBDE exposures.  For instance, studies using UGT1A-deficient 
Gunn rats exposed to phenobarbital (PB) or PCBs demonstrate that decreases in serum total 
T4 were not necessarily glucuronidation dependent (Collins and Capen, 1980;  Kato, et al., 
2004).  In vivo studies show that PCB metabolites can bind to transthyretin (Ttr), a major TH 
transport protein in plasma, (Kato, et al., 2005) and also cause increases in biliary T4 
excretion which in combination may result in decreases in circulating total T4.  Hydroxylated 
PBDEs incubated with T4 and human transthyretin show decreases in ex-vivo T4-Ttr binding 
(Hallgren and Darnerud, 2002;  Hamers et al., 2006).  This suggests that alterations in Ttr-
mediated transport may also contribute to the observed decrease in T4.     
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Xenobiotic metabolizing enzymes (XMEs) such as UGTs and cytochrome P450s 
(P450s), as well as transport proteins, are induced through the activation of a variety of 
nuclear receptors including the aryl hydrocarbon receptor (AhR), pregnane X receptor 
(PXR), and constitutive androstane receptor (CAR) (Maglich, et al., 2002;  Auyeung, et al., 
2003;  Bock and Kohle, 2004;  Wagner, et al., 2005).  The role of UGTs in the PBDE–
mediated decrease in TH has been studied, but the function transporters play in this decrease 
has yet to be determined.  In addition to UGTs, PBDEs induce cytochrome P450s (Sanders, 
et al., 2005;  Staskal et al., 2005), but it is uncertain if transport proteins are also altered, and, 
if so, what role they play in the decrease in circulating T4.  Studies have shown a correlation 
between induction of hepatic UGTs (Ugt1a1), multidrug resistance protein associated protein 
(Mrp2), and organic anion transporting proteins (Oatp1 and Oatp2) mRNA levels, with 
decreases in serum TH concentrations (Ribeiro, et al., 1996;  Mitchell, et al., 2005;  Wong, et 
al., 2005).  There is also evidence that multidrug resistance proteins (MDRs) are important in 
TH efflux (Mitchell, et al., 2005).  Collectively, these studies indicate that active transport 
along with glucuronidation and altered serum binding are possibly involved in TH decreases.  
In an effort to understand the mechanisms involved with alterations in TH 
concentrations following exposure to PBDEs, this study examines the effects of BDE 47 on 
TH homeostasis in adult female mice.  Multiple parameters including enzymatic activities 
and gene expression were assessed to identify possible mechanisms of TH disruption.  In 
particular, genes related to TH transport and metabolism were analyzed for changes 
following BDE 47 exposure.   
 
 
187 
 
B. MATERIALS AND METHODS 
 
Chemicals   
2, 2', 4, 4'-Tetrabromodiphenyl ether (BDE 47) was generously provided by Great 
Lakes Chemical Corporation (Indianapolis, IN). Purity was >98% as determined by reverse-
phase-performance liquid chromatography (HPLC).  All other chemicals used were of the 
highest grade commercially available. 
 
Animals and Treatment  
Female C57BL/6 mice (9 weeks old, 19-22g) were obtained from Charles River 
Breeding Laboratories (Raleigh, NC).  Animals were maintained on a 12- hour light/dark 
cycle at ambient temperature (22°C) and relative humidity (55±5%).  They were provided 
with Purina 5001 Rodent Chow (Ralston Purina Co., St. Louis, MO) and tap water ad 
libitum.  Mice were housed individually and allowed to acclimate for one week before study 
commencement.  Animals were held in a facility approved by the American Association for 
Accreditation of Laboratory Animal Care (AAALAC).  The Animal Care and Use 
Committee of NHEERL (U.S. EPA, RTP, NC) approved all animal protocols.  Animals were 
treated with a single daily dose for 4 consecutive days.  Mice were randomly selected for 
each treatment group (n=10/group).  Mice were administered BDE 47 in corn oil (0, 3, 10, or 
100 mg/kg/day for 4 days) by oral gavage (10 ml/kg).  Dosing solutions were prepared by 
dissolving BDE 47 in hexane followed by the addition of corn oil.  Hexane was removed 
from the dosing solutions by evaporation with a speed vacuum device (Speed Vac, Savant 
Instruments, Inc., Farmingdale, NY).   
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Serum and Tissue Collection 
24 hours after the final dose, mice were euthanized by CO2 asphyxiation followed by 
exsanguination via cardiac puncture; and blood, liver, and kidneys were collected.  Blood 
was allowed to clot for 1 hour on ice in serum separator tubes (Becton Dickinson, Franklin 
Lakes, NJ).  Blood was then centrifuged at 1200 x g for 30 min to obtain serum.  Serum was 
frozen and held at -80°C until analyzed.  Livers and kidneys were removed and weighed.  
Between 100 and 150 mg of liver or kidney were placed in RNAlater solution (Ambion, Inc., 
Austin, TX) and frozen at -80°C for subsequent RNA purification.  The remaining liver was 
frozen at -80°C for further enzyme activity analysis. 
 
Thyroid Hormone Analysis 
Serum total thyroxine (T4) concentrations were measured using the Coat-a-Count 
radioimmunoassay (RIA) kit (Diagnostic Products Corporation, Los Angeles, CA) according 
to the manufacturer’s protocol.  Each sample was measured in duplicate. All data is 
expressed as ng/ml serum T4. 
 
EROD, PROD, and T4-UGT assays 
Liver microsomal fractions were prepared (Zhou, et al., 2001;  Zhou, et al., 2002) and 
protein concentrations were measured using a protein assay kit with bovine serum albumin as 
a standard (Bio-Rad Laboratories, Hercules, CA).  Enzymatic activities for ethoxyresorufin 
O-deethylase (EROD), a marker for CYP1A1, and pentoxyresorufin O-deethylase (PROD), a 
marker for CYP2B, were measured using a spectrofluorimetric assay (DeVito et al., 1994).  
Hepatic T4-UGT activity was determined by using a modified assay (Zhou, et al., 2001;  
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Zhou, et al., 2002) based on a previously published method (Visser, et al., 1993b).  All data 
is expressed as fold change as compared to control, where controls for EROD and PROD are 
expressed as nMol resorufin/min/mg protein and controls for T4-UGT are expressed as pMol 
T4-UGT/min/mg protein. 
 
RNA isolation, relative real-time RT-PCR, and RT-PCR data analysis 
Total RNA was isolated using the RNeasy Midi Kit with DNase I digestion 
performed during column purification (Qiagen, Hilden, Germany).  To assess the integrity of 
the RNA samples, the 2100 Bioanalyzer was used (Agilent Technologies, Palo Alto, CA) 
using RNA with RNA Integrity Numbers (RINs) greater than 8.1.  Samples with RINs less 
than 8.1 were not analyzed by RT-PCR, therefore, the sample size used for many of the 
genes examined varied (n=4-6/group).  Real-time RT-PCR was performed using the ABI 
Prism 5700 Sequence Detection System (ABI, Foster City, CA).  100 ng of total RNA was 
used for each reaction.  cDNA was synthesized using TaqMan Reverse Transcriptase Kits 
(ABI, Foster City, CA).  PCR was then performed on all cDNAs using TaqMan Universal 
PCR Master Mix and TaqMan Gene Expression Assays (ABI, Foster City, CA).  These 
assays are Cyp1a1 (ABI# Mm00487218_m1), Cy2b10 (Mm00456591_m1), Ugt1a1 
(Mm0129059_m1), Ugt1a6 (Mm01290954_m1), Ugt1a7 (Mm01967851_s1), Ugt2b5 
(Mm01623253_s1), Mdr1a (Mm00440761_m1), Mdr1b (Mm0040736_m1), Mrp3 
(Mm00551550_m1), Mct8 (Mm00486202_m1), Ttr (Mm00443267_m1).   The thermal cycle 
condition for the RT reaction was as follows: 10 min at 25°C, 30 min at 48°C, and then 5 min 
at 95°C.  The PCR reaction was performed as follows:  2 min at 50°C (uracil-DNA 
glycosylase activation), 10 min at 95°C (activation of Taq DNA polymerase), and 40 cycles 
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of denaturation at 95°C for 15 s followed by annealing and extension at 60°C for 1 min.  
Data were analyzed using the Sequence Detection Systems software (ABI, Foster City, CA).  
All RT-PCR data were quantified by the ΔΔCt method (Applied Biosystems User Bulletin 2) 
relative to a calibrator sample and an endogenous control (18S).  In the ΔΔCt method, the 
control group is used as a reference point for all other dose groups; therefore, all samples are 
expressed as fold difference as compared to control. 
 
Data Analysis 
All data are presented as the mean ± standard deviation.  The statistical intergroup 
comparisons were determined by using one-way analysis of variance (ANOVA) followed by 
Dunnet’s Multiple Comparison post test (GraphPad Prism 3.0, GraphPad Software San 
Diego, CA).  The levels of probability of statistical significance are p < 0.05.  Data were 
transformed (Y=1/Y), where intergroup variability was deemed significantly different by 
Bartlett’s test for equal variances.  Data transformed due to intergroup variability include 
EROD, PROD, Cyp2b10, Ugt1a7, Mrp3, and Mct8. 
 
C. RESULTS 
 
Body weight, liver weight, and serum total T4 
There were no obvious signs of toxicity and no significant treatment effect on body 
weight, or kidney weight between treatment groups.  Liver weights and liver-to-body weight 
ratios significantly increased 14% and 10%, respectively, at 100 mg/kg/day of BDE 47 
(Table 1).  A maximal decrease in serum total T4 of almost 43% was observed at 100 
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mg/kg/day of BDE 47 with respect to controls (Figure 1).  There were no significant effects 
on liver weight or serum total T4 at the lower doses tested (3 and 10 mg/kg/day of BDE 47) 
(Table 1).  
 
Hepatic UGT induction 
To determine which UGT isoforms were induced with exposure to BDE 47, liver 
mRNA expression was analyzed by real time RT-PCR.  Treatment with BDE 47 increased 
hepatic mRNA expression of Ugt1a1, Ugt1a7 and Ugt2b5.  Specifically, 100 mg/kg/day of 
BDE 47 significantly increased hepatic Ugt1a1 and Ugt2b5 mRNA expression 1.2- and 1.3-
fold, respectively.  Ugt1a7 mRNA expression also significantly increased 1.3- and 1.7-fold at 
10 mg/kg/day and 100 mg/kg/day of BDE 47, respectively.  Ugt1a1, Ugt1a7, and Ugt2b5 
correlated with the observed decreases in T4 (R2=0.27, 0.46, and 0.22, respectively and 
p<0.05, 0.001, and 0.05, respectively).  Liver microsomes were used to determine UDP-
glucuronosyltransferase (UGT) activity with respect to T4.  Hepatic T4-UGT enzyme activity 
was unchanged with BDE 47 treatment and therefore, did not correspond with the changes 
observed in UGT mRNA expression.  The T4-UGT enzyme assay does not detect specific 
UGT isoforms.  This suggests that our assay may not be a sensitive measure of actual 
changes in individual UGT isoform activity (Table 2). 
 
Hepatic Cytochrome P450 induction 
 Effects on major xenobiotic metabolizing enzymes (XMEs) for phase I metabolism, 
were examined.  Cyp1a1 mRNA expression and EROD activity were used as markers for Ah 
receptor activation (Whitlock, 1990).  BDE 47 significantly increased hepatic EROD, a 
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marker for Cyp1a1 activity, 1.4-fold at the highest dose (100 mg/kg/day); however, hepatic 
Cyp1a1 mRNA expression was not significantly changed with treatment.  Hepatic PROD and 
Cyp2b10 mRNA expression were used as markers for CAR activation (Waxman, 1999;  
Maglich, et al., 2002;  Xiong et al., 2002;  Yamada et al., 2006).  Hepatic PROD, a marker 
for CYP2B activity, increased significantly at the 3, 10, and 100 mg/kg/day doses, 1.2- , 1.8-, 
and 4.8- fold, respectively.  Hepatic Cyp2b10 mRNA expression was increased significantly 
at 10 and 100 mg/kg/day, 2.5- and 19.9-fold, respectively.  Correlations with T4 decreases 
were significant for PROD (R2=0.57, p<0.0001) and Cyp2b10 (R2=0.44, p<0.005).  Hepatic 
Cyp3a11 mRNA expression, a marker for PXR activation (Waxman, 1999;  Xie et al., 2000), 
showed no significant changes with treatment.(Table 3). 
 
Transporter mRNA expression 
Several transporters known to transport glucuronides or thyroid hormones were 
analyzed.  Specifically, major efflux transporters in the ATP binding cassette (ABC) gene 
family, including multidrug resistance-associated proteins (MRPs), and multidrug resistance 
proteins (MDRs), were analyzed for changes in mRNA expression in liver (Table 3).  The 
expression of hepatic Mrp3 mRNA, a major sinusoidal efflux transporter of glucuronides, 
showed a significant 47% increase at 100 mg/kg/day of BDE 47.  Overall, Mrp3 mRNA 
expression correlated significantly with decreases in T4 (R2=0.46, p<0.001).  Mdr1a and 
Mdr1b encode P-glycoproteins (P-gp) in mice and can transport several substrates including 
glucuronides and thyroid hormones (Ribeiro, et al., 1996;  Mitchell, et al., 2005).  Exposures 
to BDE 47 caused a significant dose-dependent decrease at all doses tested in hepatic Mdr1a 
mRNA expression; however, the decreases did not correlate with T4 decrease (R2= 0.17, 
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p=0.08).  Mdr1b mRNA expression was unchanged in liver (Table 4).  MCT8, a membrane 
bound thyroid hormone uptake transporter (Friesema, et al., 2003) was examined for BDE 
47- related changes in mRNA expression.  Hepatic Mct8 mRNA expression significantly 
decreased 0.8-fold at 100 mg/kg/day; however, this decrease did not correlate significantly 
with decreases in T4, (R2= 0.02, p=0.56) (Table 5). 
 Mdr1a, Mdr1b, and Mrp3 mRNA expression was also measured in kidney.  BDE 47 
had no observed effect on mRNA expression of these transporters analyzed. 
 
Transthyretin mRNA expression 
Transthyretin (Ttr), a major serum transport protein in rodents was analyzed for 
effects on mRNA expression following exposures to BDE 47.  Ttr mRNA expression was 
significantly decreased at the highest dose tested (100 mg/kg/day) and correlated well with 
the observed decrease in serum T4 (R2=0.61; p<0.0001) (Table 5).  . 
 
D. DISCUSSION 
 
Previous hypotheses on TH disruption by BDE 47 have focused on two mechanisms: 
1) induction of hepatic UGT-mediated TH metabolism resulting in decreased circulating T4 
and 2) competitive binding of BDE 47 and thyroid hormones to serum transport proteins.  
This study further investigates parameters involved in the alteration of thyroid hormone 
status.  Specifically, this study aims to identify the genes activated by BDE 47, which may 
provide information as to the mechanisms by which PBDEs exert their effects.  In this study, 
BDE 47 decreased T4 and increased hepatic UGT mRNA expression in female mice.  In 
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addition, BDE 47 altered the hepatic mRNA expression of putative transporters of TH or 
glucuronides.  
In vivo studies show that decreases in TH concentrations in rats treated with BDE 47 
(Hallgren, et al., 2001;  Hallgren and Darnerud, 2002) coincide with increases in hepatic T4-
UGT activity.  In this study, BDE 47 exposures increased Ugt1a1, Ugt1a7, and Ugt2b5 
mRNA expression in mouse liver, while Ugt1a6 remained unchanged.  Changes in specific 
UGT isoforms, such as Ugt1a7 mRNA expression correlated well with decreases in T4. (R2= 
0.46, p<0.001) 
There was no increase in hepatic T4-UGT activity, which does not agree with the 
observed increases in UGT mRNA expression.  This may be because the T4-glucuronidation 
enzyme assay does not evaluate activity for specific UGT isoforms.  Alternatively, increases 
in UGT mRNA expression may not result in adequate increases of the respective enzyme 
proteins.  Some UGT activity induction can also be dependent on AhR activation.  For 
example, Ugt1a6 induction is dependent on AhR activation (Auyeung, et al., 2003;  
Nishimura, et al., 2005); therefore, the lack of significant increases in hepatic Ugt1a6 mRNA 
expression in our study further supports the idea that BDE 47 is not an agonist for AhR and 
may explain the lack of hepatic UGT activity.   
Once activated, nuclear receptors coordinately regulate genes involved in the 
detoxification (phase I and II) and elimination (phase III/transport) of xenobiotics, steroid 
hormones, and bile acids (Bock and Kohle, 2004;  Wagner, et al., 2005).  With the induction 
of genes involved in phase I and phase II metabolism, this study examined the effects of 
BDE 47 on the expression of uptake and efflux transporters in the liver.  MCT8 is a major 
thyroid hormone uptake transporter.  MCT8-null mice exhibit abnormal thyroid hormone 
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levels (decreased serum T4 and elevated serum T3) (Trajkovic et al., 2007) suggesting that the 
decrease in hepatic Mct8 mRNA expression found in the present study following BDE 47 
exposure may play an important role in the serum T4 decrease.  
P-gp, encoded by Mdr1a and Mdr1b in mice, is a major canalicular efflux transporter 
and plays a role in the transport of a diverse range of xenobiotics and steroids into the bile.  
There is also evidence that MDR transporters are important in TH efflux, in which cells 
transfected with Mdr1 cDNA increased the efflux of T3 as compared to control cells 
(Mitchell, et al., 2005).  (Nishio et al., 2005)also examined changes in P-gp in hyperthyroid 
rats.  They demonstrated that rats in a hyperthyroid state have increased levels of Mdr1a and 
P-gp in the liver.  They also found that hyperthyroid rats administered digoxin had lower 
concentrations of digoxin in serum, which may be attributable to the P-gp increases.  Studies 
from our laboratory show a decrease in the urinary elimination of BDE 47 (single, oral dose 
of 100 mg/kg) in Mdr1a/b deficient mice as compared to wild type mice1.  Together, these 
studies show that P-gp also plays an important role in defining the toxicokinetics of many 
xenobiotics.  Furthermore, these studies show that P-gp may be regulated by TH levels.  In 
the present study, hepatic Mdr1b mRNA expression was unchanged with exposure to BDE 
47, while Mdr1a mRNA expression decreased significantly, even at the lowest dose tested (3 
mg/kg/day).  Based on the cited studies, there are two possible explanations for the decrease 
in hepatic Mdr1a following BDE 47 exposure.  First, it is possible that once in a hypothyroid 
state, hepatic Mdr1a expression will decrease in response to the decrease in circulating serum 
T4.  On the other hand, decreases in hepatic P-gp may result in a longer half-life of BDE 47 in 
liver, resulting in increased opportunity for induction of UGTs, consequentially decreasing 
serum T4. 
196 
 
There were no changes in hepatic mRNA expression of sinusoidal efflux transporters, 
Mrp1 and Mrp5.  However, Mrp3 mRNA expression increased with BDE 47 exposures.  
Mrp3, a sinusoidal efflux transporter, exports glucuronides from the liver and into the blood.  
It has been suggested that the induction of Mrp3 results from the need for an alternative 
protective mechanism (Inokuchi et al., 2001;  Wagner, et al., 2005).  The increase in Mrp3 
mRNA expression, suggests that high doses of BDE 47 may saturate hepatic efflux 
transporters. The saturation of hepatic efflux transporters would require the induction of a 
back-up transporter to move glucuronides from the liver into the bloodstream.  Altogether, 
the altered expression in hepatic transporter mRNA expression suggests that BDE 47 may 
mediate changes in biliary elimination of glucuronides.  The induction of Mrp3 also shows 
that increases in glucuronidation may be a major cause of the TH decreases even though T4-
UGT enzymatic activity was unchanged as measured by our assay.  
CYP1A1, CYP2B10, and CYP3A11, classic targets for AhR, CAR, and PXR 
activation, respectively, (Maglich, et al., 2002), were measured to establish which nuclear 
receptor pathway BDE 47 may activate.  Cyp1a1 mRNA expression and associated enzyme 
activity (EROD) was used to determine the ability of BDE 47 to act through the AhR.  The 
slight increase in EROD and lack of hepatic Cyp1a1 mRNA induction at the highest dose 
tested supports data that shows BDE 47 is not an AhR agonist (Peters et al., 2004;  Sanders, 
et al., 2005).  The modest increase in EROD activity may also be due to overlapping 
regulation by CAR (Auyeung, et al., 2003;  Nishimura, et al., 2005).  Other studies suggest 
that BDE 47 may be an AhR antagonist in rats, and this may explain the small decrease in 
mouse Cyp1a1 mRNA expression seen in this study (Peters, et al., 2004;  Hamers, et al., 
2006).  Common targets for CAR activation, Cyp2b10 mRNA expression and associated 
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enzyme activity (PROD), increased significantly in liver.  The sensitive dose-dependent 
increases in hepatic PROD (3 mg/kg/day) and Cyp2b10 mRNA expression (10 mg/kg/day) 
suggests that CAR may be one of the major nuclear receptors involved in the regulation of 
the observed responses. Hepatic Cyp3a11 mRNA expression, a common target for PXR 
activation was unchanged following BDE 47 exposure.  In contrast to the reported increase in 
male mice exposed to 50 mg/kg/day BDE 47 by intraperitoneal injections for 4 days 
(Pacyniak, et al., 2007), we saw no increase in hepatic Cyp3a11 mRNA expression.  Whether 
or not this result is due to differences in exposure routes or the sex of the mice used is 
unclear. 
It is hypothesized that hydroxylated PCB metabolites (Brouwer et al., 1988;  Lans et 
al., 1994) and hydroxylated PBDE metabolites (Hallgren and Darnerud, 2002) bind to 
transthyretin causing an increase in the hepatic uptake and biliary elimination of T4.  The 
present study showed decreases in hepatic Ttr mRNA expression that correlated well with the 
observed T4 decreases (R2=0.61; p<0.0001).  This further supports the hypothesis that BDE 
47 may alter T4 transport by Ttr in rodents.  Further investigation is needed to examine what 
mechanisms may cause the decrease in Ttr mRNA expression.  Considering that thyroxine-
binding globulin (TBG) is the major TH serum carrier protein in humans and although Ttr 
may be critical during human development, it is unclear if alteration in hepatic Ttr would 
play a significant role in TH homeostasis in adult humans. 
In conclusion, this study was designed to examine TH decreases following a short-
term exposure; therefore, the doses chosen are relatively high in comparison to daily human 
exposure and are known to be non-linear in toxicokinetic mouse studies (Staskal et al., 2006).  
This report shows that active transport along with glucuronidation and alterations in TH 
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binding in serum may be involved in the TH decreases at 100 mg/kg/day BDE 47 in adult 
female mice.  Decreases in total T4 after BDE 47 exposure may be mediated through 
CAR/PXR pathways and this is evident by the induction of genes regulated by CAR/PXR, in 
particular, Cyp2b10, Ugt1a1, Ugt1a7, Ugt2b5 and Mrp3.  Although mRNA expression was 
unchanged for several of the transport proteins important in glucuronide or TH transport, this 
does not rule out possible changes in regulation at the translational or posttranslational levels 
(Peeters et al., 2002).  Together our data demonstrates that the coordinated regulation of 
phase I, phase II, phase III/transporters, serum binding proteins and thyroid hormone 
clearance following exposures to environment contaminants, such as BDE 47 are 
complicated processes, which require further examination.   
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Table A.1. 
 
Body weight, organ weights, and liver-to-body weight ratio 
Treatment Body (g) a   Liver (g) a Kidney (g) a Liver-to-body wt. ratio a 
(mg/kg/day)          
0  20.60±0.63   0.96±0.07 0.23±0.02 0.046±0.003 
3  21.33±0.72a   0.99±0.08 0.23±0.01 0.046±0.003 
10  21.03±0.60   0.92±0.07 0.23±0.02 0.044±0.002 
100  21.52±0.51b   1.09±0.06b 0.24±0.01 0.051±0.002b 
aData are expressed as mean ± standard deviation (n=10/group) 
aSignificantly different from control group (p< 0.05) 
bSignificantly different from control group (p< 0.01) 
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Table A.2. 
 
Fold change in hepatic UDPGT activity and mRNA expression 
Treatment  UDPGTa Ugt1a1a Ugt1a6a Ugt1a7a Ugt2b5a 
(mg/kg/day)  
0  1.0±0.2 1.0±0.0 1.0±0.2 1.0±0.1 1.0±0.1 
3  1.1±0.4 1.0±0.1 1.2±0.3 1.0±0.1 0.9±0.2 
10  1.1±0.2 1.1±0.1 1.2±0.3 1.3±0.2c 1.2±0.2 
100  1.1±0.3 1.2±0.1b 1.4±0.3 1.7±0.1c 1.3±0.2b 
aData are expressed as fold mean change ± standard deviation (n=4-5/group) 
bSignificantly different from control group (p< 0.05) 
cSignificantly different from control group (p< 0.01) 
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Table A.3. 
 
Fold change in hepatic cytochrome P450 activity and mRNA expression 
Treatment  Cyp1a1a ERODa Cyp2b10a PRODa Cyp3a11a 
(mg/kg/day) 
0  1.0±0.3 1.0±0.1 1.0±0.1 1.0±0.2 1.0±0.1 
3  0.8±0.3 0.9±0.1 1.2±0.4 1.2±0.2b 0.9±0.1 
10  0.8±0.3 1.0±0.1 2.5±0.8c 1.8±0.2c 1.1±0.1 
100  0.6±0.1 1.4±0.5c         19.9±2.9c 4.8±0.5c 1.2±0.2 
aData are expressed as fold change mean ± standard deviation (n=5-10/group) 
bSignificantly different from control group (p< 0.05) 
cSignificantly different from control group (p< 0.01) 
202 
 
Table A.4. 
 
Fold change in hepatic efflux transporter mRNA expression 
Treatment      Mrp3a  Mdr1aa  Mdr1ba 
(mg/kg/day)   
0  1.00±0.07          1.00±0.23         1.00±0.33       
3  0.80±0.05          0.66±0.10c        1.23±0.56       
10  1.19±0.14          0.61±0.36b       1.37±0.43       
100  1.47±0.20b         0.60±0.06b         1.27±0.59  
aData are expressed as fold change mean ± standard deviation (n=5-6/group) 
bSignificantly different from control group (p< 0.01) 
cSignificantly different from control group (p< 0.05) 
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Table A.5. 
 
Fold change in hepatic thyroid hormone transporter mRNA expression 
Treatment  Ttr a             Mct8 a                                 
(mg/kg/day)           
0         1.00±0.06        1.00±0.20       
3         0.91±0.04       1.02±0.16       
10         0.93±0.11       1.05±0.16       
100         0.73±0.04b         0.80±0.04c       
aData are expressed as fold change mean ± standard deviation (n=5-6/group) 
bSignificantly different from control group (p< 0.01) 
cSignificantly different from control group (p< 0.05) 
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Figure A.1. Total serum T4 concentrations in mice treated with BDE 47 
*Significantly different from control group (p< 0.0001) 
Data are expressed as mean ± standard deviation (n=9-10/group). 
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